<SEC-DOCUMENT>0001104659-26-085061.txt : 20260720
<SEC-HEADER>0001104659-26-085061.hdr.sgml : 20260720
<ACCEPTANCE-DATETIME>20260720160612
ACCESSION NUMBER:		0001104659-26-085061
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20260716
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260720
DATE AS OF CHANGE:		20260720

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELUTIA INC.
		CENTRAL INDEX KEY:			0001708527
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				474790334
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39577
		FILM NUMBER:		261186718

	BUSINESS ADDRESS:	
		STREET 1:		12510 PROSPERITY DRIVE
		STREET 2:		SUITE 370
		CITY:			SILVER SPRING
		STATE:			MD
		ZIP:			20904
		BUSINESS PHONE:		240-247-1143

	MAIL ADDRESS:	
		STREET 1:		12510 PROSPERITY DRIVE
		STREET 2:		SUITE 370
		CITY:			SILVER SPRING
		STATE:			MD
		ZIP:			20904

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AZIYO BIOLOGICS, INC.
		DATE OF NAME CHANGE:	20170605
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2620864d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:elut="http://elutia.com/20260716">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_031_elut_elutia.com_20260716 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20260716_20260716 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DEntityCentralIndexKey_0001708527 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2026-07-16" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-07-16" id="Fact000004" name="dei:EntityCentralIndexKey">0001708527</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="elut-20260716.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2026-07-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708527</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-07-16</xbrli:startDate>
        <xbrli:endDate>2026-07-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="font-size: 10pt">UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="font-size: 10pt">SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="font-size: 10pt">Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="font-size: 10pt">FORM&#160;<span id="xdx_90F_edei--DocumentType_c20260716__20260716_zUMGDOHv2G03" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-07-16" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="font-size: 10pt">CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="font-size: 10pt">Pursuant to Section&#160;13 or 15(d) of
the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">Date
of Report (Date of earliest event reported): <span style="text-decoration: underline">July 20, 2026 (<span id="xdx_90A_edei--DocumentPeriodEndDate_c20260716__20260716_zzLMcKigaCC6">
<ix:nonNumeric contextRef="AsOf2026-07-16" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">July 16, 2026</ix:nonNumeric></span></span></span><span style="text-decoration: underline">)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90A_edei--EntityRegistrantName_c20260716__20260716_zFSEr9wvWspc" style="font-size: 14pt"><b><span style="text-decoration: underline"><ix:nonNumeric contextRef="AsOf2026-07-16" id="Fact000011" name="dei:EntityRegistrantName">ELUTIA INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its
charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-size: 10pt">
    <td style="font-size: 10pt; vertical-align: top; text-align: center; width: 32%"><b style="font-size: 10pt"><span style="text-decoration: underline; font-size: 10pt"><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20260716__20260716_z2jBHK5574N9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-07-16" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></b></td>
    <td style="font-size: 10pt; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font-size: 10pt; vertical-align: top; text-align: center; width: 32%"><b style="font-size: 10pt"><span style="text-decoration: underline; font-size: 10pt"><span id="xdx_903_edei--EntityFileNumber_c20260716__20260716_zW8OM7cEEAT2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-07-16" id="Fact000013" name="dei:EntityFileNumber">001-39577</ix:nonNumeric></span></span></b></td>
    <td style="font-size: 10pt; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font-size: 10pt; vertical-align: top; text-align: center; width: 32%"><b style="font-size: 10pt"><span style="text-decoration: underline; font-size: 10pt"><span id="xdx_905_edei--EntityTaxIdentificationNumber_c20260716__20260716_zcRIbAY04R8b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-07-16" id="Fact000014" name="dei:EntityTaxIdentificationNumber">47-4790334</ix:nonNumeric></span></span></b></td></tr>
  <tr style="font-size: 10pt">
    <td style="font-size: 10pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">(State
or other jurisdiction of</span></p>
                                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">incorporation)</span></p></td>
    <td style="font-size: 10pt; vertical-align: bottom"><span style="font-size: 10pt; font-style: normal; font-weight: normal">&#160;</span></td>
    <td style="font-size: 10pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">(Commission</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">File
    Number)</span></p></td>
    <td style="font-size: 10pt; vertical-align: bottom"><span style="font-size: 10pt; font-style: normal; font-weight: normal">&#160;</span></td>
    <td style="font-size: 10pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">(IRS
    Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_901_edei--EntityAddressAddressLine1_c20260716__20260716_zWp6KnOygaL1" style="font-size: 10pt"><b><span style="text-decoration: underline"><ix:nonNumeric contextRef="AsOf2026-07-16" id="Fact000015" name="dei:EntityAddressAddressLine1">20
Firstfield Road</ix:nonNumeric></span></b></span><b><span style="text-decoration: underline"><span style="font-size: 10pt">, <span id="xdx_901_edei--EntityAddressCityOrTown_c20260716__20260716_zKr9YFZYI0G9"><ix:nonNumeric contextRef="AsOf2026-07-16" id="Fact000016" name="dei:EntityAddressCityOrTown">Gaithersburg</ix:nonNumeric></span></span></span></b><b><span style="text-decoration: underline"><span style="font-size: 10pt">,
<span id="xdx_906_edei--EntityAddressStateOrProvince_c20260716__20260716_zGlNTlrb9ryi"><ix:nonNumeric contextRef="AsOf2026-07-16" id="Fact000017" name="dei:EntityAddressStateOrProvince">MD</ix:nonNumeric> </span></span></span></b><b><span style="text-decoration: underline"><span id="xdx_903_edei--EntityAddressPostalZipCode_c20260716__20260716_zGHQNviN8TMa" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-07-16" id="Fact000018" name="dei:EntityAddressPostalZipCode">20878</ix:nonNumeric></span></span></b><span style="text-decoration: underline"><span style="font-size: 10pt">&#160;</span></span></p>

<p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">(Address
of principal executive offices) (Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="font-size: 10pt"><span style="text-decoration: underline; font-size: 10pt">(<span id="xdx_905_edei--CityAreaCode_c20260716__20260716_zFb8791nX2nl" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-07-16" id="Fact000019" name="dei:CityAreaCode">240</ix:nonNumeric></span></span></b><b style="font-size: 10pt"><span style="text-decoration: underline; font-size: 10pt">)
<span id="xdx_904_edei--LocalPhoneNumber_c20260716__20260716_z2Zpz6OOIQx7" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-07-16" id="Fact000020" name="dei:LocalPhoneNumber">247-1170</ix:nonNumeric></span></span></b><span style="text-decoration: underline; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">N/A</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">(Former
name or former address, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form&#160;8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-size: 10pt; vertical-align: top">
    <td style="font-size: 10pt; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; font-family: Wingdings"><span id="xdx_903_edei--WrittenCommunications_c20260716__20260716_zGLV16T6K86" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-07-16" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="font-size: 10pt; width: 98%"><span style="font: 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425) </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-size: 10pt; vertical-align: top">
    <td style="font-size: 10pt; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; font-family: Wingdings"><span id="xdx_90B_edei--SolicitingMaterial_c20260716__20260716_zeSg2nz6c83f" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-07-16" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="font-size: 10pt; width: 98%"><span style="font: 10pt Times New Roman, Times, Serif">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-size: 10pt; vertical-align: top">
    <td style="font-size: 10pt; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; font-family: Wingdings"><span id="xdx_90B_edei--PreCommencementTenderOffer_c20260716__20260716_zf6sToUkMD4" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-07-16" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="font-size: 10pt; width: 98%"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-size: 10pt; vertical-align: top">
    <td style="font-size: 10pt; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; font-family: Wingdings"><span id="xdx_906_edei--PreCommencementIssuerTenderOffer_c20260716__20260716_zTdraEd99zF9" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-07-16" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="font-size: 10pt; width: 98%"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-size: 10pt; vertical-align: top">
    <td style="font-size: 10pt; vertical-align: bottom; width: 38%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline; font-size: 10pt">Title
    of each class</span></span></td>
    <td style="font-size: 10pt; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">&#160;</span></td>
    <td style="font-size: 10pt; width: 26%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline; font-size: 10pt">Trading
Symbol</span></span><span style="text-decoration: underline; font-size: 10pt">(s)</span></td>
    <td style="font-size: 10pt; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">&#160;</span></td>
    <td style="font-size: 10pt; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline; font-size: 10pt">Name
    of each exchange on which registered</span></span></td></tr>
  <tr style="font-size: 10pt; vertical-align: top">
    <td style="font-size: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><b style="font-size: 10pt"><span id="xdx_905_edei--Security12bTitle_c20260716__20260716_z1p707fzheMh" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-07-16" id="Fact000025" name="dei:Security12bTitle">Class&#160;A
    Common Stock, $0.001 par value per share</ix:nonNumeric></span></b></td>
    <td style="font-size: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b style="font-size: 10pt"><span id="xdx_908_edei--TradingSymbol_c20260716__20260716_zyofHZz2FfR6" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-07-16" id="Fact000026" name="dei:TradingSymbol">ELUT</ix:nonNumeric></span></b></span></td>
    <td style="font-size: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b style="font-size: 10pt">The <span id="xdx_906_edei--SecurityExchangeName_c20260716__20260716_zQ7Uw1CDpA6l" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-07-16" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-size: 10pt">Emerging growth company </span><span style="font-size: 10pt; font-family: Wingdings"><span style="font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_905_edei--EntityEmergingGrowthCompany_c20260716__20260716_zlw8qMOYFetj"><ix:nonNumeric contextRef="AsOf2026-07-16" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Item 1.01</b></span><b>
Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Agreement to Sell SimpliDerm Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 16, 2026, Elutia Inc., a Delaware corporation (the &#8220;Company&#8221;
or &#8220;Elutia&#8221;), entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Cellution Biologics Inc.
, a Delaware corporation (&#8220;Cellution Biologics&#8221;). Subject to the terms and conditions of the Purchase Agreement, at the closing
(the &#8220;Closing&#8221;) of the transactions contemplated by the Purchase Agreement (collectively, such transactions, the &#8220;Asset
Purchase&#8221;), Cellution Biologics will purchase from the Company substantially all of the assets related to the Company&#8217;s business
of commercializing, manufacturing, distributing, selling and/or marketing human acellular dermis (hADM) products for use in the field
of breast reconstruction under the SimpliDerm&#174; brand (the &#8220;SimpliDerm Business&#8221;). The assets of the SimpliDerm Business
constitute substantially all of the assets currently held in Elutia&#8217;s Women&#8217;s Health segment. Cellution Biologics is only
assuming certain liabilities related to performance of the contracts transferred in the Asset Purchase (such liabilities, the &#8220;Assumed
Liabilities&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The
Purchase Agreement provides for aggregate consideration payable to the Company of up to $11 million, consisting of: (i) a base purchase
price of $8&#160;million in cash, payable at Closing, subject to adjustment for any inventory shortfall; (ii) a contingent payment of
up to $2&#160;million, payable upon completion of certain technology transfer and manufacturing transition milestones within an 18-month
period following the Closing, subject to reduction for sales shortfalls against monthly SimpliDerm sales targets during such transition
period; and (iii) contingent payments of up to $1&#160;million, in the aggregate, in the form of earn-out payments, payable for any four
of the first five quarters following the Closing in which SimpliDerm sales exceed a specified quarterly revenue target (collectively,
the &#8220;Purchase Price&#8221;).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Purchase Agreement, the
Company has agreed, for a five-year period following the Closing, to be subject to certain non-competition restrictions in the business
of manufacturing, marketing, distributing or selling human acellular dermis products. The Company has also agreed not to solicit Cellution
Biologics&#8217; employees and independent contractors for a period of five years following the Closing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and Cellution Biologics have also
negotiated a transition services agreement, to be entered into at Closing, pursuant to which the Company will agree to perform certain
transition services for a period of time following the Closing with respect to Cellution Biologics&#8217; use and operation of the assets
purchased in the Asset Purchase.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Purchase Agreement contains customary representations, warranties
and covenants of the parties. The Company and Cellution Biologics have agreed to indemnify each other from and against losses the respective
parties may incur arising out of breaches of the other party&#8217;s representations, warranties and covenants contained in the Purchase
Agreement. In addition, Cellution Biologics has agreed to indemnify the Company for losses relating to the Assumed Liabilities (as defined
in the Purchase Agreement), and the Company has agreed to indemnify Cellution Biologics for losses relating to the Excluded Assets and
Excluded Liabilities (each as defined in the Purchase Agreement). The Company has also agreed to indemnify Cellution Biologics for losses
related to the operation of the SimpliDerm Business prior to Closing, certain transaction expenses, certain successor-liability matters,
and certain specified litigation matters. Certain of the indemnification obligations of the parties under the Purchase Agreement are subject
to specified survival limitations, including an 18-month general survival period, a three-year survival period for certain special representations,
and a six-year or longer survival period for certain fundamental representations. The Company&#8217;s liability under the Purchase Agreement
is subject to a deductible amount equal to 10% of the Purchase Price, overall cap amounts ranging from 10% to 100% of the Purchase Price
depending on the nature of the representations, and other customary exceptions and limitations. The remedies provided under the Purchase
Agreement&#8217;s indemnification provisions are the parties&#8217; sole and exclusive remedies, subject to customary carve-outs for fraud
and specific performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Closing is subject to customary closing conditions, including,
among others, (i) the accuracy of representations and warranties set forth in the Purchase Agreement (subject to customary materiality
qualifiers), (ii) the absence of any Material Adverse Effect (as defined in the Purchase Agreement) with respect to the SimpliDerm Business,
(iii) material compliance with covenants set forth in the Purchase Agreement, (iv) the execution and delivery of certain related ancillary
documents, (v) no termination or material impairment of assumed or shared contracts, (vi) resolution of certain supply related matters,
and (vii) certain other conditions set forth in the Purchase Agreement. Subject to the satisfaction or waiver of the conditions to Closing,
the Company expects the Closing to occur in the second half of 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company and Cellution Biologics are each permitted under certain
circumstances to terminate the Purchase Agreement, including in the event that (i) the Closing has not occurred by January 16, 2027, (ii)
any final and nonappealable order is issued and effective or a law is enacted that prohibits or makes illegal the Asset Purchase, or (iii)
if the other party to the Purchase Agreement has breached any representation, warranty, covenant or other agreement such that the closing
conditions relating to either the accuracy of representations or the satisfaction of covenants by the other party are not met and cannot
be cured as provided in the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing description of the Purchase Agreement and the Asset Purchase
does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Purchase Agreement, which is
filed as Exhibit 10.1 to this Current Report on Form 8-K (this &#8220;Form 8-K&#8221;) and is incorporated herein by reference. The Purchase
Agreement is not intended to provide any other factual information about the Company, Cellution Biologics, or their respective owners,
subsidiaries and affiliates. The representations, warranties and covenants contained in the Purchase Agreement (i) were made solely for
purposes of the Purchase Agreement and as of the date of the Purchase Agreement, (ii) were solely for the benefit of the parties to the
Purchase Agreement, (iii) may be subject to qualifications and limitations agreed upon by the parties to the Purchase Agreement, including
being qualified by confidential disclosures made for the purposes of allocating contractual risk among the parties to the Purchase Agreement
instead of establishing these matters as facts and (iv) may be subject to standards of materiality applicable to the contracting parties
that differ from those applicable to security holders of the Company. Investors and security holders of the Company should not rely on
the representations, warranties and covenants or any description thereof as characterizations of the actual state of facts or condition
of the Company. Moreover, information concerning the subject matter of the representations, warranties and covenants may change after
the date of the Purchase Agreement, which subsequent information may or may not be fully reflected in public disclosures by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Item 7.01</b></span><b>
Regulation FD Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 16, 2026, Elutia issued a press release announcing the Purchase
Agreement, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information in this Item 7.01 (including Exhibit 99.1) of this
Current Report on Form 8-K is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, nor shall
it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly set forth by specific reference in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Forward-Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This report contains &#8220;forward-looking statements&#8221; within
the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements can be identified by words such as &#8220;projects,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221;
&#8220;would,&#8221; &#8220;should,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221;
&#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;promise&#8221; or similar references to future periods. All
statements contained in this report that do not relate to matters of historical fact should be considered forward-looking statements,
including any statements and information concerning the Company&#8217;s plans for the closing of the sale of the SimpliDerm Business,
which is subject to customary closing conditions, including if and when the Asset Purchase will be consummated, and any statements regarding
the maximum of up to $3 million in contingent technology transfer and commercial milestone and earn-out payments, which if earned, shall
form part of the consideration and are conditioned upon satisfaction of certain milestones and metrics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Forward-looking statements are based on management&#8217;s current
assumptions and expectations of future events and trends, which affect or may affect our business, strategy, operations or financial performance,
and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking
statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and other important factors
that may cause actual results, performance or achievements to differ materially from those contemplated or implied in this report, including,
but not limited to: the occurrence of any event, change or circumstance that could delay the Asset Purchase or give rise to termination
of the Purchase Agreement; the risk that the technology transfer and commercial milestone payments are reduced, delayed, or not earned
or received; the outcome of any legal proceedings instituted against the Company following announcement of the Asset Purchase; the inability
to consummate the Asset Purchase due to failure to satisfy closing conditions; the risk that the Asset Purchase disrupts Elutia&#8217;s
current plans and operations, including distraction of management and employees; costs related to the Asset Purchase; changes in applicable
laws or regulations; and other risks and uncertainties which can be found in the &#8220;Risk Factors&#8221; section of Elutia&#8217;s
public filings with the Securities and Exchange Commission (&#8220;SEC&#8221;), including Elutia&#8217;s Annual Report on Form 10-K for
the year ended December 31, 2025, as such factors may be updated from time to time in Elutia&#8217;s other filings with the SEC, including
Elutia&#8217;s Quarterly Reports on Form 10-Q, accessible on the SEC&#8217;s website at www.sec.gov and the Investor Relations page of
Elutia&#8217;s website at https://investors.elutia.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Because forward-looking statements are inherently subject to risks
and uncertainties, you should not rely on these forward-looking statements as predictions of future events. Any forward-looking statement
made by Elutia in this report is based only on information currently available and speaks only as of the date on which it is made. Except
as required by applicable law, Elutia expressly disclaims any obligations to publicly update any forward-looking statements, whether written
or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Item 9.01</b></span><b>
Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; padding: 2pt 4pt; width: 21%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt; width: 79%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 2pt 4pt"><a href="tm2620864d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">10.1*&#8224;</span></span></a></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt"><a href="tm2620864d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asset Purchase Agreement, dated July 16, 2026, by and between Cellution Biologics Inc. and Elutia Inc.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 2pt 4pt"><a href="tm2620864d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt"><a href="tm2620864d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release of Elutia Inc., dated July 16, 2026</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 2pt 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*Certain confidential information contained in this Exhibit, marked
in brackets, has been omitted, because it is both not material and of the type of information that the registrant treats as private or
confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8224; Schedules have been omitted pursuant to Item 601(a)(5) of
Regulation S-K. The Company undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td colspan="2" style="padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ELUTIA INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td colspan="2" style="padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Registrant)</i></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td colspan="2" style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: July 20, 2026</span></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Matthew Ferguson</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td colspan="2" style="padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew Ferguson</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td colspan="2" style="padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjUEKwjAQRU/QOwxZi8ZoF3Zp0SJWkSLiNtpRgm2mTKLWI3lLY4s4DAzD/+9/IQYio6WpkOE4L3LYY91U2iMUeEFGe8bgSFfrBMIt8GqcZ2199/7AlAKDgYmHSp2C0FkfxmGZgIxHcjZSU5CTJFaw24joq6dkL6ZE642uQNsSdkwNG/SaX33CXrdkqX51VQdkZ8gmMB7KXn6DkmMFW3roJ/HNQZ6nIhp0E4mM6d4E16L1aL8kLCqsQ53r6f9GHwleSpE= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tm2620864d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&#8239;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><I>Execution Version</I></B></P>



<P STYLE="margin: 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&#8239;HAVE
BEEN OMITTED AND REPLACED WITH &ldquo;[***]&rdquo;. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT&#8239;BECAUSE IT IS
(i)&#8239;NOT MATERIAL AND (ii)&#8239;<FONT STYLE="text-transform: uppercase">THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION
AS PRIVATE OR CONFIDENTIAL.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSET PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BY AND BETWEEN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CELLUTION BIOLOGICS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ELUTIA INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">July&#8239;16, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&#8239;I
    DEFINITIONS</B></FONT></TD>
    <TD STYLE="text-align: right"><B>1</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&#8239;</TD>
    <TD STYLE="text-align: right">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&#8239;II
    SALE AND PURCHASE</B></FONT></TD>
    <TD STYLE="text-align: right"><B>1</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&#8239;</TD>
    <TD STYLE="text-align: right">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.1</B></FONT></TD>
    <TD STYLE="width: 85%">Assets and Liabilities</TD>
    <TD STYLE="text-align: right; width: 5%">1</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.2</B></FONT></TD>
    <TD>Purchase Price</TD>
    <TD STYLE="text-align: right">2</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.3</B></FONT></TD>
    <TD>Closing</TD>
    <TD STYLE="text-align: right">3</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.4</B></FONT></TD>
    <TD>Closing Obligations</TD>
    <TD STYLE="text-align: right">3</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.5</B></FONT></TD>
    <TD>Inventory Adjustment</TD>
    <TD STYLE="text-align: right">4</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.6</B></FONT></TD>
    <TD>Transition Milestone Payment</TD>
    <TD STYLE="text-align: right">7</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.7</B></FONT></TD>
    <TD>Earnout Payments.</TD>
    <TD STYLE="text-align: right">9</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.8</B></FONT></TD>
    <TD>Tax Withholding</TD>
    <TD STYLE="text-align: right">10</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in">&#8239;</TD>
    <TD>&#8239;</TD>
    <TD STYLE="text-align: right">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&#8239;III
    REPRESENTATIONS AND WARRANTIES OF SELLER</B></FONT></TD>
    <TD STYLE="text-align: right"><B>11</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&#8239;</TD>
    <TD STYLE="text-align: right">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.1</B></FONT></TD>
    <TD>Organization and Good Standing</TD>
    <TD STYLE="text-align: right">11</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.2</B></FONT></TD>
    <TD>Authority; No Conflict</TD>
    <TD STYLE="text-align: right">11</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.3</B></FONT></TD>
    <TD>Financial Information</TD>
    <TD STYLE="text-align: right">12</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.4</B></FONT></TD>
    <TD>Assets</TD>
    <TD STYLE="text-align: right">13</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.5</B></FONT></TD>
    <TD>Intellectual Property; Information Systems</TD>
    <TD STYLE="text-align: right">13</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.6</B></FONT></TD>
    <TD>Material Customers and Material Suppliers.</TD>
    <TD STYLE="text-align: right">14</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.7</B></FONT></TD>
    <TD>Distributor Agreements</TD>
    <TD STYLE="text-align: right">14</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.8</B></FONT></TD>
    <TD>Assumed Contracts; No Defaults</TD>
    <TD STYLE="text-align: right">15</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.9</B></FONT></TD>
    <TD>Insurance</TD>
    <TD STYLE="text-align: right">15</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.10</B></FONT></TD>
    <TD>Product Safety and Product Recalls</TD>
    <TD STYLE="text-align: right">15</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.11</B></FONT></TD>
    <TD>Proceedings; Orders</TD>
    <TD STYLE="text-align: right">15</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.12</B></FONT></TD>
    <TD>Governmental Authorizations</TD>
    <TD STYLE="text-align: right">16</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.13</B></FONT></TD>
    <TD>Compliance with Legal Requirements</TD>
    <TD STYLE="text-align: right">16</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.14</B></FONT></TD>
    <TD>Shared Contracts</TD>
    <TD STYLE="text-align: right">16</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.15</B></FONT></TD>
    <TD>FDA and Regulatory Compliance.</TD>
    <TD STYLE="text-align: right">16</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.16</B></FONT></TD>
    <TD>Business Associates</TD>
    <TD STYLE="text-align: right">18</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.17</B></FONT></TD>
    <TD>Product Complaints and Warranty</TD>
    <TD STYLE="text-align: right">18</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.18</B></FONT></TD>
    <TD>Taxes</TD>
    <TD STYLE="text-align: right">19</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.19</B></FONT></TD>
    <TD>Personal Information</TD>
    <TD STYLE="text-align: right">20</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.20</B></FONT></TD>
    <TD>Related Persons</TD>
    <TD STYLE="text-align: right">21</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.21</B></FONT></TD>
    <TD>Absence of Certain Changes, Events and Conditions</TD>
    <TD STYLE="text-align: right">21</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.22</B></FONT></TD>
    <TD>Brokers or Finders</TD>
    <TD STYLE="text-align: right">21</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.23</B></FONT></TD>
    <TD>SEC Filings</TD>
    <TD STYLE="text-align: right">21</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.24</B></FONT></TD>
    <TD>Inspections; Limitation of Buyer&rsquo;s Warranties</TD>
    <TD STYLE="text-align: right">22</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in">&#8239;</TD>
    <TD>&#8239;</TD>
    <TD STYLE="text-align: right">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&#8239;IV
    REPRESENTATIONS AND WARRANTIES OF BUYER</B></FONT></TD>
    <TD STYLE="text-align: right"><B>22</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&#8239;</TD>
    <TD STYLE="text-align: right">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.1</B></FONT></TD>
    <TD>Organization and Good Standing</TD>
    <TD STYLE="text-align: right">22</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.2</B></FONT></TD>
    <TD>Authority; No Conflict</TD>
    <TD STYLE="text-align: right">22</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.3</B></FONT></TD>
    <TD>Brokers or Finders</TD>
    <TD STYLE="text-align: right">23</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.4</B></FONT></TD>
    <TD>Inspections; Limitation of Seller&rsquo;s Warranties</TD>
    <TD STYLE="text-align: right">23</TD></TR>
</TABLE>

<P STYLE="margin: 0">&#8239;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&#8239;V</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>PRE-CLOSING
    COVENANTS AND AGREEMENTS</B></FONT></TD>
    <TD STYLE="text-align: right"><B>24</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&#8239;</TD>
    <TD STYLE="text-align: right">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1</B></FONT></TD>
    <TD>Access and Investigation</TD>
    <TD STYLE="text-align: right">24</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2</B></FONT></TD>
    <TD STYLE="width: 85%">Conduct of the SimpliDerm Business by Seller During Executory Period</TD>
    <TD STYLE="text-align: right; width: 5%">24</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.3</B></FONT></TD>
    <TD>Exclusivity</TD>
    <TD STYLE="text-align: right">25</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.4</B></FONT></TD>
    <TD>Notification of Certain Matters</TD>
    <TD STYLE="text-align: right">25</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.5</B></FONT></TD>
    <TD>Notices, Consents, and Filings</TD>
    <TD STYLE="text-align: right">26</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.6</B></FONT></TD>
    <TD>Loss Proceeds</TD>
    <TD STYLE="text-align: right">26</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.7</B></FONT></TD>
    <TD>Commercially Reasonable Efforts</TD>
    <TD STYLE="text-align: right">26</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.8</B></FONT></TD>
    <TD>Updates to Annexes</TD>
    <TD STYLE="text-align: right">26</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in">&#8239;</TD>
    <TD>&#8239;</TD>
    <TD STYLE="text-align: right">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&#8239;VI
    ADDITIONAL COVENANTS AND AGREEMENTS</B></FONT></TD>
    <TD STYLE="text-align: right"><B>27</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&#8239;</TD>
    <TD STYLE="text-align: right">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.1</B></FONT></TD>
    <TD>Shared Contracts; Key Personnel</TD>
    <TD STYLE="text-align: right">27</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.2</B></FONT></TD>
    <TD>Proration of Taxes; Bulk Sales</TD>
    <TD STYLE="text-align: right">27</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.3</B></FONT></TD>
    <TD>Misdirected Payments</TD>
    <TD STYLE="text-align: right">28</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.4</B></FONT></TD>
    <TD>Books and Records</TD>
    <TD STYLE="text-align: right">28</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.5</B></FONT></TD>
    <TD>Public Announcements and Other Communications</TD>
    <TD STYLE="text-align: right">29</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.6</B></FONT></TD>
    <TD>Operating Unit Names</TD>
    <TD STYLE="text-align: right">29</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.7</B></FONT></TD>
    <TD>Non-Assignable Contracts</TD>
    <TD STYLE="text-align: right">29</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.8</B></FONT></TD>
    <TD>Technology Transfer.</TD>
    <TD STYLE="text-align: right">29</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.9</B></FONT></TD>
    <TD>Further Assurances</TD>
    <TD STYLE="text-align: right">30</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in">&#8239;</TD>
    <TD>&#8239;</TD>
    <TD STYLE="text-align: right">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&#8239;VII
    CONDITIONS TO CLOSING</B></FONT></TD>
    <TD STYLE="text-align: right"><B>30</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&#8239;</TD>
    <TD STYLE="text-align: right">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.1</B></FONT></TD>
    <TD>Conditions to Obligations of the Parties</TD>
    <TD STYLE="text-align: right">30</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.2</B></FONT></TD>
    <TD>Conditions to Obligations of Buyer</TD>
    <TD STYLE="text-align: right">31</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.3</B></FONT></TD>
    <TD>Conditions to Obligations of Seller</TD>
    <TD STYLE="text-align: right">31</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in">&#8239;</TD>
    <TD>&#8239;</TD>
    <TD STYLE="text-align: right">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&#8239;VIII
    INDEMNIFICATION</B></FONT></TD>
    <TD STYLE="text-align: right"><B>32</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&#8239;</TD>
    <TD STYLE="text-align: right">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.1</B></FONT></TD>
    <TD>Survival</TD>
    <TD STYLE="text-align: right">32</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.2</B></FONT></TD>
    <TD>Indemnification Obligations of Seller</TD>
    <TD STYLE="text-align: right">32</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.3</B></FONT></TD>
    <TD>Indemnification Obligations of Buyer</TD>
    <TD STYLE="text-align: right">32</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.4</B></FONT></TD>
    <TD>Time Limitations</TD>
    <TD STYLE="text-align: right">33</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.5</B></FONT></TD>
    <TD>Certain Other Limitations and Guidelines</TD>
    <TD STYLE="text-align: right">34</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.6</B></FONT></TD>
    <TD>Procedure for Indemnification &ndash; Third-Party Claims</TD>
    <TD STYLE="text-align: right">35</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.7</B></FONT></TD>
    <TD>Procedure for Indemnification &ndash; Direct Claims</TD>
    <TD STYLE="text-align: right">35</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.8</B></FONT></TD>
    <TD>Payment</TD>
    <TD STYLE="text-align: right">35</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.9</B></FONT></TD>
    <TD>Exclusive Remedies</TD>
    <TD STYLE="text-align: right">35</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.10</B></FONT></TD>
    <TD>Tax Treatment of Indemnification Payments</TD>
    <TD STYLE="text-align: right">36</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in">&#8239;</TD>
    <TD>&#8239;</TD>
    <TD STYLE="text-align: right">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&#8239;IX</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>TERMINATION</B></FONT></TD>
    <TD STYLE="text-align: right"><B>36</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&#8239;</TD>
    <TD STYLE="text-align: right">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.1</B></FONT></TD>
    <TD>Termination Events</TD>
    <TD STYLE="text-align: right">36</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.2</B></FONT></TD>
    <TD>Effect of Termination</TD>
    <TD STYLE="text-align: right">37</TD></TR>
</TABLE>

<P STYLE="margin: 0">&#8239;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&#8239;X
    GENERAL PROVISIONS</B></FONT></TD>
    <TD STYLE="text-align: right"><B>37</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&#8239;</TD>
    <TD STYLE="text-align: right">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.1</B></FONT></TD>
    <TD STYLE="width: 85%">Expenses</TD>
    <TD STYLE="text-align: right; width: 5%">37</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.2</B></FONT></TD>
    <TD>Successors and Assigns; No Third Party Beneficiaries</TD>
    <TD STYLE="text-align: right">37</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.3</B></FONT></TD>
    <TD>Notices</TD>
    <TD STYLE="text-align: right">37</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.4</B></FONT></TD>
    <TD>Entire Agreement; Modification</TD>
    <TD STYLE="text-align: right">38</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.5</B></FONT></TD>
    <TD>Waiver</TD>
    <TD STYLE="text-align: right">38</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.6</B></FONT></TD>
    <TD>Severability</TD>
    <TD STYLE="text-align: right">39</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.7</B></FONT></TD>
    <TD>Governing Law; Waiver of Jury Trial</TD>
    <TD STYLE="text-align: right">39</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.8</B></FONT></TD>
    <TD>Enforcement of Agreement; Remedies</TD>
    <TD STYLE="text-align: right">39</TD></TR>
</TABLE>
<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.9</B></FONT></TD>
    <TD STYLE="width: 85%">Counterparts; Execution of Agreement</TD>
    <TD STYLE="text-align: right; width: 5%">39</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.10</B></FONT></TD>
    <TD>Rules of Construction</TD>
    <TD STYLE="text-align: right">40</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.11</B></FONT></TD>
    <TD>Set Off</TD>
    <TD STYLE="text-align: right">41</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Annexes</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annex&#8239;A</FONT></TD>
    <TD STYLE="text-align: center; width: 8%">-</TD>
    <TD STYLE="text-align: justify; width: 80%">Defined Terms</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annex&#8239;B</FONT></TD>
    <TD STYLE="text-align: center">-</TD>
    <TD STYLE="text-align: justify">Purchased Assets</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annex&#8239;C</FONT></TD>
    <TD STYLE="text-align: center">-</TD>
    <TD STYLE="text-align: justify">Excluded Assets</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annex&#8239;D</FONT></TD>
    <TD STYLE="text-align: center">-</TD>
    <TD STYLE="text-align: justify">Assumed Contracts</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annex&#8239;E</FONT></TD>
    <TD STYLE="text-align: center">-</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation Methodologies</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annex&#8239;F</FONT></TD>
    <TD STYLE="text-align: center">-</TD>
    <TD STYLE="text-align: justify">Transition Milestones</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annex&#8239;G</FONT></TD>
    <TD STYLE="text-align: center">&#8239;</TD>
    <TD>Indemnification Matters</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Exhibits:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit&#8239;A</FONT></TD>
    <TD STYLE="text-align: center; width: 8%">-</TD>
    <TD STYLE="text-align: justify; width: 80%">Form of Bill of Sale and Assignment and Assumption Agreement</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit&#8239;B</FONT></TD>
    <TD STYLE="text-align: center">-</TD>
    <TD STYLE="text-align: justify">Form of IP Assignment Agreement</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit&#8239;C</FONT></TD>
    <TD STYLE="text-align: center">-</TD>
    <TD STYLE="text-align: justify">Form of Transition Services Agreement</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit&#8239;D</FONT></TD>
    <TD STYLE="text-align: center">-</TD>
    <TD>Form of Restrictive Covenant Agreement</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSET PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Asset Purchase Agreement
(this &ldquo;<U>Agreement</U>&rdquo;), dated as of July&#8239;16, 2026 (the &ldquo;<U>Execution Date</U>&rdquo;), is by and between Cellution
Biologics Inc., a Delaware corporation (&ldquo;<U>Buyer</U>&rdquo;), and Elutia Inc., a Delaware corporation (&ldquo;<U>Seller</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Seller
is engaged in the business of commercializing, manufacturing, distributing, selling and/or marketing human acellular dermis (hADM) products
for use in the field of breast reconstruction under the SimpliDerm&reg; brand (the &ldquo;<U>SimpliDerm Business</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Parties desire to enter into this Agreement whereby Seller sells and assigns to Buyer, and Buyer purchases and assumes from Seller, certain
specifically identified Assets and certain specifically identified Liabilities of Seller related to the SimpliDerm Business, respectively,
in accordance with the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Parties, intending to
be legally bound, hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&#8239;I<BR>
DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth on <U>Annex&#8239;A</U>
are the definitions of certain capitalized terms used in this Agreement, as well as cross-references to the applicable portions of this
Agreement where certain other capitalized terms are defined.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&#8239;II<BR>
SALE AND PURCHASE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B>2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B> <B><U>Assets and Liabilities</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
accordance with the terms of this Agreement, at the Closing, Seller shall sell, convey, grant, assign, transfer, and deliver to Buyer,
and Buyer shall purchase and acquire from Seller, free and clear of all Encumbrances (other than Permitted Encumbrances), all of Seller&rsquo;s
right, title, and interest in and to those Assets set forth on <U>Annex&#8239;B</U> (collectively, the &ldquo;<U>Purchased Assets</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
anything in this Agreement to the contrary, Buyer shall only purchase and acquire the Purchased Assets, and Buyer shall not purchase
or acquire, and shall not be deemed to acquire, any other Assets of Seller, including but not limited to those Assets set forth on <U>Annex&#8239;C</U>
and any Assets used or held for use exclusively in the Retained Business (all such other Assets of Seller not included in the definition
of &ldquo;Purchased Assets&rdquo;, collectively, the &ldquo;<U>Excluded Assets</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Buyer
will not assume any Liabilities of Seller or its Affiliates, other than Seller&rsquo;s executory performance obligations under those
Seller Contracts listed on <U>Annex&#8239;D</U> that are assigned to Buyer in accordance with the terms of this Agreement (collectively,
the &ldquo;<U>Assumed Contracts</U>&rdquo;) and, in each case, to the extent, and only to the extent, any such executory performance
obligation with respect to any such Assumed Contract relates solely to periods after the Closing and is to be performed in the Ordinary
Course, and specifically excluding all Liabilities with respect to any such Assumed Contract related to any (i)&#8239;failure to perform,
improper performance, breach, default, or violation under any such Assumed Contract that occurred prior to or in connection with the
Closing, (ii)&#8239;breach of warranty, product liability, product recall, product warning, tort, infringement, or violation of Legal
Requirement that occurred prior to or in connection with the Closing, (iii)&#8239;Proceeding that is based on facts or circumstances existing
prior to or at the Closing, or (iv)&#8239;inaccuracy in, or breach of, any representation, warranty, covenant, agreement, or obligation
of Seller in the Transaction Documents, or as would otherwise be contrary to any express indemnification obligation of Seller in this
Agreement (collectively, the &ldquo;<U>Assumed Liabilities</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
anything in this Agreement to the contrary, except for the Assumed Liabilities, Buyer shall not assume or be responsible to pay, perform,
or discharge any Liabilities of Seller (including all Liabilities and Proceedings (i)&#8239;as a result or, in connection with, or related
to any product liability, recalls, product warnings, warranty claims arising from sales of the Seller Products, distributor disputes,
Seller&rsquo;s failure to comply with Legal Requirements, tort, or infringement, in each case, related to or in connection with any of
the businesses (including the SimpliDerm Business), operations, assets, or Liabilities of Seller or any of Seller&rsquo;s Affiliates
conducted, existing, or arising at or prior to the Closing, (ii)&#8239;arising out of Seller&rsquo;s ownership of the Purchased Assets
or Seller&rsquo;s operation of the SimpliDerm Business at or prior to the Closing, (iii)&#8239;that are Taxes of Seller or Taxes imposed
with respect to the SimpliDerm Business or the Purchased Assets for any Tax period ending on or prior to the Closing Date (iv)&#8239;relating
to any of Seller&rsquo;s employee Liabilities (including all Benefit Plans), or (v)&#8239;otherwise based on facts or circumstances existing
prior to or at the Closing, any breach of any Assumed Contracts prior to or at the Closing, and all Liabilities arising under any terminated
Contracts or any other Contract of Seller that is not an Assumed Contract) (collectively, the &ldquo;<U>Excluded Liabilities</U>&rdquo;).
Seller and Seller&rsquo;s Affiliates shall remain solely responsible for all of the Excluded Liabilities and will timely pay, perform,
and discharge, as applicable, all obligations under the Excluded Liabilities. For the avoidance of doubt, the Excluded Liabilities shall
include (A)&#8239;any product liability, mass tort, class action, failure-to-warn, recall, adverse event, regulatory action, or similar
claim arising from products manufactured, processed, distributed, marketed, promoted, or sold prior to the Closing, regardless of when
such claim is asserted or (B)&#8239;any Taxes that would have been revealed by or otherwise reflected on any applicable Tax Clearance
Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B>2.2</B> <B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Purchase Price</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
aggregate purchase price for the Purchased Assets (the &ldquo;<U>Purchase Price</U>&rdquo;) is a dollar amount equal to (i)&#8239;the
Base Price, <I>minus </I>(ii)&#8239;the amount of any Inventory Shortfall, <I>plus</I> (iii)&#8239;the amount of all Earnout Payments earned
and payable pursuant to <U>Section&#8239;2.7</U>, <I>plus</I> (iv)&#8239;the Transition Milestone Payment to the extent payable pursuant
to <U>Section&#8239;2.6</U>, <I>plus</I> (iv)&#8239;the assumption of the Assumed Liabilities, in each case, as applicable, as adjusted
pursuant to this Agreement, including <U>Section&#8239;2.6</U>, <U>Section&#8239;2.7</U>, and <U>ARTICLE&#8239;VIII</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;At
the Closing, Buyer shall pay to Seller the Estimated Closing Cash Consideration by wire transfer of immediately available funds to the
Purchase Price Bank Account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Parties agree that the Transactions constitute an &ldquo;applicable asset acquisition&rdquo; within the meaning of Section&#8239;1060
of the Code. Accordingly, the Parties agree to report the Transactions on IRS Form&#8239;8594, and for any other required purposes, in
a manner consistent with the Allocation Schedule as finally determined. Within thirty (30) days after the finalization of the Post-Closing
Adjustment Amount in accordance with <U>Section&#8239;2.5</U>, Buyer shall provide Seller with an allocation schedule (the &ldquo;<U>Allocation
Schedule</U>&rdquo;), which allocates the Purchase Price (and any other item of consideration for U.S. federal income Tax purposes) among
the Purchased Assets in accordance with and as provided by Section&#8239;1060 of the Code and applicable Treasury Regulations (and any
similar provision of state or local Legal Requirements, as applicable) and consistent with the allocation methodologies set forth on
<U>Annex&#8239;E</U>. Upon delivery of the Allocation Schedule to Seller, the Allocation Schedule will be final, binding, and conclusive
on the Parties; <U>provided that</U> Buyer shall consider in good faith any written comments delivered by Seller within fifteen (15)
days of receipt of the Allocation Schedule. No Party shall take a position on any Tax Return or other Tax Filing or in any Proceeding
before any Tax Authority with regard to the determination or collection of any Tax that is in any manner inconsistent with the Allocation
Schedule, as finally determined or otherwise adjusted in accordance with this <U>Section&#8239;2.2(c)</U>. To the extent permitted by
applicable Legal Requirements, the Parties agree to notify each other in writing with respect to the initiation of any Proceeding by
any Tax Authority directly relating to the Allocation Schedule (for avoidance of doubt, excluding any such Proceeding that involves such
Party but only indirectly relates to the Allocation Schedule) and agree to consult and use commercially reasonable efforts to cooperate
with each other with respect to any such Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Closing</U></B>.
Subject to the terms of this Agreement, the Parties shall consummate the Transactions (the &ldquo;<U>Closing</U>&rdquo;) no later than
three Business Days after the last of the conditions to the Closing set forth in <U>ARTICLE&#8239;VII</U> has been satisfied or waived
(other than conditions that by their nature must be satisfied on the Closing Date, but subject to the satisfaction or waiver of such
conditions), and the Parties shall, and shall cause their respective Representatives to, conduct the Closing remotely through the exchange
of Transaction Documents and signatures thereto by electronic mail, or other means of electronic transmission (including pdf or any electronic
signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.simplyagree.com), or by such other method,
at such other time, on such other date, or at such other place as the Parties mutually agree upon in writing, effective as of 11:59:59
p.m.&#8239;(Eastern Time) (the &ldquo;<U>Effective Time</U>&rdquo;) on the Closing Date. All Transactions that will occur on and as of
the Closing Date will be deemed to have occurred simultaneously as of the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Closing
Obligations</U></B>. In addition to any other documents to be delivered under, or actions to be taken pursuant to, other provisions of
this Agreement, at the Closing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Seller
shall deliver, or cause to be delivered, to Buyer the following (collectively, the &ldquo;<U>Seller Closing Documents</U>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;with
respect to the Purchased Assets, a bill of sale and assignment and assumption agreement, in substantially the form attached hereto as
<U>Exhibit&#8239;A</U> (the &ldquo;<U>Bill of Sale</U>&rdquo;), duly executed by Seller;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;with
respect to the Seller IP Rights included in the Purchased Assets, an assignment of intellectual property, in substantially the form attached
hereto as <U>Exhibit&#8239;B</U> (the &ldquo;<U>IP Assignment Agreement</U>&rdquo;), duly executed by Seller;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
transition services agreement, in substantially the form attached hereto as <U>Exhibit&#8239;C</U> (the &ldquo;<U>TSA</U>&rdquo;), duly
executed by Seller;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
restrictive covenant agreement, in substantially the form attached hereto as <U>Exhibit&#8239;D</U> (the &ldquo;<U>Restrictive Covenant
Agreement</U>&rdquo;), duly executed by Seller;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
properly completed IRS Form&#8239;W-9, duly executed by Seller;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;evidence,
in form and substance reasonably acceptable to Buyer, that any Encumbrances on the Purchased Assets (other than Permitted Encumbrances)
have been released;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;evidence,
in form and substance reasonably acceptable to Buyer, that those notices required to be given and Filings required to be made by Seller
in connection with the execution, delivery, and performance of the Transaction Documents and the consummation and performance of the
Transactions have been duly given to or made with the appropriate Persons;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(viii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
certificate of good standing for Seller issued by the Secretary of State of the State of Delaware and certificates of existence, compliance,
and good standing (or the equivalent) for Seller issued by each other jurisdiction in which Seller currently operates the SimpliDerm
Business and in which Seller is qualified to do business, all issued by the Secretary of State (or other applicable Governmental Authority)
of such jurisdiction, and all dated no more than 10 Business Days prior to the Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(ix)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
requisite resolutions or actions of the board of directors of Seller approving the execution, delivery, and performance of the Transaction
Documents and the consummation and performance of the Transactions; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(x)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
certificate of a duly authorized officer of Seller certifying that all of the conditions set forth in <U>Section&#8239;7.2(a)</U>, <U>Section&#8239;7.2(b)</U>,
<U>Section&#8239;7.2(c)</U>, and <U>Section&#8239;7.2(i)</U>&#8239;have been satisfied, duly executed by such officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Buyer
shall deliver, or cause to be delivered, to Seller the following (collectively, the &ldquo;<U>Buyer Closing Documents</U>&rdquo;): (i)&#8239;the
Bill of Sale, (ii)&#8239;the IP Assignment Agreement, (iii)&#8239;the TSA, and (iv)&#8239;the Restrictive Covenant Agreement, in the case
of each of clauses (i)&#8239;through (iv), duly executed by Buyer, and (v)&#8239;a certificate of a duly authorized officer of Buyer certifying
that all of the conditions set forth in <U>Section&#8239;7.3(a)</U>&#8239;and <U>Section&#8239;7.3(b)</U>&#8239;have been satisfied, duly
executed by such officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B>2.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B> <B><U>Inventory Adjustment</U>.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Seller
and Buyer shall complete a joint physical inventory count no later than two Business Days prior to the Closing Date. Seller shall then
prepare and deliver to Buyer prior to the Closing, a statement (the &ldquo;<U>Estimated Inventory Statement</U>&rdquo;) setting forth
Seller&rsquo;s good faith estimates of (i)&#8239;Inventory Value as of the Effective Time, taking into account such joint physical inventory
count (the &ldquo;<U>Estimated Inventory Value</U>&rdquo;) together with a list of the Acquired Inventory as of the Effective Time, and
(ii)&#8239;calculation of the Estimated Inventory Shortfall, if any, based on such Estimated Inventory Value. Seller shall arrange with
common carrier for the physical delivery all of the Acquired Inventory to Buyer&rsquo;s designated warehouse no later than two Business
Days after the Closing Date. Within ten Business Days following the Closing, Buyer shall cause to be conducted a physical count of the
Acquired Inventory to determine the Inventory Value (the &ldquo;<U>Inventory Count</U>&rdquo;). Seller shall be entitled to observe the
Inventory Count in a manner that does not unreasonably interfere with the businesses and operations of Buyer or any of Buyer&rsquo;s
Affiliates. The result of the Inventory Count, as adjusted for activity occurring between the Effective Time and the date of the Inventory
Count, shall be used in order to determine the Closing Inventory Value as of the Closing Date. For purposes of the Estimated Inventory
Value and the Closing Inventory Value, the value of all Unusable Acquired Inventory shall be excluded. Buyer shall also have the right
to review and validate any documentation provided by Buyer pursuant to <U>Section&#8239;7.2(f)</U>&#8239;before determining the commercial
usability of such Acquired Inventory for purposes of calculating the Closing Inventory Value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Within
ninety (90) days after the Closing Date, Buyer shall prepare and deliver to Seller a statement (the &ldquo;<U>Closing Inventory Statement</U>&rdquo;)
setting forth (A)&#8239;its calculation of the actual Inventory Value as of the Effective Time (the &ldquo;<U>Closing Inventory Value</U>&rdquo;)
together with a list of Acquired Inventory as of the Effective Time, which shall be based, in part, on the Inventory Count, and (B)&#8239;its
calculation of the Post-Closing Adjustment Amount based thereon; provided that, if the Closing Inventory Value, as finally determined
pursuant to this <U>Section&#8239;2.5</U>, is greater than the Target Inventory Value, then the Closing Inventory Value shall be deemed
to equal the Target Inventory Value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
post-Closing adjustment shall be an amount equal to the Closing Inventory Value, as finally determined pursuant to this <U>Section&#8239;2.5</U>
(including the proviso set forth in <U>Section&#8239;2.5(b)</U>), <I>minus </I>the Estimated Inventory Value (the &ldquo;<U>Post-Closing
Adjustment Amount</U>&rdquo;). Promptly, and in any event no later than the second (2<SUP>nd</SUP>) Business Day following the determination
and final resolution thereof in accordance with the terms of this <U>Section&#8239;2.5</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;if
the Post-Closing Adjustment Amount is a positive number, then Buyer shall pay or cause to be paid to Seller an amount equal to the Post-Closing
Adjustment Amount, by wire transfer of immediately available funds to the Purchase Price Bank Account (or such other bank account in
the United States designated by Seller in a written notice to Buyer);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;if
the Post-Closing Adjustment Amount is a negative number, then Seller shall pay or cause to be paid to Buyer an amount equal to the absolute
value of the Post-Closing Adjustment Amount, by wire transfer of immediately available funds to the account designated by Buyer to Seller
in writing; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;if
the Post-Closing Adjustment Amount is equal to $0.00, then neither Buyer, on the one hand, nor Seller, on the other hand, shall be obliged
to make any payment to the other pursuant to this <U>Section&#8239;2.5(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
the event that Seller does not agree with the Closing Inventory Value set forth in the Closing Inventory Statement, Seller shall be entitled,
no later than 60 calendar days of the delivery of the Closing Inventory Statement (the &ldquo;<U>Inventory Dispute Period</U>&rdquo;),
to give Buyer written notice (a &ldquo;<U>Inventory Dispute Notice</U>&rdquo;) of such disagreement, which disagreement must be based
solely on Buyer&rsquo;s mathematical error, failure to calculate Inventory Value in accordance with this Agreement or Buyer not having
followed the terms of this Agreement. The Inventory Dispute Notice shall set forth in reasonable detail the specific items of Inventory
with which the Seller does not agree and the basis for such objection (the &ldquo;<U>Disputed Inventory Items</U>&rdquo;). Any Inventory
items not specifically identified as disputed in an Inventory Dispute Notice that is timely delivered shall be deemed accepted by Seller
and final and agreed for all purposes of this Agreement, absent Fraud or intentional misconduct. In the event that Seller (A)&#8239;does
not deliver an Inventory Dispute Notice during the Inventory Dispute Period or (B)&#8239;confirms in writing that they accept the Closing
Inventory Statement delivered by the Buyer, the Closing Inventory Value set forth on such Closing Inventory Statement shall be deemed
accepted by the Seller and to be final and agreed for all purposes of this Agreement, absent Fraud or intentional misconduct, and the
Purchase Price will be finally determined at such time. In the event that Seller delivers an Inventory Dispute Notice within the Inventory
Dispute Period, Seller and Buyer shall, for a period of not less than 30 days (the &ldquo;<U>Negotiation Period</U>&rdquo;) after delivery
of the Inventory Dispute Notice, attempt in good faith to mutually determine the Inventory Value of the Disputed Inventory Items and
mutually determine any resulting adjustments to the Closing Inventory Value. In the event that Buyer and Seller mutually determine in
writing the Inventory Value of the Disputed Inventory Items and resulting Closing Inventory Value, then such adjusted Closing Inventory
Value shall irrevocably be deemed to be final for all purposes of this Agreement, absent Fraud or intentional misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
Buyer and Seller fail to resolve all of the Disputed Inventory Items within the Negotiation Period, then either Buyer or Seller will
be entitled to submit the Disputed Inventory Items remaining in dispute (and only such Disputed Inventory Items, as all other matters
with respect to, and all other components of, the Closing Inventory Statement (including those Disputed Inventory Items resolved by Buyer
and Seller during the Negotiation Period) will be deemed final, binding, and conclusive on the Parties for all purposes under this Agreement
and not subject to further dispute or challenge) to the Independent Accounting Firm for resolution in accordance with the guidelines
and procedures set forth in this Agreement. If Disputed Inventory Items are submitted to the Independent Accounting Firm for resolution
in accordance with the immediately preceding sentence, then (i)&#8239;Buyer and Seller shall furnish, or cause to be furnished, to the
Independent Accounting Firm such work papers and other documents and information relating to such Disputed Inventory Items as the Independent
Accounting Firm requests and as are reasonably available to such Party or such Party&rsquo;s Representatives, and Buyer and Seller will
be afforded the opportunity to present to the Independent Accounting Firm any material relating to such Disputed Inventory Items, (ii)&#8239;Buyer
and Seller shall instruct the Independent Accounting Firm not to revise any element of the Closing Inventory Statement that is not such
a Disputed Inventory Item or assign a value to any element of such a Disputed Inventory Items greater than the largest value for such
item claimed by either Buyer or Seller less than the smallest value for such item claimed by Buyer or Seller, (iii)&#8239;Buyer and Seller
shall instruct the Independent Accounting Firm to deliver the Independent Accounting Firm&rsquo;s determination in a written notice to
Buyer and Seller within 60 days of the submission to the Independent Accounting Firm of such Disputed Inventory Items, and such determination
(to the extent compliant with the instructions required by <U>Section&#8239;2.5(e)(ii)</U>&#8239;and absent manifest error) will be deemed
final, binding, and conclusive on the Parties for all purposes under this Agreement and not subject to further dispute or challenge and
will be used in the determination of the Post-Closing Adjustment Amount and all components thereof, (iv)&#8239;neither Buyer nor Seller
shall participate in any ex-parte communications regarding the Disputed Inventory Items with the Independent Accounting Firm without
the other Party; and (v)&#8239;the fees and expenses of the Independent Accounting Firm will be allocated and payable by Buyer and Seller
in proportion to the amounts by which the proposals of Buyer and Seller respectively, differed from the Independent Accounting Firm&rsquo;s
final determination of such Disputed Inventory Items, and Buyer and Seller shall instruct the Independent Accounting Firm to determine
such proportions in the Independent Accounting Firm&rsquo;s final determination pursuant to this <U>Section&#8239;2.5(d)</U>. For example,
if Seller submits an Inventory Dispute Notice for $1,000, and if Buyer contests only $500 of the amount so claimed by Seller, and if
the Independent Accounting Firm ultimately resolves such dispute by awarding Seller $300 of the $500 contested amount, then the fees
and expenses of the Independent Accounting Firm will be allocated 60% (i.e., $300/$500) to Buyer and 40% (i.e., $200/$500) to Seller.
The Parties are entitled to enter and reduce to judgment any award given by the Independent Accounting Firm in accordance with this <U>Section&#8239;2.5(d)</U>&#8239;in
a court of competent jurisdiction if payment is not timely made in accordance with <U>Section&#8239;2.5(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
final determination of the Closing Inventory Value in accordance with this <U>Section&#8239;2.5</U> shall, in the absence of Fraud or
intentional misconduct, be conclusive for all purposes of this Agreement, and shall be binding on Buyer and Seller and the Independent
Accounting Firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Parties shall treat each payment made under this <U>Section&#8239;2.5</U>, <U>Section&#8239;2.6</U>, and <U>Section&#8239;2.7</U> as an
adjustment to the Purchase Price for U.S. federal (and applicable state and local) income Tax purposes, unless&#8239;a final &ldquo;determination&rdquo;
(within the meaning of Section&#8239;1313 of the Code) by a Tax Authority with respect to any such payment causes such payment not to
be treated as an adjustment to the Purchase Price for U.S. federal (and applicable state and local) income Tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Transition
Milestone Payment</U>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Buyer
shall pay to Seller the Transition Milestone Payment (as adjusted pursuant to the terms of this Agreement) as follows: (i)&#8239;no later
than five Business Days after completion of all of the transition milestones set forth on <U>Annex&#8239;F</U> (the &ldquo;<U>Transition
Milestones</U>&rdquo;) and the final determination of the amount of all Milestone Payment Reductions for the Guaranteed Months during
which the Parties completed the Transition Milestones, a dollar amount equal to (A)&#8239;the Transition Milestone Payment <I>minus </I>(B)&#8239;the
aggregate amount of Milestone Payment Reductions for each Guaranteed Month that it took to complete all of the Transition Milestones
<I>minus</I> (C)&#8239;the product of (x)&#8239;18 <I>minus </I>the number of Guaranteed Months that it took to complete each of the Transition
Milestones <I>multiplied by </I>(y)&#8239;[***]; and (ii)&#8239;no later than five Business Days after the final determination of the amount
of all Milestone Payment Reductions for the remaining Guaranteed Months, a dollar amount equal to (A)&#8239;the remaining portion of the
Transition Milestone Payment (which, for the avoidance of doubt, would equal the Transition Milestone Payment <I>minus</I> the aggregate
amount of Milestone Payment Reductions for each Guaranteed Month that it took to complete all of the Transition Milestones <I>minus</I>
the payment made pursuant to <U>Section&#8239;2.6(a)(i)</U>) <I>minus </I>(B)&#8239;any Milestone Payment Reductions for the remaining
Guaranteed Months; <U>provided</U>, <U>however</U>, that failure to achieve a Transition Milestone due to Buyer&rsquo;s action or inaction
shall not excuse Buyer from paying the Transition Milestone Payment. For example, if the Parties complete the Transition Milestones within
the first seven Guaranteed Months following the Closing and there were Milestone Payment Reductions of (x)&#8239;[***] during the first
seven Guaranteed Months and (y)&#8239;[***] during the final [***] Guaranteed Months, then Buyer shall pay to Seller (I)&#8239;[***] ([***]
<I>minus </I>[***] <I>minus </I>the product of [***] <I>multiplied by</I> [***] no later than five Business Days after completion of
all of the Transition Milestones and the final determination of the amount of all Milestone Payment Reductions for such seven Guaranteed
Months; and (II)&#8239;the remaining [***] ([***] (i.e., the total Transition Milestone Payment) <I>minus </I>[***] (i.e., the aggregate
amount of Milestone Payment Reductions for the first seven Guaranteed Months) <I>minus</I> [***] (i.e., the partial Transition Milestone
Payment made with respect to the first seven Guaranteed Months pursuant to <U>Section&#8239;2.6(a)(i)</U>) <I>minus </I>[***] (i.e., the
aggregate amount of Milestone Payment Reductions for the last [***] Guaranteed Months)) no later than five Business Days after the final
determination of the amount of all Milestone Payment Reductions for the remaining eleven Guaranteed Months. The Parties shall use commercially
reasonable efforts to complete the Transition Milestones no later than the date that is [***] months after the Closing Date (or such
later date as mutually agreed in writing); <U>provided</U> that, for the avoidance of doubt, the Transition Milestones shall not be considered
completed (and none of the Transition Milestone Payment shall be due and payable) unless and until completion of all Transition Milestones.
The Transition Milestones shall be deemed completed upon Buyer&rsquo;s written confirmation (such confirmation not to be unreasonably
withheld, conditioned or delayed) that each Transition Milestone has been completed in all material respects in accordance with this
Agreement. If Buyer reasonably determines that a Transition Milestone has not been completed, Buyer shall provide Seller with a written
notice describing in reasonable detail the deficiencies. Seller shall have a reasonable opportunity to cure such deficiencies, following
which Buyer shall promptly reassess the applicable Transition Milestone. Notwithstanding the foregoing, if Buyer has not provided written
confirmation that all Transition Milestones have been completed on or before the date that is [***] months after the Closing Date, both
Parties agree to negotiate in good faith to determine whether any completed Transition Milestones should be eligible for a partial payment
of the Transition Milestone Payment. Any such partial payment shall be paid (as adjusted pursuant to the terms of this Agreement) only
for Transition Milestones completed in all material respects and accepted by Buyer (such acceptance not to be unreasonably withheld,
conditioned or delayed), and shall not constitute acceptance of any incomplete Transition Milestones or waive any rights or remedies
of Buyer (under this Agreement or otherwise) with respect to any incomplete Transition Milestones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
following defined terms shall have the meaning set forth below as used in this <U>Section&#8239;2.6</U> and throughout this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">&ldquo;<U>Guaranteed Month</U>&rdquo;
                                            means each full or partial calendar month during the Guaranteed Period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">&ldquo;<U>Guaranteed Period</U>&rdquo;
                                            means the period beginning on the Closing Date and ending on 18-month anniversary of the
                                            Closing Date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in">(iii)</TD><TD STYLE="text-align: justify">&ldquo;<U>Sales Shortfall</U>&rdquo;
                                            means [***] minus the actual SimpliDerm Sales in a given Guaranteed Month; <U>provided</U>
                                            that, for any partial Guaranteed Month, such calculation shall be prorated to account for
                                            the days in such Guaranteed Month that are a part of the Guaranteed Period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in">(iv)</TD><TD STYLE="text-align: justify">&ldquo;<U>Profitability Shortfall</U>&rdquo;
                                            means Buyer&rsquo;s Standard Pre-Tax Profit Margin multiplied by the Sales Shortfall.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in">(v)</TD><TD STYLE="text-align: justify">&ldquo;<U>Profitability Target</U>&rdquo;
                                            means [***]; <U>provided</U> that, for any partial Guaranteed Month, such amount shall be
                                            prorated to account for the days in such calendar month that are a part of the Guaranteed
                                            Period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in">(vi)</TD><TD STYLE="text-align: justify">&ldquo;<U>Standard Pre-Tax Profit Margin</U>&rdquo;
                                            shall be [***].</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
Buyer experiences a Sales Shortfall in any Guaranteed Month, then the Transition Milestone Payment shall be reduced on a dollar-for-dollar
basis by an aggregate amount equal to, with respect to each Guaranteed Month, the lesser of (i)&#8239;the Profitability Shortfall for
such Guaranteed Month and (ii)&#8239;the Profitability Target (any such reduction in a given calendar month, a &ldquo;<U>Milestone Payment
Reduction</U>&rdquo;). For example, if a Sales Shortfall has occurred in a given Guaranteed Month and the Sales Shortfall in such Guaranteed
Month is [***], then the Profitability Shortfall shall be [***] ([***] x [***]) and the Transition Milestone Payment shall be reduced
by (and the Milestone Payment Reduction for such month shall equal) [***], and if the Milestone Payment Reduction was equal to [***]
in all 18 Guaranteed Months, then the total aggregate reduction to the Transition Milestone Payment would be equal to [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If,
after the Closing, any Unusable Acquired Inventory constitutes Released Inventory, the Inventory Value of such Released Inventory shall
first be applied as an offset against any Milestone Payment Reduction. To the extent the Inventory Value of such Released Inventory exceeds
the Milestone Payment Reduction for such Guaranteed Month, Buyer shall either, at the Buyer&rsquo;s option (i)&#8239;pay Seller the excess
amount within ten (10)&#8239;Business Days following the month in which such Released Inventory was released or re-released or (ii)&#8239;provide
notice to Seller (within ten (10)&#8239;Business Days following the month in which such Released Inventory was released or re-released)
that Buyer is applying such excess amount to offset any prior Guaranteed Month&rsquo;s Milestone Payment Reduction. Seller shall promptly
provide the corresponding release documentation and all supporting information and documentation reasonably necessary for Buyer to review
and validate the commercial usability of any Released Inventory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If,
after Closing, any Acquired Inventory that was included as a part of the Closing Inventory Value as finally determined in accordance
with <U>Section&#8239;2.5</U> subsequently cannot be commercially released or utilized because it does not satisfy the agreed Supplier
release criteria or otherwise fails to meet the release standards agreed by the Parties at Closing or constitutes Unusable Acquired Inventory,
then the Transition Milestone Payment shall be reduced on a dollar-for-dollar basis by an amount equal to the value of such Acquired
Inventory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;As
promptly as practicable, but in no event later than 30 days after the end of each month of the Guaranteed Period, Buyer shall prepare
and deliver to Seller a written statement setting forth Buyer&rsquo;s good faith calculation of the Milestone Payment Reduction for such
month, together with reasonably supporting detail (such calculation, an &ldquo;<U>Milestone Payment Reduction Calculation</U>&rdquo;).
The Milestone Payment Reduction Calculation shall be binding and conclusive upon the Parties upon the earlier to occur of: (i)&#8239;Seller&rsquo;s
written notice to the Buyer of its acceptance of the Milestone Payment Reduction Calculation and (ii)&#8239;15 days following the Seller&rsquo;s
receipt of the Milestone Payment Reduction Calculation, unless Seller provides written notice of disagreement to the Buyer within such
15-day period (such period, the &ldquo;<U>Milestone Payment Reduction Objection Period</U>&rdquo;). During each Milestone Payment Reduction
Objection Period, Buyer shall provide Seller with a reasonable opportunity, in a manner that does not unreasonably interfere with the
businesses and operations of Buyer or any of Buyer&rsquo;s Affiliates, to review any books and records and work papers used in preparing
such applicable Milestone Payment Reduction Calculation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
dispute resolution procedures set forth in <U>Section&#8239;2.5(d)</U>&#8239;through <U>Section&#8239;2.5(f)</U>&#8239;shall apply, <I>mutatis
mutandis</I>, to the resolution of any dispute with respect to a Milestone Payment Reduction Calculation, with references therein to
the &ldquo;Closing Inventory Statement&rdquo; being deemed references to the applicable Milestone Payment Reduction Calculation and with
such other conforming changes as the context requires. Notwithstanding anything in this Agreement to the contrary, the dispute resolution
mechanism contained in this <U>Section&#8239;2.6(g)</U>&#8239;is the exclusive mechanism for resolving disputes regarding the Milestone
Payment Reduction Calculation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>2.7</B></TD><TD STYLE="text-align: justify"><B><U>Earnout Payments</U>.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
following defined terms shall have the meaning set forth below as used in this <U>Section&#8239;2.7</U> and throughout this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Earnout
Payment</U>&rdquo; means an amount equal to [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Earnout
Period</U>&rdquo; means, as applicable, each of the first five consecutive full calendar quarter periods immediately following the Closing
Date. For the avoidance of doubt, each Earnout Period shall end on the last day of the applicable fiscal quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Earnout
Target</U>&rdquo; means [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>SimpliDerm
Sales</U>&rdquo; means, with respect to each Earnout Period, actual revenue, determined in accordance with GAAP, that is derived from
sales of the Seller Products (net of returns, rebates, chargebacks, customary trade and cash discounts, freight and shipping pass-throughs
and excluding intercompany sales and extraordinary expenses) during such Earnout Period, in accordance with the example set forth on
<U>Schedule&#8239;2.7(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
the SimpliDerm Sales for a given Earnout Period exceed the Earnout Target, then Buyer shall pay to Seller the Earnout Payment for such
Earnout Period; <U>provided</U> that in no event shall the aggregate amount of all Earnout Payments exceed $1,000,000. For the avoidance
of doubt, if the aggregate amount paid by Buyer to Seller equals $1,000,000 in total, then Buyer shall have no further obligation to
make any additional Earnout Payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;As
promptly as practicable, but in no event later than 60 days after the end of each Earnout Period, Buyer shall prepare and deliver to
Seller a written statement setting forth Buyer&rsquo;s good faith calculation of the SimpliDerm Sales for such Earnout Period, together
with reasonably supporting detail and whether Seller is eligible for an Earnout Payment for such Earnout Period (such calculation, an
 &ldquo;<U>Earnout Payment Calculation</U>&rdquo;). The Earnout Payment Calculation shall be binding and conclusive upon the Parties upon
the earlier to occur of: (i)&#8239;Seller&rsquo;s written notice to the Buyer of its acceptance of the Earnout Payment Calculation and
(ii)&#8239;30 days following the Seller&rsquo;s receipt of the Earnout Payment Calculation, unless Seller provides written notice of disagreement
to the Buyer within such 30-day period (such period, the &ldquo;<U>Earnout Objection Period</U>&rdquo;). During the Earnout Objection
Period, Buyer shall provide Seller with a reasonable opportunity, in a manner that does not unreasonably interfere with the businesses
and operations of Buyer or any of Buyer&rsquo;s Affiliates, to review any books and records and work papers used in preparing such Earnout
Payment Calculation. The aggregate amount of all Earnout Payments shall not exceed $1,000,000. For the avoidance of doubt, if Buyer has
paid Seller [***] for each of the first four Earnout Periods following the Closing, then there shall be no Earnout Payment for the fifth
Earnout Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
dispute resolution procedures set forth in <U>Section&#8239;2.5(d)</U>&#8239;through <U>Section&#8239;2.5(f)</U>&#8239;shall apply, <I>mutatis
mutandis</I>, to the resolution of any dispute with respect to an Earnout Payment Calculation, with references therein to the &ldquo;Closing
Inventory Statement&rdquo; being deemed references to the applicable Earnout Payment Calculation and with such other conforming changes
as the context requires. Notwithstanding anything in this Agreement to the contrary, the dispute resolution mechanism contained in this
<U>Section&#8239;2.7(d)</U>&#8239;is the exclusive mechanism for resolving disputes regarding the Earnout Payment Calculations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;For
purposes of preparing an Earnout Payment Calculation and a Milestone Payment Reduction Calculation, SimpliDerm Sales shall be determined
in accordance with GAAP, as reasonably determined by Buyer. During each Earnout Period and the Guaranteed Period, Buyer (i)&#8239;will
keep Seller reasonably informed of any material developments outside the Ordinary Course of business relating to SimpliDerm Sales, (ii)&#8239;will
act in good faith with respect to Buyer&rsquo;s operation of the SimpliDerm Business, and (iii)&#8239;will not knowingly take any action
or omit to take any action for the purpose of avoiding an Earnout Payment, increasing a Milestone Payment Reduction, or materially reducing
SimpliDerm Sales. Except as expressly set forth in the immediately preceding sentence, nothing contained in this Agreement requires,
or will be construed to require, Buyer to maintain the SimpliDerm Business, any of the Purchased Assets, or any of the Assumed Liabilities
separately (or with separate books and records) or otherwise restrict in any way management of Buyer from operating the SimpliDerm Business,
the Purchased Assets, and the Assumed Liabilities in any respect and making all customer and other business decisions in the manner that
Buyer deems appropriate in Buyer&rsquo;s sole discretion and without taking into consideration the impact of such actions on any Earnout
Payment or Milestone Payment Reduction. For avoidance of doubt, neither Buyer nor any of Buyer&rsquo;s Affiliates (i)&#8239;owes Seller
any fiduciary or other duty in respect of this <U>Section&#8239;2.7</U>, or (ii)&#8239;is making any representations or warranties to Seller
with respect to the operations of the SimpliDerm Business, any of the Purchased Assets, or any of the Assumed Liabilities after the Closing
or with respect to any estimates or projections relating to SimpliDerm Sales for the applicable Earnout Period or during the Guaranteed
Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Seller
acknowledges and agrees that the right to receive any Earnout Payment pursuant to this Agreement: (i)&#8239;does not represent an equity
or other ownership interest in Buyer or any of Buyer&rsquo;s Affiliates; (ii)&#8239;does not carry voting, dividend, or liquidation rights;
(iii)&#8239;is not represented by any form of certificate or instrument; (iv)&#8239;does not bear any interest; and (v)&#8239;is not assignable
or transferable (other than by testamentary disposition or the laws of intestacy).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Within
five Business Days of the final determination of the amount of an Earnout Payment for a particular Earnout Period in accordance with
this <U>Section&#8239;2.7</U>, Buyer shall pay to Seller the amount of such Earnout Payment by wire transfer of immediately available
funds to the Purchase Price Bank Account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Tax
Withholding</U></B>. Notwithstanding anything in this Agreement to the contrary, Buyer is entitled to deduct and withhold from any portion
of the Purchase Price, or other payment payable by Buyer pursuant to this Agreement, such amounts that are required to be deducted and
withheld under the Code or any other Legal Requirement with respect to the making of such payment. Other than with respect to Seller&rsquo;s
failure to provide an IRS Form&#8239;W-9 in accordance with <U>Section&#8239;2.4(a)(v)</U>&#8239;or any compensatory payment, Buyer shall
provide Seller with notice of any intent to deduct or withhold any amount, and the Parties shall cooperate in good faith to reduce or
eliminate any such deduction or withholding to the extent permitted under the Code or any other Legal Requirement. To the extent that
amounts are so deducted and withheld and paid over to the appropriate Tax Authority, such amounts will be deemed for all purposes of
this Agreement as having been paid to the Person in respect of which such deduction and withholding were made and no deduction or withholding
effectuated in accordance with this <U>Section&#8239;2.8</U> will constitute or be deemed to constitute a breach of any of Buyer&rsquo;s
obligations under this Agreement. For the avoidance of doubt, nothing in this <U>Section&#8239;2.8</U> shall limit Buyer&rsquo;s right
or obligation to deduct or withhold any amount where required by applicable Legal Requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&#8239;III<BR>
REPRESENTATIONS AND WARRANTIES<BR>
OF SELLER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Seller hereby represents
and warrants to Buyer as of the Execution Date as follows, qualified by the attached disclosure schedules (collectively, the &ldquo;<U>Disclosure
Schedules</U>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Organization
and Good Standing</U></B>. Seller is a corporation duly organized, validly existing, and in good standing under the Legal Requirements
of the State of Delaware, and Seller has full power and authority to own or lease the Purchased Assets owned or leased, respectively,
by Seller as they are now owned or leased, and to carry on the SimpliDerm Business as it is now being conducted. Seller is duly qualified
and licensed to do business and is in good standing in all jurisdictions where the character of the Purchased Assets owned or leased
by Seller or the nature of Seller&rsquo;s activities, including the SimpliDerm Business, makes such qualification necessary, and each
jurisdiction where Seller is qualified and licensed to do business is set forth on <U>Schedule&#8239;3.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B>3.2</B> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Authority; No Conflict</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This
Agreement has been duly and validly executed by Seller, and this Agreement (assuming due authorization, execution, and delivery by Buyer)
constitutes the legal, valid, and binding obligation of Seller, enforceable against Seller in accordance with its terms, except as enforceability
is limited by the Enforceability Exceptions. Upon the delivery and execution by Seller of each of the Seller Closing Documents, each
Seller Closing Documents (assuming due authorization, execution, and delivery by the other party or parties thereto, if applicable) will
constitute the legal, valid, and binding obligation of Seller, enforceable against Seller in accordance with the terms thereof, except
as enforceability is limited by the Enforceability Exceptions. Seller has the right, power, and authority to execute and deliver this
Agreement and the Seller Closing Documents to which Seller is a party and to perform Seller&rsquo;s obligations under this Agreement
and the Seller Closing Documents, and such actions have been duly authorized by all necessary corporate action by Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth on <U>Schedule&#8239;3.2(b)</U>, neither the execution, delivery, or performance of any of the Transaction Documents by Seller
nor the consummation or performance of any of the Transactions by Seller will, directly or indirectly (with or without notice or lapse
of time or both), (i)&#8239;contravene, conflict with, or result in a violation or breach of any provision of any of the Governance Documents
of Seller, (ii)&#8239;contravene, conflict with, or result in a violation or breach of any Legal Requirement to which Seller is subject,
(iii)&#8239;contravene, conflict with, or result in a violation or breach of, constitute a default under, or give any Governmental Authority
the right to revoke, withdraw, suspend, cancel, terminate, or modify any Seller Governmental Authorization, (iv)&#8239;contravene, conflict
with, or result in a violation or breach of, constitute a default under, or give any Person the right to declare a default or exercise
any remedy under, accelerate the maturity or performance of or payment under, or cancel, terminate, or modify any Assumed Contract, or
(v)&#8239;result in the creation or imposition of any Encumbrance upon any of the Purchased Assets (other than Permitted Encumbrances).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth on <U>Schedule&#8239;3.2(c)</U>, Seller is not required to give any notice to, make any Filing with, or obtain any Consent
from any Person in connection with the execution, delivery, and performance of any of the Transaction Documents or the consummation and
performance of the Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Financial Information</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; background-color: white">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Attached
to <U>Schedule&#8239;3.3(a)</U>&#8239;are accurate and complete copies of the unaudited financial statements of the SimpliDerm Business
as of and for each of the years ended December&#8239;31, 2024 and 2025 (collectively, the &ldquo;<U>Fiscal Year Financial Statements</U>&rdquo;),
and the unaudited financial statements of the SimpliDerm Business as of and for the three (3)-month period ended March&#8239;31, 2026
(collectively, the &ldquo;<U>Interim Financial Statements</U>&rdquo;). The Financial Statements fairly present in all material respects
the financial position and results of operations of the SimpliDerm Business as of the dates and for the periods specified, and have been
prepared in accordance with GAAP applied on a consistent basis throughout the periods covered by the Financial Statements (except, in
the case of the Interim Financial Statements, for normal recurring year-end adjustments (the effect of which will not, individually or
in the aggregate, be material) and the absence of footnotes (that, if presented, would not differ materially from those included in the
Fiscal Year Financial Statements)).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth on <U>Schedule&#8239;3.3(b)</U>, Seller does not have any Liabilities relating to, or otherwise arising from the SimpliDerm
Business except for (i)&#8239;Liabilities reflected or reserved against in the Interim Financial Statements, (ii)&#8239;current Liabilities
incurred in the Ordinary Course since March&#8239;31, 2026, none of which results from, arises out of, relates to, is in the nature of,
or was caused by any breach of Contract or warranty, infringement, professional error or omission, act or event creating a severance
obligation, wrongful discharge claim, or similar Liability, tort, violation of any Legal Requirement, or Proceeding, and (iii)&#8239;the
Transaction Expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All
Accounts Receivable represent valid obligations arising from products actually sold or services actually provided by Seller with respect
to the SimpliDerm Business in the Ordinary Course. The Accounts Receivable are current and, to the Knowledge of Seller, collectible in
accordance with their terms, net of the respective reserves, if any, reflected in the accounting records of Seller as of the Closing
Date, which reserves are sufficient and calculated in accordance with GAAP. There is no pending contest, claim, or right of set-off under
any Contract with any obligor of an Account Receivable relating to the amount or validity of such Account Receivable. <U>Schedule 3.3(c)</U>&#8239;contains
a list of all Accounts Receivable as of March&#8239;31, 2026, which list sets forth the aging of such Accounts Receivable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All
information (including financial, operational, commercial, and technical information) provided by or on behalf of Seller to Buyer or
Buyer&rsquo;s Representatives in connection with the Transactions, including through the Virtual Data Room, is accurate and complete
in all material respects and does not contain any untrue statement of a material fact or omit to state any material fact necessary to
make such information not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth on <U>Schedule&#8239;3.3(e)</U>, all Acquired Inventory (whether or not reflected in the Financial Statements) is usable,
merchantable, saleable, not expired, not damaged, and compliant with applicable quality requirements and otherwise of a quality and quantity
that may be used and sold in the Ordinary Course. The quantities of each item of Acquired Inventory are not excessive and are reasonable
in the present circumstances of Seller. All Acquired Inventory is owned by Seller free and clear of all Encumbrances (other than Permitted
Encumbrances). Acquired Inventory includes inventory held on a consignment basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Seller
is a going concern and is able to pay its Liabilities, debts and obligations as they become due in the Ordinary Course. The fair value
of the property of Seller, not including the Purchased Assets and taking into account the Transactions, is greater than the amount of
Seller&rsquo;s Liabilities as such value is established and Liabilities evaluated for purposes of Section&#8239;101(32) of the United
States Bankruptcy Code. No transfer of property is being made and no obligation is being incurred in connection with the Transactions
with the intent to hinder, delay, or defraud either present or future creditors of Seller or any of its Affiliates. Seller has not incurred,
nor plans to incur, debts or Liabilities beyond its ability to pay as they become absolute and matured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Assets</U></B>.
Except as set forth on <U>Schedule&#8239;3.4</U>, Seller has good, valid, and marketable title to all of the Purchased Assets (including,
for the avoidance of doubt, all Seller IP Rights and all inventory included in the Purchased Assets) and all of the Purchased Assets
are free and clear of all Encumbrances (other than Permitted Encumbrances). The tangible Purchased Assets are in good operating condition
and repair, ordinary wear and tear excepted, and none of which are in need of maintenance or repair, except for ordinary, routine maintenance
and repair that are not material in nature or cost. At the Closing, the Purchased Assets will include all of those Assets necessary to
conduct the SimpliDerm Business as presently conducted. None of the Excluded Assets are material to the SimpliDerm Business. Seller has
never commercialized, manufactured, distributed, sold and/or marketed the Seller Products for any use other than solely for use in the
field of breast reconstruction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B>3.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B> <B><U>Intellectual Property; Information Systems</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Schedule&#8239;3.5(a)</U>&#8239;(i)&#8239;sets
forth an accurate and complete list of all registered Marks, Net Names, Patents, and Copyrights, and material unregistered Marks and
Copyrights, that comprise the Seller IP Rights owned or used in connection with the SimpliDerm Business, or any Purchased Asset, and
(ii)&#8239;indicates for any such registered Seller IP Right, where applicable, the jurisdictions, dates issued, dates filed, registration
numbers, and the owners of record. Seller owns all right, title, and interest in and to all Seller IP Rights, free and clear of all Encumbrances
(other than Permitted Encumbrances). In each case in which Seller has acquired, other than through a license, any Intellectual Property
Rights from any Person with respect to the SimpliDerm Business or any Purchased Asset, Seller obtained a valid and enforceable assignment
sufficient to irrevocably transfer all rights in and to such Intellectual Property Rights to Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Seller IP Rights and, to the Knowledge of Seller, all Intellectual Property Rights licensed, used, or exploited by Seller with respect
to the SimpliDerm Business or any Purchased Asset are valid and subsisting, in full force and effect, and have not been cancelled, expired,
or abandoned. Neither the execution and delivery of any of the Transaction Documents nor the consummation and performance of the Transactions
will (i)&#8239;result in the loss or impairment of Buyer&rsquo;s right to own, license, use, and exploit any of the Seller IP Rights,
as compared to such rights of Seller as of the date immediately prior to the Closing Date or (ii)&#8239;obligate Buyer to pay any royalties
or other amounts to any Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Seller
is not infringing, misappropriating, diluting, or violating any of the Intellectual Property Rights of another Person and, to the Knowledge
of Seller, no Person is infringing, misappropriating, diluting, or violating any of the Seller IP Rights. Seller has not received any
written communications with respect to the SimpliDerm Business in the past five years (i)&#8239;alleging that Seller has infringed, misappropriated,
diluted, or violated any Intellectual Property Rights of any Person, or (ii)&#8239;that have offered to license or grant any other rights
or immunities under any Intellectual Property Rights of any Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All
Information Systems used by Seller with respect to the SimpliDerm Business (i)&#8239;operate and perform in all material respects as necessary
for the conduct of the SimpliDerm Business as currently conducted and in accordance with their documentation and functional specifications
and (ii)&#8239;are free from all computer programs, instructions, routines, features, and code intended to, or that have the ability to,
disable or interfere with the operations of the Information Systems, including viruses, worms, Trojan horses, time bombs, spyware, and
other types of malware. Seller has commercially reasonable information security safeguards in place to maintain the confidentiality,
integrity, and availability of the information stored, processed, and/or transmitted by the Information Systems that are used to conduct
the SimpliDerm Business. Seller has not allowed unauthorized access, acquisition, disclosure, or use of any of the foregoing. Seller
has in place adequate disaster recovery plans, procedures, and facilities to ensure the ongoing operation and performance of the SimpliDerm
Business in the event of a disruption to the Information Systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B>3.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B> <B><U>Material Customers and Material Suppliers.</U></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Schedule&#8239;3.6(a)-1</U>
sets forth an accurate and complete list of all of the customers of the SimpliDerm Business during the twelve (12) month periods ended
December&#8239;31, 2024 and December&#8239;31, 2025, and during the three (3)-month period ended March&#8239;31, 2026 (collectively, the
 &ldquo;<U>Material Customers</U>&rdquo;), and the amount of revenue attributable to each Material Customer that was generated for Seller
with respect to the SimpliDerm Business during each such period. Except as set forth on <U>Schedule 3.6(a)-2</U>, Seller has not received
any written notice that any of the Material Customers has ceased to use Seller&rsquo;s goods or services or intends to not use Buyer&rsquo;s
goods or services after the Closing or otherwise not continue such Material Customer&rsquo;s relationship with Buyer in substantially
the same manner after the Closing as with Seller prior to the Closing. Seller has not received from any Material Customer or given to
any Material Customer any written notice of force majeure, impossibility of performance, frustration of purpose, or similar written notice
of non-performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Schedule&#8239;3.6(b)-1</U>
sets forth an accurate and complete list of all of the suppliers and vendors of the SimpliDerm Business during the twelve (12) month
periods ended December&#8239;31, 2024 and December&#8239;31, 2025, and during the three (3)-month period ended March&#8239;31, 2026 (collectively,
the &ldquo;<U>Material Suppliers</U>&rdquo;), and the dollar amount of purchases from or spent with each Material Supplier by the SimpliDerm
Business during each such period. Except as set forth on <U>Schedule 3.6(b)-2</U>, Seller has not received any written notice that there
will be any material increase in the price of any supplies, merchandise, or other goods and services, or that any Material Supplier will
not sell or provide such supplies, merchandise, or other goods and services to Buyer at any time after the Closing on terms and conditions
substantially similar to those terms and conditions offered to Seller immediately prior to the Closing, subject to general and customary
price increases. Seller has not received from any Material Supplier or given to any Material Supplier any written notice of force majeure,
impossibility of performance, frustration of purpose, or similar written notice of non-performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Distributor
Agreements</U></B>. <U>Schedule 3.7</U> sets forth an accurate and complete list of all current and former distributor, distribution,
reseller, and sales representative Contracts relating to the Seller Products (collectively, the &ldquo;<U>Distributor Agreements</U>&rdquo;).
Seller has provided to Buyer accurate and complete copies of all such Distributor Agreements. Except as set forth on <U>Schedule 3.7</U>,
(a)&#8239;there are no surviving obligations, restrictions, non-compete or exclusivity provisions, minimum purchase requirements, or other
continuing obligations under any terminated or expired Distributor Agreement that could restrict or adversely affect Buyer&rsquo;s ability
to sell, market, or distribute the Seller Products following the Closing, (b)&#8239;there are no pending or, to the Knowledge of Seller,
threatened claims, disputes, or demands from any current or former distributor or sales representative relating to the Seller Products,
including any claims for commissions, fees, damages, or other compensation, and (c)&#8239;Seller has not granted any rights to any distributor
or sales representative that would conflict with or limit Buyer&rsquo;s ownership and operation of the SimpliDerm Business following
the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Assumed
Contracts; No Defaults</U></B>. Seller has provided to Buyer accurate and complete copies of each written Assumed Contract and has provided
to Buyer an accurate and complete description of the material terms of each oral Assumed Contract. Except as set forth on <U>Schedule&#8239;3.8-1</U>,
(i)&#8239;each of the Assumed Contracts is in full force and effect, and is a legal, valid, binding, and enforceable (except as enforceability
is limited by the Enforceability Exceptions) obligation of Seller and, to the Knowledge of Seller, each other party thereto, (ii)&#8239;Seller
and, to the Knowledge of Seller, each other party to the Assumed Contracts (A)&#8239;have performed all material obligations required
to be performed by them respectively under the Assumed Contracts and (B)&#8239;are not currently, and for the prior two years have not
been, in breach of or default under the Assumed Contracts in any material respect, (iii)&#8239;Seller has not received or given any notice
of (A)&#8239;breach or default or (B)&#8239;force majeure, impossibility of performance, frustration of purpose, or similar notice of non-performance,
in each case with respect to the foregoing clauses&#8239;(iii)(A)&#8239;and (iii)(B), with respect to any Assumed Contract, and (iv)&#8239;each
Assumed Contract is assignable by Seller to Buyer in connection with the Transactions without the Consent of any Person other than those
Consents set forth on <U>Schedule&#8239;3.2(c)</U>, and such assignment will not result in a breach, default, or violation of, or give
rise to any right of termination, cancellation, or loss of any material benefit under, any such Assumed Contract. During the prior two
years, Seller has not released or waived any material rights under any Assumed Contract or any Distributor Agreement. There are no renegotiations
regarding or outstanding rights to negotiate any amounts to be paid or payable to or by Seller under any of the Assumed Contracts or
any of the Distributor Agreements, except with respect to immaterial amounts in the Ordinary Course, and no Person has made a demand
for such negotiations. Seller has disclosed all Contracts, settlements, restrictions, disputes, and obligations involving the parties
as well as any third party that could impact the manufacturing, supply, commercialization, or competition relating to the SimpliDerm
Business which, in each case, are described on <U>Schedule&#8239;3.8-2</U>. At the Closing, the Assumed Contracts and the Shared Contracts,
collectively, constitute all of the material Contracts necessary to conduct the SimpliDerm Business as presently conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Insurance</U></B>.
<U>Schedule&#8239;3.9-1</U> sets forth an accurate and complete list of all policies of insurance (including &ldquo;self-insurance&rdquo;
programs) covering any portion of the SimpliDerm Business or any of the Purchased Assets (together with all successor insurance policies,
the &ldquo;<U>Insurance Policies</U>&rdquo;). <U>Schedule&#8239;3.9-2</U> sets forth an accurate and complete list of all pending claims
under the Insurance Policies (and any predecessor insurance policies) and all claims made or paid under the Insurance Policies (and any
predecessor insurance policies) since January&#8239;1, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Product
Safety and Product Recalls</U></B>. Except as set forth on <U>Schedule&#8239;3.10</U>: (a)&#8239;all Seller Products comply in all material
respects with all applicable Legal Requirements, including all requirements of the FDA and any other applicable Governmental Authority,
(b)&#8239;there have been no product recalls, withdrawals, seizures, field corrections, or market actions (whether voluntary or otherwise)
with respect to any Seller Products, and no such actions are pending or, to the Knowledge of Seller, threatened, (c)&#8239;Seller has
not received any notice from any Governmental Authority or any other Person regarding any actual, alleged, or potential defect, failure,
or safety issue with respect to any Seller Products, (d)&#8239;there are no pending or, to the Knowledge of Seller, threatened product
liability claims, warranty claims, or similar claims relating to any Seller Products sold, distributed, or otherwise made available by
Seller, and (e)&#8239;all manufacturing, processing, packaging, labeling, and storage of Seller Products have been conducted in compliance
in all material respects with all applicable Legal Requirements, including current good manufacturing practices and current good tissue
practices, and all related quality records are accurate and complete in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B>3.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B> <B><U>Proceedings; Orders</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth on <U>Schedule 3.11(a)</U>, there is, and for the past five years there has been, no Proceeding pending or, to the Knowledge
of Seller, threatened by or against Seller, or any Affiliate of Seller (that, in each case, relates to the SimpliDerm Business or any
Purchased Asset or Assumed Liability).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;There
is no Order to which Seller is subject or bound, or any Affiliate of Seller is subject or bound (that, in each case, relates to the SimpliDerm
Business or any Purchased Asset or Assumed Liability).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Governmental
Authorizations</U></B>. Seller holds in Seller&rsquo;s name and, as applicable, has submitted, all Governmental Authorizations necessary
to own, operate, and use the Purchased Assets and carry on and conduct the SimpliDerm Business as currently conducted (collectively,
the &ldquo;<U>Seller Governmental Authorizations</U>&rdquo;). Set forth on <U>Schedule&#8239;3.12</U> is an accurate and complete list
of all of the Seller Governmental Authorizations, along with the issuance and expiration date of each of the Seller Governmental Authorizations
and the identity of the Governmental Authority that issued each of the Seller Governmental Authorizations. Each Seller Governmental Authorization
is (and, since the date of grant, has been) in good standing, valid, and in full force and effect. All quality records, regulatory files,
submissions, and correspondence relating to the Seller Governmental Authorizations and the SimpliDerm Business are accurate and complete
in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Compliance
with Legal Requirements</U></B>. Seller is, and during the past five years has been, in compliance in all material respects with all
applicable Legal Requirements applicable to the conduct of the SimpliDerm Business or the ownership and use of the Purchased Assets.
Seller has not received any notice from any Governmental Authority or other Person (that, in each case, relates to the SimpliDerm Business
or any Purchased Asset or Assumed Liability) (a)&#8239;regarding any actual, alleged, or potential violation of or failure to comply with
any Legal Requirement or (b)&#8239;requiring Seller to enter into or consent to the issuance of any cease and desist order, formal agreement,
directive, commitment, or memorandum of understanding, or to adopt any resolutions or similar undertakings. To the Knowledge of Seller,
no investigation or inquiry is being, or in the past five years has been, conducted by any Governmental Authority with respect to the
SimpliDerm Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Shared
Contracts</U></B>. <U>Schedule&#8239;3.14-1</U> sets forth an accurate and complete list of all Shared Contracts. Seller has provided
to Buyer accurate and complete copies of each Shared Contract (including all modifications, amendments, and supplements thereto and waivers
thereunder). Each of the Shared Contracts is in full force and effect, and is a legal, valid, binding, and enforceable (except as enforceability
is limited by the Enforceability Exceptions) obligation of Seller and, to the Knowledge of Seller, each other party thereto. Except as
set forth on <U>Schedule&#8239;3.14-2</U>, Seller and, to the Knowledge of Seller, each other party to the Shared Contracts (A)&#8239;have
performed all material obligations required to be performed by them respectively under the Shared Contracts and (B)&#8239;are not currently,
and for the prior two years have not been, in breach of or default under the Shared Contracts in any material respect, Seller has not
received or given any notice of (1)&#8239;breach or default or (2)&#8239;force majeure, impossibility of performance, frustration of purpose,
or similar notice of non-performance, in each case with respect to the foregoing clauses&#8239;(1)&#8239;and (2), with respect to any Shared
Contract. During the prior two years, Seller has not released or waived any material rights under any Shared Contract. There are no renegotiations
regarding or outstanding rights to negotiate any amounts to be paid or payable to or by Seller under any of the Shared Contracts, except
with respect to immaterial amounts in the Ordinary Course, and no Person has made a demand for such negotiations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B>3.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B> <B><U>FDA and Regulatory Compliance</U>.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&#8239;Seller
and, to the Knowledge of Seller, its suppliers, distributors and sales agents, hold all material Governmental Authorizations which are
required to entitle them to own, produce, manufacture, market, distribute and sell, as applicable, the Seller Products in the jurisdictions
in which they are sold by Seller from any applicable Governmental Authority that enforces medical and dental device Legal Requirements,
including the FDCA, (ii)&#8239;to the Knowledge of Seller, all such Governmental Authorizations are valid and in full force and effect
and (iii)&#8239;Seller is in compliance, in all material respects, with the terms of such Governmental Authorizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;As
to each Seller Product subject to the FDCA or similar Legal Requirements that is or has been developed, manufactured, tested, distributed
and/or marketed by or on behalf of Seller, such Seller Product is being or has been developed, manufactured, tested, distributed and/or
marketed in compliance in all material respects with all applicable requirements under the FDCA and similar foreign Legal Requirements,
as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All
material reports, documents, claims, licenses, permits, and authorizations and notices related to the Seller Products required to be
filed, maintained or furnished to the FDA or any other Governmental Authority by Seller have been so filed, maintained or furnished.
All such reports, documents, claims, licenses, permits, and authorizations and notices related to the Seller Products were complete and
accurate in all material respects on the date filed (or were corrected in or supplemented by a subsequent filing). Seller is in compliance,
in all material respects, with any applicable Legal Requirement regarding the retention of records and documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;With
respect to each Seller Product, Seller has not made any untrue statement of a material fact or fraudulent statement to the FDA or any
other Governmental Authority, failed to disclose a material fact required to be disclosed to the FDA or any other Governmental Authority,
or committed an act, made a statement, or failed to make a statement that, at the time such disclosure was made, would reasonably be
expected to cause the FDA to invoke its policy respecting &ldquo;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities,&rdquo;
set forth in 56 Fed. Reg. 46191 (September&#8239;10, 1991) or any other Governmental Authority to invoke any similar policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;There
have been no recalls, field notifications or seizures requested or ordered or, to the Knowledge of Seller, threatened by the FDA or any
other Governmental Authority with respect to any of the Seller Products. Seller has not undertaken a voluntary recall or market withdrawal
of any of the Seller Products in any of the jurisdictions in which the Seller Products are and have been sold. Seller has disclosed all
material adverse events, complaints, investigations, recalls, warning letters, regulatory correspondence, and known facts that could
reasonably be expected to result in a material regulatory action with respect to the SimpliDerm Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;During
the last five years, Seller has not received any written FDA Form&#8239;483, warning letter, untitled letter or other similar notification
in any jurisdiction with respect to the Seller Products. Seller has not received any written warning letter, written communication or
document from any Governmental Authority (or any customer of Seller) relating to any of the Seller Products that assert lack of compliance
by Seller in any material respect with any applicable Legal Requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
the Knowledge of Seller, Seller has sold the Seller Products in compliance, in all material respects, with the FDCA and if applicable,
comparable foreign Legal Requirements. Seller has not received any written notice or other written communication that (i)&#8239;the FDA
or other Governmental Authority has commenced, or threatened to initiate, any action to withdraw any PMA, premarket clearance, premarket
notification exemption, rights or other approval or request the recall of any Seller Products; (ii)&#8239;alleges any violation of applicable
Legal Requirement or any PMA by Seller with respect to any Seller Products that would reasonably be expected to result in a Seller Material
Adverse Effect; or (iii)&#8239;asserts any actual or alleged violation of, or failure to comply with the FDCA or comparable foreign Legal
Requirements, with respect to the Seller Products or their manufacture or sale that would reasonably be expected to result in a Seller
Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Schedule
3.15(h)</U>&#8239;contains a description of all FDA correspondence, inspection findings, quality events, CAPAs, deviations, and manufacturing
issues relating to the Seller Products, including the manufacturing process, and Seller has provided accurate and complete copies of
all correspondence with or to Seller, in each case, with respect to the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Business Associates</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Schedule
3.16(a)</U>&#8239;contains an accurate and complete list of all independent contractors of Seller that provide services to the SimpliDerm
Business (collectively, the &ldquo;<U>Business Associates</U>&rdquo;), setting forth for each of the Business Associates the following
information, as applicable: (i)&#8239;name; (ii)&#8239;title or position; (iii)&#8239;engagement date; (iv)&#8239;current compensation rate;
(v)&#8239;commission, bonus, or other incentive-based compensation; and (vi)&#8239;whether such Business Associate is authorized to work
as a result of a visa or other similar work authorization and, if so, the type of visa and expiration date of such work authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth on <U>Schedule&#8239;3.16(b)</U>, the engagement of each Business Associate is terminable at the will of Seller, and Seller
is not a party to any independent contractor, non-competition, or non-solicitation Contract with any current or former independent contractor
of Seller providing services to, or for the benefit of, the SimpliDerm Business. All compensation, including fees, commissions, and bonuses,
due and payable to the Business Associates for services performed have been lawfully paid in full. No Business Associate has given notice
terminating such Business Associate&rsquo;s engagement. No Business Associate is subject to any current disciplinary warnings or procedures
or any actual or threatened Proceeding with respect to the SimpliDerm Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All
Business Associates are either citizens of the United States or have the requisite authorizations to legally work in the United States.
All Business Associates characterized and treated by Seller as independent contractors are properly treated as independent contractors
under all applicable Legal Requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Seller
has not received, during the past five years, any written notice alleging that any Business Associate is (and to the Knowledge of Seller,
no Business Associate is) subject to any Contract containing covenants that in any way purport to restrict such Business Associate from
engaging in any line of business, competing with any Person, or soliciting any potential customer, supplier, distributor, lessor, lessee,
licensor, licensee, employee, independent contractor, or any other Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Seller
has not received notice of any material employment, contractor, discrimination, harassment, retaliation, wage-hour, or similar claims
relating to any individual whose services are or were material to the SimpliDerm Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B>3.17&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B> <B><U>Product Complaints and Warranty</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Seller
has provided or made available to Buyer copies of the terms and conditions of sale for each of the Seller Products, including all guaranty,
warranty, and indemnity provisions, and Seller has not given to any Person any product guaranty or warranty, right of return, or other
indemnity other than on terms that do not materially differ from such standard terms and conditions of sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth on <U>Schedule&#8239;3.17(b)</U>, (i)&#8239;each Seller Product or service rendered by Seller in the SimpliDerm Business has
been in conformity in all material respects with all applicable contractual commitments and warranties, (ii)&#8239;there are no material
design, manufacturing, or other defects, latent or otherwise, with respect to any Seller Products, and (iii)&#8239;each Seller Product
contains all warnings required by applicable Legal Requirements and such warnings are in accordance with reasonable industry practice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Schedule&#8239;3.17(c)</U>&#8239;sets
forth an accurate and complete list of all product complaints, clinical complaints, adverse event reports, medical device reports, and
similar matters received or filed by (or on behalf of) Seller with respect to the Seller Products during the past five years, together
with a description of the nature and status of each such matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B>3.18&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B> <B><U>Taxes</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Seller
has duly filed all Tax Returns required to be filed with respect to the SimpliDerm Business or any of the Purchased Assets (which are
accurate and complete in all respects) and has timely paid in full, or caused to be paid in full, all Taxes (whether or not shown on
any Tax Return) due and payable with respect to the SimpliDerm Business or any of the Purchased Assets. Seller has timely withheld and
paid all Taxes, or set aside for timely payment (in each case, with respect to the SimpliDerm Business or any Purchased Asset) required
to have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor, creditor, shareholder,
member, or other Person, and all applicable Forms W-2 and 1099 (and any state equivalent forms) have been properly completed and timely
filed with the appropriate Tax Authority. All Persons who have provided services to the SimpliDerm Business and have been classified
by Seller as independent contractors for the purposes of Tax withholding Legal Requirements were properly classified, and Seller has
fully and accurately reported their compensation on IRS Forms&#8239;1099 when required to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;A
list of all jurisdictions where Seller files Tax Returns or charges and remits sales or use Taxes (that, in each case, relates to the
SimpliDerm Business or any Purchased Asset) is set forth on <U>Schedule&#8239;3.18(b)</U>. All sales, goods and services, and value added
Taxes (that, in each case, relates to the SimpliDerm Business or any Purchased Asset) required to be collected and remitted by Seller
have been properly collected and timely remitted (or set aside for timely remittance). All sales Tax exemption certificates with respect
to the SimpliDerm Business or any of the Purchased Assets have been obtained by Seller and all such certificates have been properly completed
and maintained. Seller has not engaged in any activity with respect to the SimpliDerm Business or any Purchased Asset that has created
a taxable nexus or permanent establishment in any jurisdiction where Seller does not file Tax Returns, and no claim has been made by
any Tax Authority in a jurisdiction where Seller does not file Tax Returns with respect to the SimpliDerm Business or any Purchased Asset
that Seller is or could be subject to taxation by such jurisdiction with respect to the SimpliDerm Business or any Purchased Asset. There
are no Encumbrances (other than Permitted Encumbrances) on any of the Purchased Assets or otherwise affecting Seller that arose from
any failure (or alleged failure) to pay any Tax and, to the Knowledge of Seller, no Tax Authority is in the process of imposing any Encumbrance
(other than Permitted Encumbrances) for Taxes on any of the Purchased Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
examination or audit of any Tax Return of Seller by any Tax Authority is currently in progress or, to the Knowledge of Seller, threatened
in writing. No assessment or other Proceeding by any Tax Authority is pending or, to the Knowledge of Seller, threatened in writing with
respect to the Taxes, or Tax Returns reflecting the Taxes, of the SimpliDerm Business or any Purchased Asset. All deficiencies asserted,
or assessments made, against Seller with respect to the SimpliDerm Business or any Purchased Asset as a result of any examination relating
to Taxes by any Tax Authority have been paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Seller
has complied in all material respects with all applicable unclaimed property, abandoned property, and escheat Laws relating to the SimpliDerm
Business and the Purchased Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Seller
is not a party to or bound by any Tax indemnification agreement, Tax sharing agreement, Tax allocation agreement, or similar Contract
(other than ordinary course commercial Contracts not primarily related to Taxes), nor does Seller have any Liability or potential Liability
to another Person under any such agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Seller
has not waived or extended (or requested or been requested to waive or extend) any statute of limitations or other period for the assessment
or collection of any Tax with respect to the SimpliDerm Business or any Purchased Asset that remains in effect. No power of attorney
granted by Seller with respect to any Tax with respect to the SimpliDerm Business or any Purchased Asset is currently in force.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Seller
has not requested, and is not the subject of or bound by, any private letter ruling, technical advice memorandum, closing agreement,
offer in compromise, gain recognition agreement, or similar ruling, agreement or arrangement with any Tax Authority with respect to any
Tax with respect to the SimpliDerm Business, or any Purchased Asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Seller
has not participated in any &ldquo;listed transaction&rdquo; within the meaning of Treasury Regulations Section&#8239;1.6011-4(b)(2),
in each case, that relates to the SimpliDerm Business or any Purchased Asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Seller
has not received any written notice from any Tax Authority asserting nexus, unpaid sales Tax, or similar material Tax liability relating
to the SimpliDerm Business. Seller is not party to any voluntary disclosure agreement, amnesty program, or settlement arrangement with
respect to Taxes of the SimpliDerm Business or the Purchased Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Seller Products are and have always been exempt from sales and use Tax, and Seller is not and has never had any registered sales and
use Tax accounts in any jurisdiction applicable to the Seller Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.19&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Personal
Information</U></B>. Seller is, and during the past five years has been, in compliance in all material respects with, in each case, with
respect to the SimpliDerm Business or any Purchased Asset, (a)&#8239;all applicable Legal Requirements regarding Personal Information
(&ldquo;<U>Privacy Laws and Standards</U>&rdquo;) and (b)&#8239;all of the Seller Contracts and such Seller&rsquo;s internal and external
policies and procedures (collectively, the &ldquo;<U>Seller Privacy Requirements</U>&rdquo;) relating to (i)&#8239;the privacy and protection
of Personal Information, including the privacy of users of Seller Sites, and (ii)&#8239;the access, use, collection, storage, maintenance,
disclosure, transfer, and any other processing of any Personal Information accessed, used, collected, stored, maintained, disclosed,
transferred, or otherwise processed by or for Seller or by or for any other Persons having authorized access to the records of Seller.
Upon the execution and delivery of the Transaction Documents and consummation and performance of the Transactions, Buyer will have the
right to access, use, collect, store, maintain, disclose, transfer, and process Personal Information held by Seller as of immediately
prior to the Closing on substantially the same terms as Seller as of immediately prior to the Closing. All Seller Sites and all materials
distributed or marketed by Seller, in each case, with respect to the SimpliDerm Business or any Purchased Asset, have at all times made
all disclosures to users or customers required by Privacy Laws and Standards and the Seller Privacy Requirements, and none of such disclosures
made or contained in any of the Seller Sites or in any such materials has been inaccurate, misleading, or deceptive or in violation of
any Privacy Laws and Standards or Seller Privacy Requirements. Seller has at all times taken all steps reasonably necessary (including
implementing and monitoring compliance with adequate measures with respect to technical and physical security) to ensure that Personal
Information is protected against loss and against unauthorized access, use, collection, storage, maintenance, disclosure, transfer, modification,
or other misuse, and there has been no unauthorized access, use, collection, storage, maintenance, disclosure, transfer, modification,
or other misuse of such Personal Information. The execution, delivery, and performance of the Transaction Documents and the consummation
and performance of the Transactions comply with all Privacy Laws and Standards and Seller Privacy Requirements. No Proceeding is pending
or has otherwise been made, asserted, or, to the Knowledge of Seller, threatened against Seller by any Person alleging a violation of
such Person&rsquo;s privacy or personal or confidentiality rights under any Privacy Laws and Standards or Seller Privacy Requirements.
Seller has not received any complaint regarding Seller&rsquo;s use, collection, storage, maintenance, disclosure, transfer, or processing
of Personal Information. Seller has disclosed all actual or suspected security incidents, data breaches, ransomware incidents, privacy
complaints, OCR investigations, and reportable privacy events related to the SimpliDerm Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.20&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Related
Persons</U></B>. Except as set forth on <U>Schedule&#8239;3.20</U>, no Related Person (a)&#8239;is or, at any time on or after January&#8239;1,
2022, has been, directly or indirectly, an owner of more than five percent, or an Affiliate, of any Material Customer or Material Supplier,
or otherwise involved in any business arrangement or relationship with the SimpliDerm Business or any Material Customer or Material Supplier,
other than employment arrangements with Seller entered into in the Ordinary Course, (b)&#8239;owns, or on or after January&#8239;1,&#8239;2022
has owned, directly or indirectly, any material Asset or right, tangible or intangible, used by Seller in the SimpliDerm Business, or
(c)&#8239;is engaged, or at any time has engaged, directly or indirectly, in competition with Seller or the SimpliDerm Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.21&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Absence
of Certain Changes, Events and Conditions</U></B>. During the period from and including January&#8239;1, 2026 through the present, (a)&#8239;Seller
has (i)&#8239;conducted the SimpliDerm Business solely in the Ordinary Course and (ii)&#8239;used commercially reasonable efforts to (A)&#8239;maintain,
keep, and preserve Seller&rsquo;s Assets in good condition and repair, (B)&#8239;preserve the SimpliDerm Business intact, (C)&#8239;keep
available the services of Seller&rsquo;s employees and independent contractors, and (D)&#8239;preserve the goodwill of Seller&rsquo;s
customers, suppliers, distributors, lessors, lessees, licensors, licensees, creditors, employees, and independent contractors, as well
as all others having business dealings or relations with Seller, and (b)&#8239;there has not been any Seller Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.22&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Brokers
or Finders</U></B>. No investment banker, financial advisor, broker, finder, or other intermediary has been retained by or is authorized
to act on behalf of Seller that could be entitled to any fee, commission, or other similar payment from Buyer, Seller, or any of their
respective Affiliates with respect to the Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.23&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>SEC
Filings</U></B>. Since January&#8239;1, 2022, Seller has filed or furnished, as applicable, all reports, schedules, forms, proxy statements,
or other documents required to be filed or furnished by Seller with the United States Securities and Exchange Commission (collectively,
the &ldquo;<U>Seller SEC Documents</U>&rdquo;). As of their respective filing or furnishing dates (or, if amended or superseded by a
subsequent filing or furnishing prior to the Execution Date, as of the date of the last such amendment or superseding filing or furnishing),
none of the Seller SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be
stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading,
in each case, with respect to the SimpliDerm Business. All information and documents relating to the SimpliDerm Business made available
to Buyer through the Virtual Data Room are, in all material respects, true, accurate and complete and do not omit any material fact necessary
to make such information, taken as a whole, misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.24&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Inspections;
Limitation of Buyer&rsquo;s Warranties</U></B>. In entering into this Agreement and the other Transaction Documents, Seller relied solely
upon its own investigation and analysis and the representations and warranties expressly contained in <U>ARTICLE&#8239;IV</U> and the
other Transaction Documents and no other representations or warranties of Buyer, any of its Affiliates or any other Person, either express
or implied, and Seller, on its own behalf and on behalf of its Affiliates and Representatives, acknowledges, represents, warrants and
agrees that, other than those representations and warranties expressly set forth in <U>ARTICLE&#8239;IV</U> (in each case, as qualified
by the Disclosure Schedules) and the other Transaction Documents, neither Buyer, nor any of its Affiliates, Representatives nor any other
Person makes or has made any representation or warranty on behalf of Buyer, either express or implied, (i)&#8239;as to the accuracy or
completeness of any of the information provided or made available to Seller or any of its Affiliates or Representatives or financing
sources (including lenders) prior to the execution of this Agreement (and has relied solely on such express representations and warranties
in <U>ARTICLE&#8239;IV</U> and the other Transaction Documents) or (ii)&#8239;with respect to any projections, forecasts, estimates, plans
or budgets of future revenues, expenses or expenditures, future results of operations (or any component thereof), future cash flows (or
any component thereof) or future financial condition (or any component thereof) of Buyer or the SimpliDerm Business heretofore or hereafter
delivered to or made available to Seller or any of its Affiliates or Representatives or financing sources (including lenders) (and has
relied solely on such express representations and warranties in <U>ARTICLE&#8239;IV</U> and the other Transaction Documents). Without
limiting the generality of the foregoing, Seller, on its own behalf and on behalf of its Affiliates and each of its Representatives,
acknowledges, represents, warrants and agrees that neither Buyer nor any of its Affiliates or Representatives or any other Person makes
or has made, and shall not be deemed to have made, any representations or warranties in the materials relating to the business, assets
or liabilities of Buyer (including the SimpliDerm Business after the Closing) made available to Seller, including due diligence materials,
memorandum or similar materials, or in any presentation of the business of Buyer (including the SimpliDerm Business after the Closing)
by management or other Representatives of Buyer, any of its Affiliates or others in connection with the Transactions, and no statement
contained in any such materials or made in any such presentation shall be deemed a representation or warranty hereunder other than the
express representations and warranties in <U>ARTICLE&#8239;IV</U> and the other Transaction Documents. It is understood that any cost
estimates, projections or other predictions, any data, any financial information or any memoranda or offering materials or presentations,
including but not limited to, any offering memorandum or similar materials made available to Seller and its Representatives and advisors
are not and shall not be deemed to be or to include representations or warranties of Buyer (including the SimpliDerm Business after the
Closing) or any of its Affiliates other than the express representations and warranties in <U>ARTICLE&#8239;IV</U> and the other Transaction
Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&#8239;IV<BR>
REPRESENTATIONS AND WARRANTIES OF BUYER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Buyer hereby represents and
warrants to Seller as of the Execution Date as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Organization
and Good Standing</U></B>. Buyer is a corporation duly incorporated, validly existing, and in good standing under the Legal Requirements
of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B>4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B> <B><U>Authority; No Conflict</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This
Agreement has been duly and validly executed by Buyer, and this Agreement (assuming due authorization, execution, and delivery by Seller)
constitutes the legal, valid, and binding obligation of Buyer, enforceable against Buyer in accordance with its terms, except as enforceability
is limited by the Enforceability Exceptions. Upon the delivery and execution by Buyer of each of the Buyer Closing Documents to which
Buyer is a party, each of such Buyer Closing Documents (assuming due authorization, execution, and delivery by the other party or parties
thereto, if applicable) will constitute the legal, valid, and binding obligation of Buyer, enforceable against Buyer, as applicable,
in accordance with the terms thereof, except as enforceability is limited by the Enforceability Exceptions. Buyer has the right, power,
and authority to execute and deliver this Agreement and the Buyer Closing Documents to which Buyer is a party and to perform Buyer&rsquo;s
obligations under this Agreement and the Buyer Closing Documents to which Buyer is a party, and such actions have been duly authorized
by all necessary corporate action by Buyer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Neither
the execution, delivery, or performance of any of the Transaction Documents by Buyer nor the consummation or performance of any of the
Transactions by Buyer will, directly or indirectly (with or without notice or lapse of time or both) (i)&#8239;contravene, conflict with,
or result in a violation or breach of any provision of any of the Governance Documents of Buyer, (ii)&#8239;contravene, conflict with,
or result in a violation or breach of any Legal Requirement to which Buyer is subject, except for any such contravention, conflict, violation,
or breach, in each case, that would not reasonably be expected to cause a Buyer Material Adverse Effect, or (iii)&#8239;contravene, conflict
with, or result in a violation or breach of, constitute a default under, or give any Person the right to declare a default or exercise
any remedy under, accelerate the maturity or performance of or payment under, or cancel, terminate, or modify any material Contract to
which Buyer is party to or which Buyer&rsquo;s Assets are bound, except for any such contravention, conflict, violation, breach, default,
remedy, acceleration, cancellation, termination, or modification that would not reasonably be expected to cause a Buyer Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Buyer
is not required to give any notice to, make any Filing with, or obtain any Consent from any Person in connection with the execution,
delivery, and performance of any of the Transaction Documents or the consummation and performance of the Transactions, except for any
such notice, Filing, or Consent (i)&#8239;that has already been given, made, or obtained or will be given, made, or obtained as of the
Closing, or (ii)&#8239;where the failure to give such notice, make such Filing, or obtain such Consent, in each case, would not reasonably
be expected to cause a Buyer Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Brokers
or Finders</U></B>. No investment banker, financial advisor, broker, finder, or other intermediary has been retained by or is authorized
to act on behalf of Buyer that could be entitled to any fee, commission, or other similar payment from Buyer, Seller, or any of their
respective Affiliates with respect to the Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Inspections;
Limitation of Seller&rsquo;s Warranties</U></B>. In entering into this Agreement and the other Transaction Documents, Buyer relied solely
upon its own investigation and analysis and the representations and warranties expressly contained in <U>ARTICLE&#8239;III</U> (in each
case, as qualified by the Disclosure Schedules) and the other Transaction Documents and no other representations or warranties of Seller,
any of its Affiliates or any other Person, either express or implied, and Buyer, on its own behalf and on behalf of its Affiliates and
Representatives, acknowledges, represents, warrants and agrees that, other than those representations and warranties expressly set forth
in <U>ARTICLE&#8239;III</U> (in each case, as qualified by the Disclosure Schedules) and the other Transaction Documents, neither Seller,
nor any of its Affiliates, Representatives nor any other Person makes or has made any representation or warranty on behalf of Seller,
either express or implied, (i)&#8239;as to the accuracy or completeness of any of the information provided or made available to Buyer
or any of its Affiliates or Representatives or financing sources (including lenders) prior to the execution of this Agreement (and has
relied solely on such express representations and warranties in <U>ARTICLE&#8239;III</U> (in each case, as qualified by the Disclosure
Schedules) and the other Transaction Documents) or (ii)&#8239;with respect to any projections, forecasts, estimates, plans or budgets
of future revenues, expenses or expenditures, future results of operations (or any component thereof), future cash flows (or any component
thereof) or future financial condition (or any component thereof) of the SimpliDerm Business heretofore or hereafter delivered to or
made available to Buyer or any of its Affiliates or Representatives or financing sources (including lenders) (and has relied solely on
such express representations and warranties in <U>ARTICLE&#8239;III</U> (in each case, as qualified by the Disclosure Schedules) and the
other Transaction Documents). Without limiting the generality of the foregoing, Buyer, on its own behalf and on behalf of its Affiliates
and each of its Representatives, acknowledges, represents, warrants and agrees that neither the Seller nor any of its Affiliates or Representatives
or any other Person makes or has made, and shall not be deemed to have made, any representations or warranties in the materials relating
to the business, assets or liabilities of the SimpliDerm Business made available to Buyer, including due diligence materials, memorandum
or similar materials, or in any presentation of the business of the SimpliDerm Business by management or other Representatives of the
SimpliDerm Business, Seller, any of its Affiliates or others in connection with the Transactions, and no statement contained in any such
materials or made in any such presentation shall be deemed a representation or warranty hereunder other than the express representations
and warranties in <U>ARTICLE&#8239;III</U> (in each case, as qualified by the Disclosure Schedules) and the other Transaction Documents.
It is understood that any cost estimates, projections or other predictions, any data, any financial information or any memoranda or offering
materials or presentations, including but not limited to, any offering memorandum or similar materials made available to Buyer and its
Representatives and advisors are not and shall not be deemed to be or to include representations or warranties of the SimpliDerm Business
or Seller or any of its Affiliates other than the express representations and warranties in <U>ARTICLE&#8239;III</U> (in each case, as
qualified by the Disclosure Schedules) and the other Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&#8239;V</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRE-CLOSING COVENANTS AND AGREEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Access
and Investigation</U></B>. During the Executory Period, Seller shall, if and as reasonably requested by Buyer, (a)&#8239;provide Buyer
and Buyer&rsquo;s Representatives with reasonable access, during normal business hours, to the SimpliDerm Business, the Purchased Assets,
and the Assumed Liabilities, (b)&#8239;furnish and make available to Buyer and Buyer&rsquo;s Representatives such financial, operating,
and other data and information relating to any of the SimpliDerm Business, the Purchased Assets, or the Assumed Liabilities as Buyer
or any of Buyer&rsquo;s Representatives reasonably request, and (c)&#8239;cause Seller&rsquo;s Representatives to cooperate with Buyer
and Buyer&rsquo;s Representatives in Buyer&rsquo;s investigation of the SimpliDerm Business, the Purchased Assets, and the Assumed Liabilities.
During the Executory Period and commencing with the month ended June&#8239;30, 2026, Seller shall, within 30 days (or, solely with respect
to the month ending June&#8239;30, 2026 (and the month ending September&#8239;30, 2026 if Closing has not occurred prior to such date),
within 45 days) after the end of each month, deliver to Buyer a copy of the unaudited financial statements of the SimpliDerm Business
(including the sales register) as of and for the end of such month (collectively, the &ldquo;<U>Monthly Financial Statements</U>&rdquo;),
and each Monthly Financial Statement shall be prepared in substantially the same manner and form as the Interim Financial Statements.
No later than five Business Days after the Execution Date, Seller shall deliver the Monthly Financial Statements for the months ended
April&#8239;30, 2026 and May&#8239;31, 2026. If the Closing Date occurs after the tenth calendar day of any month, then Seller shall also
provide the sales register for each full month prior to the Closing to the extent that Seller has not yet provided the Monthly Financial
Statements for such month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B>5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B> <B><U>Conduct of the SimpliDerm Business by Seller During Executory Period</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;During
the Executory Period, Seller shall (i)&#8239;conduct the SimpliDerm Business solely in the Ordinary Course, (ii)&#8239;maintain, keep,
and preserve the Assets associated with, related to, used, held for use, or otherwise useful in connection with the SimpliDerm Business
in good condition and repair, (iii)&#8239;use commercially reasonable efforts to (A)&#8239; preserve the SimpliDerm Business intact, (B)&#8239;keep
available the services of the Key Personnel and Business Associates, (C)&#8239;preserve the goodwill of the SimpliDerm Business&rsquo;s
customers, suppliers, distributors, lessors, lessees, licensors, licensees, creditors, and independent contractors, as well as others
having business dealings or relations with the SimpliDerm Business and (D)&#8239;preserve relationships with all Material Customers, Material
Suppliers, GPOs,&#8239;IDNs, and distributors, and (iv)&#8239;maintain customer relationships, supply arrangements, pricing, commercial
policies and operating performance consistent with the business and financial performance of the SimpliDerm Business in Q1 2026. Seller
shall use commercially reasonable efforts to maintain the revenue, gross margin and EBITDA of the SimpliDerm Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Without
limiting the generality of the foregoing, during the Executory Period, except (i)&#8239;as otherwise expressly provided in this Agreement,
or (ii)&#8239;as expressly consented to in writing by Buyer (such consent to be given at Buyer&rsquo;s discretion), Seller shall not (A)&#8239;release
any Person from, or modify or waive any provision of, any non-competition, confidentiality, or non-solicitation related to the SimpliDerm
Business, (B)&#8239;acquire or otherwise obtain or sell or otherwise dispose of any of the Purchased Assets (or, had such Assets been
acquired or obtained prior to the Execution Date, would have constituted Purchased Assets), (C)&#8239;take any action, permit any action
to be taken, or omit from taking any action, in each case, that would cause any of the changes, events, or conditions described in <U>Section&#8239;3.21</U>
to occur, in each case, with respect to the SimpliDerm Business, or (D)&#8239;authorize, or enter into any Contract to do, any of the
foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exclusivity</U></B>.
During the Executory Period, Seller shall not, and Seller shall cause each of its Affiliates and the respective Representatives of Seller
and each of its Affiliates not to, directly or indirectly, (i)&#8239;initiate, solicit, entertain, discuss, encourage, facilitate, respond
to, or accept any inquiries or the making of any proposals or offers (including by providing any non-public information) from any Person
(other than Buyer and Buyer&rsquo;s Representatives acting on behalf of Buyer) concerning (A)&#8239;any transfer, sale, or license of
all or any portion of the Assets associated with, related to, used, held for use, or otherwise useful in connection with the SimpliDerm
Business (other than the sale of inventory in the Ordinary Course), or (B)&#8239;any acquisition, business combination, amalgamation,
change of control, merger, or other similar transaction involving the SimpliDerm Business, whether structured as an Asset sale, equity
sale, merger, tender offer, or otherwise (collectively, an &ldquo;<U>Acquisition Proposal</U>&rdquo;), (ii)&#8239;have any discussion
(other than to provide notice as to the existence of the obligations under this <U>Section&#8239;5.3</U>) with or provide any information
to any Person (other than Buyer and Buyer&rsquo;s Representatives acting on behalf of Buyer) relating, directly or indirectly, to any
Acquisition Proposal, (iii)&#8239;approve or recommend, or propose to approve or recommend, whether publicly or to any director, manager,
shareholder, member, or owner of Seller, any Acquisition Proposal, or (iv)&#8239;approve or recommend, or propose to approve or recommend,
or execute or enter into, any letter of intent, agreement in principal, merger agreement, acquisition agreement, option agreement, or
other similar Contract (whether or not binding) related to any Acquisition Proposal, or propose, whether publicly or to any director,
manager, shareholder, member, or owner of Seller, or agree to do any of the foregoing related to any Acquisition Proposal. Seller shall
immediately notify Buyer in writing if Seller or any of its Affiliates or any of the respective Representatives of Seller or any of its
Affiliates receives any proposals, offers, or requests for information with respect to an Acquisition Proposal, and shall provide Buyer
with copies of all written communications with respect to any such proposals, offers, or requests for information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notification
of Certain Matters</U></B>. During the Executory Period, each Party (as applicable, the &ldquo;<U>Notifying Party</U>&rdquo;) shall promptly
notify the other Party (the &ldquo;<U>Notified Party</U>&rdquo;) of (a)&#8239;any notice or other communication from or with any Governmental
Authority in connection with the Transactions, (b)&#8239;any notice from any Person alleging that the Consent of such Person is or could
be required in connection with any of the Transaction Documents or the Transactions, (c)&#8239;any Proceeding commenced or threatened
against the Notifying Party in connection with any of the Transaction Documents or the Transactions, (d)&#8239;any Order issued or threatened
to be issued against the Notifying Party in connection with any of the Transaction Documents or the Transactions, (e)&#8239;the occurrence
of any event or the existence of any fact or circumstance that causes, or would reasonably be expected to cause, any representation or
warranty of the Notifying Party contained in this Agreement to be untrue or inaccurate at or prior to the Closing, or (f)&#8239;any failure
of the Notifying Party to comply with any of the Notifying Party&rsquo;s covenants, obligations, or agreements contained in this Agreement.
Notwithstanding anything in this Agreement to the contrary, the delivery of any notice by the Notifying Party and the information or
knowledge obtained by the Notified Party pursuant to this <U>Section&#8239;5.4</U> will not (i)&#8239;affect or modify, or be deemed to
affect or modify, any representation, warranty, covenant, obligation, or agreement contained in this Agreement, the conditions to the
obligations of the Parties to consummate the Closing in <U>Article&#8239;VII</U>, or otherwise prejudice in any way the rights and remedies
of the Notified Party under this Agreement, including pursuant to <U>Article&#8239;VIII</U>, (ii)&#8239;affect or modify, or be deemed
to affect or modify, the Notified Party&rsquo;s reliance on the representations, warranties, covenants, obligations, and agreements made
by the Notifying Party in this Agreement, or (iii)&#8239;amend or supplement, or be deemed to amend or supplement, the Schedules or prevent
or cure any misrepresentation, breach of warranty, or breach of covenant, obligation, or agreement by the Notifying Party. Notwithstanding
the generality of the foregoing, Seller shall promptly notify Buyer of any material development involving any Material Supplier, Material
Customer, contract manufacturer, distributor, Governmental Authority or regulatory authority that could reasonably be expected to adversely
affect the SimpliDerm Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notices,
Consents, and Filings</U></B>. As promptly as practicable after the Execution Date (and, in any event, no later than ten Business Days
after the Execution Date), Seller shall give all notices and make all Filings and request all Consents and Governmental Authorizations
set forth on <U>Schedule&#8239;3.2(c)</U>&#8239;other than Consents required for Shared Contracts. As promptly as practicable after the
Execution Date, Seller shall use Seller&rsquo;s reasonable best efforts to obtain, or cause to be obtained, all Consents and Governmental
Authorizations that are or become required in connection with the execution, delivery, and performance of this Agreement or any of the
other Transaction Documents to which Seller is a party and the consummation and performance of the Transactions, including all Consents
and Governmental Authorizations set forth on <U>Schedule&#8239;3.2(c)</U>&#8239;other than Consents for Shared Contracts. Buyer shall reasonably
cooperate with Seller in seeking to obtain such Consents and Governmental Authorizations. To the fullest extent permitted by applicable
Legal Requirements, the Parties shall jointly agree upon the form of the notices, Filings, and Consents contemplated by this <U>Section&#8239;5.5</U>,
and shall promptly provide the other Party with copies of all such notices, Filings, and Consents. Seller shall provide Buyer with periodic
updates on the status of each notices, Filings, and Consents contemplated by this <U>Section&#8239;5.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Loss
Proceeds</U></B>. Notwithstanding anything in this Agreement to the contrary, if, prior to the Closing, any of the Purchased Assets,
or any other Assets associated with, related to, used, held for use, or otherwise useful in connection with the SimpliDerm Business that,
but for any such taking, sale, destruction, or condemnation, would have been a Purchased Asset, is taken by eminent domain (or is sold
in lieu thereof), is the subject of a pending taking, or is destroyed or condemned, then Seller shall give Buyer prompt written notice
of any such event. Seller shall not (a)&#8239;settle or compromise or agree to any settlement or compromise of any insurance proceeds
or condemnation claim or award (&ldquo;<U>Loss Proceeds</U>&rdquo;) or (b)&#8239;use the Loss Proceeds for any purpose (including the
restoration or repair of such Assets), in each such case, without the prior written consent of Buyer (such consent not to be unreasonably
withheld, conditioned or delayed). Subject to the foregoing sentence, Seller shall reserve all Loss Proceeds in a segregated account
and not commingle any Loss Proceeds with other funds and all such Loss Proceeds will be deemed a Purchased Asset and the property of
Buyer following the Closing without the payment of any additional consideration therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Commercially
Reasonable Efforts</U></B>. Subject to the terms of this Agreement and except where a different standard is expressly set forth in this
Agreement, each Party shall use such Party&rsquo;s commercially reasonable efforts to take, or cause to be taken, all actions and to
do, or cause to be done, all things necessary or desirable under applicable Legal Requirements to consummate the Transactions and to
cause all of the conditions precedent to each other Party&rsquo;s obligations set forth in <U>Article&#8239;VII</U> to be satisfied. Seller
shall use commercially reasonable efforts to extend the expiration dates of each GPO agreement and IDN agreement relating to any and
all Seller Products that are included in the Purchased Assets, each of which is set forth on <U>Schedule 5.7</U>, to a date that is twelve
(12) months from the effective date of the applicable renewal or extension of such GPO agreement or IDN agreement. Seller&rsquo;s obligation
to use commercially reasonable efforts shall remain in full force and effect until each GPO agreement and IDN agreement set forth on
<U>Schedule 5.7</U> is either extended (in accordance with this <U>Section&#8239;5.7</U>), terminated, or renewed. Seller obtaining such
extensions shall not be a condition to Buyer&rsquo;s obligation to consummate the Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Updates
to Annexes</U></B>. During the Executory Period, Seller shall notify Buyer in writing prior to (if practicable) or promptly after (if
prior written notice is not practicable) the occurrence of any of the following: (a)&#8239;any acquisition of any Assets that are to constitute
Purchased Assets; (b)&#8239;any disposition of any Assets that were to constitute Purchased Assets; or (c)&#8239;any acquisition of Assets
that are to constitute Excluded Assets (the foregoing clauses (a)&#8239;through (c)&#8239;in no way limit or otherwise modify Seller&rsquo;s
obligations in this Agreement or in any other Transaction Document, including <U>Section&#8239;5.2</U>). During the Executory Period,
the Parties shall, upon the written request of Buyer, from time to time update (i)&#8239;<U>Annex&#8239;B</U> to include those Assets that
are to constitute Purchased Assets and that are acquired by Seller prior to the Closing (subject to the other provisions of this Agreement,
including <U>Section&#8239;5.2</U>) and that Buyer desires to include as Purchased Assets and to remove those Assets that were to constitute
Purchased Assets and that are disposed of by Seller prior to the Closing (subject to the other provisions of this Agreement, including
<U>Section&#8239;5.2</U>) and that Buyer desires to remove as Purchased Assets; and (ii)&#8239;<U>Annex&#8239;C</U> to include those Assets
that are to constitute Excluded Assets and that are acquired by Seller prior to the Closing (subject to the other provisions of this
Agreement, including <U>Section&#8239;5.2</U>) and that Buyer desires to include as Excluded Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&#8239;VI<BR>
ADDITIONAL COVENANTS AND AGREEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Shared
Contracts; Key Personnel</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as otherwise set forth on <U>Schedule&#8239;6.1(a)</U>, Seller shall use its commercially reasonable efforts to cause the Shared Contracts
to be assigned in whole or in part or otherwise replaced with separate contracts that are substantially the same (and, in any event,
no worse for Buyer than) the terms of the applicable Shared Contracts so that (i)&#8239;Buyer shall be entitled to the rights and benefits
and shall assume the related portion of any Liabilities, inuring to the SimpliDerm Business or the Seller Products to the same extent
received and borne by Seller in accordance with such Shared Contract prior to such assignment or separation; <U>provided</U> that Buyer
shall assume Liabilities under such Shared Contracts solely to the extent that such Liabilities would constitute Assumed Liabilities
if the portion of the Shared Contract inuring to the SimpliDerm Business and Seller Products had constituted an Assumed Contract that
had been transferred to Buyer and (ii)&#8239;Seller shall be entitled to the rights and benefits, and shall assume the related portion
of any Liabilities, inuring to the Excluded Assets or the Retained Business (other than the SimpliDerm Business) to the same extent received
and borne in accordance with such Shared Contract prior to such separation or assignment. In the event any Shared Contract cannot be
so partially assigned by its terms or otherwise, or cannot be amended or separated (which, for the avoidance of doubt, shall include
any Contract with any Supplier), then the Parties shall take such other reasonable and legally permissible actions (including by providing
prompt notice to the other Party with respect to any relevant claim of Liability or other relevant matters arising in connection with
a Shared Contract so as to allow such other party the ability to exercise any applicable rights under such Shared Contract) to cause
Buyer to receive the rights and benefits of that portion of each Shared Contract that relates to the SimpliDerm Business or Seller Products,
as the case may be (in each case, to the extent so related), as if such Shared Contract had been assigned to (or amended to allow assignment
to) Buyer pursuant to this <U>Section&#8239;6.1(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Seller
shall make the individuals listed on <U>Schedule 6.1(b)</U>&#8239;(the &ldquo;<U>Key Personnel</U>&rdquo;) available to Buyer. Seller
shall ensure the continued availability of the Key Personnel throughout the Technology Transfer and transition services periods contemplated
by this Agreement and the TSA. Seller shall ensure that personnel possessing material knowledge relating to manufacturing, quality, regulatory
affairs, product specifications, technology transfer, customer relationships, distributor relationships, GPO agreements,&#8239;IDN agreements,
and commercialization of the Seller Products remain reasonably available to support Buyer during the term of the Technology Transfer,
TSA, and any other agreed transition period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B>6.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B> <B><U>Proration of Taxes; Bulk Sales</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
the case of any taxable period beginning before and ending after the Closing Date, the portion of any personal property Tax or other
applicable non-income Tax (&ldquo;<U>Prorated Taxes</U>&rdquo;) attributable to the Purchased Assets or the SimpliDerm Business shall
be prorated between Buyer and Seller on a per diem basis with Seller being responsible for any such Prorated Tax attributable to the
period ending at the end of the day of the Closing Date and Buyer responsible for any such Prorated Tax attributable to the period commencing
after the Closing Date. Prorated Taxes shall be timely paid, and any Tax Return with respect to any Prorated Tax shall be prepared, by
the Party responsible for filing any such Tax Return under applicable Law. The paying Party shall be entitled to reimbursement from the
non-paying Party in accordance with this <U>Section&#8239;6.2(a)</U>. Upon payment of any Prorated Tax, the paying Party shall present
a statement to the non-paying Party setting forth the amount of reimbursement to which the paying Party is entitled under this <U>Section&#8239;6.2(a)</U>,
together with such supporting evidence (such as a receipt of payment from an applicable Tax Authority or other written confirmation of
payment) as is reasonably necessary to calculate the amount to be reimbursed. The non-paying Party shall make such reimbursement promptly
but in no event later than 15 Business Days after the presentation of such statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All
Transfer Taxes arising in connection with or resulting from the Transactions shall be paid 100% by Seller, and Seller shall prepare and
file all Tax Returns and other documentation relating to Transfer Taxes; provided that Seller shall permit Buyer to review and comment
on each such Tax Return or other document prior to filing, and Buyer shall cooperate in the execution of any such Tax Return or other
document if necessary pursuant to applicable Legal Requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Parties agree to waive all bulk sales, bulk transfer, or similar Legal Requirements. The Parties further agree that any Liability arising
out of the failure of Seller to comply with the requirements and provisions of any bulk sales, bulk transfer, or similar Legal Requirement
is an Excluded Liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Misdirected
Payments</U></B>. From and after the Closing, if Seller or any of Seller&rsquo;s Affiliates receives or collects any funds relating to
any of the Purchased Assets or any accounts or notes receivable owned by (or otherwise payable to) Buyer, then Seller shall, and shall
cause Seller&rsquo;s Affiliates to, remit such funds to Buyer within five Business Days after receipt of such funds. From and after the
Closing, if Buyer or any of Buyer&rsquo;s Affiliates receives or collects any funds relating to any of the Excluded Assets, then Buyer
shall, and shall cause Buyer&rsquo;s Affiliates to, remit such funds to Seller within five Business Days after receipt of such funds.
If Seller does not timely pay Buyer in accordance with the foregoing sentence, then Buyer will have the option, in Buyer&rsquo;s sole
discretion, to recover all such amounts payable to Buyer pursuant to <U>Section&#8239;10.11</U>, in addition to all other rights and remedies
available to Buyer at law, in equity, or by Legal Requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B>6.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B> <B><U>Books and Records</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
facilitate the resolution of any claims made by or against or incurred by Seller prior to the Closing, or for any other reasonable purpose,
for the seven-year period immediately following the Closing, Buyer shall (i)&#8239;retain copies of all material books, records, and documents
included within the Purchased Assets that relate to the SimpliDerm Business and its operations for periods prior to the Closing, and
(ii)&#8239;upon reasonable advance written notice, afford Seller&rsquo;s Representatives with reasonable access (including the right to
make, at Seller&rsquo;s expense, photocopies), during normal business hours and in a manner that does not unreasonably interfere with
the businesses and operations of Buyer and Buyer&rsquo;s Affiliates, to such books, records, and documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
facilitate the resolution of any claims made by or against or incurred by Buyer after the Closing, or for any other reasonable purpose,
for the seven-year period immediately following the Closing, Seller shall (i)&#8239;retain copies of all material books, records, and
documents not included within the Purchased Assets that relate to the SimpliDerm Business and its operations for periods prior to the
Closing, and (ii)&#8239;upon reasonable advance written notice, afford Buyer&rsquo;s Representatives with reasonable access (including
the right to make, at Buyer&rsquo;s expense, photocopies), during normal business hours and in a manner that does not unreasonably interfere
with the businesses and operations of Seller and Seller&rsquo;s Affiliates, to such books, records, and documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
anything in this Agreement to the contrary, (i)&#8239;no Party is obligated to provide any other Party with access to any books, records,
or documents pursuant to this <U>Section&#8239;6.4</U>, if such access would destroy or waive any legal privilege or be in violation of
any applicable Legal Requirement or Contract, and (ii)&#8239;if the Parties are in an adversarial relationship in any Proceeding, the
furnishing of any books, records, or documents pursuant to this <U>Section&#8239;6.4</U> will be subject to applicable rules&#8239;relating
to discovery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Public
Announcements and Other Communications</U></B>. Unless required by applicable Legal Requirements, neither Party shall make any public
disclosure or permit any of such Party&rsquo;s Affiliates or Representatives to make any public disclosure (whether or not in response
to an inquiry) with respect to the Transaction Documents and the Transactions unless previously approved by the other Party in writing
(such approval not to be unreasonably withheld, conditioned, or delayed). Buyer may, in its sole discretion, issue a press release or
other public disclosure with respect to the Transaction Documents and the Transactions without the prior consent of Seller; provided,
however, Buyer shall provide Seller a reasonable opportunity to review and comment on such press release or other public disclosure in
advance of such issuance to the extent practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Operating
Unit Names</U></B>. From and after the Closing Date, Seller shall not use, and Seller shall not allow any of Seller&rsquo;s Affiliates
to use, &ldquo;SimpliDerm&rdquo; or any derivation or variation thereof (collectively, the &ldquo;<U>Operating Unit Names</U>&rdquo;).
Seller shall cooperate with Buyer in making the Operating Unit Names available to Buyer in each jurisdiction in which Seller conducted
the SimpliDerm Business prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Non-Assignable
Contracts</U></B>. If any Assumed Contract or other Contract included in the Purchased Assets is not capable of being assigned to Buyer
at the Closing without the Consent of any Person that has not been obtained as of the Closing (each, a &ldquo;<U>Non-Assignable Contract</U>&rdquo;),
then, notwithstanding anything in this Agreement to the contrary, this Agreement and any applicable Transaction Document shall not constitute
an assignment of, or an attempted assignment of, such Non-Assignable Contract (and all Liabilities pursuant to such Non-Assignable Contract
shall constitute Excluded Liabilities). Following the Closing, Seller shall (a)&#8239;hold each Non-Assignable Contract in trust for the
sole benefit of Buyer, (b)&#8239;continue to perform all obligations under each Non-Assignable Contract as directed by Buyer, (c)&#8239;pass
through to Buyer all economic benefits received by Seller under each Non-Assignable Contract, and (d)&#8239;use commercially reasonable
efforts to obtain the Consent necessary to assign each Non-Assignable Contract to Buyer as promptly as practicable. Upon receipt of any
such Consent, Seller shall promptly assign the applicable Non-Assignable Contract to Buyer at no additional cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B>6.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B> <B><U>Technology Transfer</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;As
promptly as practicable after the Closing (and, in any event, no later than the expiration of the TSA in accordance with the terms thereof),
Seller shall provide to Buyer, a complete technology transfer package (the &ldquo;<U>Technology Transfer Package</U>&rdquo;) sufficient
to enable Buyer or its applicable Affiliates or designees to independently manufacture, process, test, release, package, label, store,
distribute, and commercialize the Seller Products without further material reliance on Seller or the TSA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Technology Transfer Package shall include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[***];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[***];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[***];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[***];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[***];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[***];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[***];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(viii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[***];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(ix)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[***];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(x)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[***];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(xi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[***];
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">(xii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
addition to delivering the Technology Transfer Package, Seller shall provide on-site and remote training, technical assistance, quality
support, regulatory support, and engineering support pursuant to the TSA until Seller has delivered the complete Technology Transfer
Package (such services, together with the Technology Transfer Package, are collectively referred to as the &ldquo;<U>Technology Transfer</U>&rdquo;).
The Technology Transfer shall not be deemed complete until Buyer reasonably confirms that the Technology Transfer Package enables independent
manufacture of Seller Products meeting existing specifications and quality standards. Seller represents that all manufacturing know-how,
SOPs, validation records, quality records, specifications, testing methods, and other information necessary to manufacture SimpliDerm
have been provided to Buyer, and Seller shall indemnify Buyer for any Damages, directly or indirectly, as a result of, in connection
with, or related to incomplete or inaccurate transfer documentation in the Technology Transfer Package.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Further
Assurances</U></B>. Following the Closing, the Parties shall reasonably cooperate with each other and with their respective Representatives
in connection with any steps required to be taken as part of their respective obligations under this Agreement, and the Parties agree
(a)&#8239;to furnish upon request to the other Parties such further information, (b)&#8239;to execute and deliver to each other Party such
other documents, and (c)&#8239;to do such other acts and things, all as the other Parties reasonably request, for the purpose of carrying
out the intent of this Agreement and the Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&#8239;VII<BR>
CONDITIONS TO CLOSING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Conditions
to Obligations of the Parties</U></B>. The obligation of each Party to consummate the Transactions is subject to the satisfaction (or,
where legally permissible, waiver by such Party in writing), at or prior to the Closing, of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;no
Governmental Authority has enacted, issued, promulgated, enforced, or entered any Legal Requirement that is in effect and has the effect
of restraining or prohibiting the consummation and performance of the Transactions, otherwise making the Transactions illegal, or causing
any of the Transactions to be rescinded following the Closing; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;no
Proceeding is pending or threatened that if adversely decided would have the effect of restraining or prohibiting the consummation and
performance of the Transactions, otherwise making the Transactions illegal, or causing any of the Transactions to be rescinded following
the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Conditions
to Obligations of Buyer</U></B>. The obligation of Buyer to consummate the Transactions is subject to the satisfaction (or, where legally
permissible, waiver by Buyer in writing), at or prior to the Closing, of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;each
of the representations and warranties contained in <U>Article&#8239;III</U> (other than the Seller Fundamental Representations and the
representations and warranties contained in <U>Section&#8239;3.3(a)</U>) that does not contain an express materiality qualification (including
a Seller Material Adverse Effect qualification) must be true and correct in all material respects as of the Closing with the same effect
as though made at and as of the Closing. Each of the representations and warranties contained in <U>Article&#8239;III</U> (other than
the Seller Fundamental Representations and the representations and warranties contained in <U>Section&#8239;3.3(a)</U>) that contains
an express materiality qualification (including a Seller Material Adverse Effect qualification) must be true and correct in all respects
as of the Closing with the same effect as though made at and as of the Closing. Each of the Seller Fundamental Representations and the
representations and warranties contained in <U>Section&#8239;3.3(a)</U>&#8239;must be true and correct in all respects as of the Closing
with the same effect as though made at and as of the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
Seller Material Adverse Effect must not have occurred since the Execution Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Seller
must have performed and complied in all material respects with all of the covenants, obligations, and agreements that Seller is required
to perform or to comply with pursuant to this Agreement at or prior to the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Seller
must have delivered, or caused to be delivered, the Seller Closing Documents in accordance with <U>Section&#8239;2.4(a)</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;no
Assumed Contract or Shared Contract shall have been terminated, materially modified, or otherwise has been materially impaired or ceased
to be available to Seller;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[***];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[***];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;with
respect to each Shared Contract or other Assumed Contract that is not assigned at the Closing, Seller shall have delivered the agreed
allocation methodology, operating procedures, invoicing process, payment flow, responsibility matrix and all other reasonably necessary
information to enable Buyer to operate under such Contract immediately following the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Seller
shall certify that, as of the Closing, (i)&#8239;Seller has not received notice of termination under any Assumed Contract or Shared Contract,
(ii)&#8239;to the Knowledge of Seller, no counterparty to any Assumed Contract or Shared Contract has any intention to terminate or materially
modify such Assumed Contract or Shared Contract, and (iii)&#8239;Seller is not in material breach or default under any such Assumed Contract
or Shared Contract; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Conditions
to Obligations of Seller</U></B>. The obligations of Seller to consummate the Transactions are subject to the satisfaction (or, where
legally permissible, waiver by Seller in writing), at or prior to the Closing, of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;each
of the representations and warranties contained in <U>ARTICLE&#8239;IV</U> (other than the Buyer Fundamental Representations) that does
not contain an express materiality qualification (including a Buyer Material Adverse Effect qualification) must be true and correct in
all material respects as of the Closing with the same effect as though made at and as of the Closing. Each of the representations and
warranties contained in <U>ARTICLE&#8239;IV</U> (other than the Buyer Fundamental Representations) that contains an express materiality
qualification (including a Buyer Material Adverse Effect qualification) must be true and correct in all respects as of the Closing with
the same effect as though made at and as of the Closing. Each of the Buyer Fundamental Representations must be true and correct in all
respects as of the Closing with the same effect as though made at and as of the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Buyer
must have performed and complied in all material respects with all of the covenants, obligations, and agreements that Buyer is required
to perform or to comply with pursuant to this Agreement at or prior to the Closing; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Buyer
must have delivered, or caused to be delivered, the Buyer Closing Documents in accordance with <U>Section&#8239;2.4(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&#8239;VIII<BR>
INDEMNIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Survival</U></B>.
All representations, warranties, covenants, obligations, and agreements in this Agreement, and the right to commence any claim with respect
thereto, will survive the Closing and the consummation and performance of the Transactions and continue in full force and effect for
the time periods set forth in <U>Section&#8239;8.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Indemnification
Obligations of Seller</U></B>. From and after the Closing and subject to the limitations set forth in this <U>Article&#8239;VIII</U>,
Seller shall indemnify Buyer and Buyer&rsquo;s Affiliates, their respective equity holders, and the Representatives of each of the foregoing
(collectively, the &ldquo;<U>Buyer Indemnified Persons</U>&rdquo;), and shall save and hold each of them harmless against, and shall
pay, compensate, and reimburse each of them for, any Damages that any such Buyer Indemnified Person suffers, sustains, or becomes subject
to, directly or indirectly, as a result of, in connection with, or related to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
inaccuracy in or breach of any representation or warranty made in <U>Article&#8239;III</U> or the certificate delivered pursuant to <U>Section&#8239;2.4(a)(x)</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
nonfulfillment, nonperformance, or other breach of any covenant, obligation, or agreement of Seller in this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
(i)&#8239;Excluded Asset, (ii)&#8239;Excluded Liability, (iii)&#8239;Transaction Expenses; or (iv)&#8239;to the extent related to any period
prior to the Closing, other Liability (other than an Assumed Liability) imposed under any common law doctrine of de facto merger, by
operation of law, or by reason of Buyer&rsquo;s status as transferee of, or successor to, the SimpliDerm Business or any of the Purchased
Assets; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
of the matters set forth on <U>Annex&#8239;G</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Indemnification
Obligations of Buyer</U></B>. From and after the Closing and subject to the limitations set forth in this <U>Article&#8239;VIII</U>, Buyer
shall indemnify Seller, their respective equity holders, and the Representatives of each of the foregoing (collectively, the &ldquo;<U>Seller
Indemnified Persons</U>&rdquo;), and shall save and hold each of them harmless against, and shall pay, compensate, and reimburse each
of them for, any Damages that any such Seller Indemnified Person suffers, sustains, or becomes subject to, directly or indirectly, as
a result of, in connection with, or related to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
inaccuracy in or breach of any representation or warranty made in <U>ARTICLE&#8239;IV </U>or the certificate delivered pursuant to <U>Section&#8239;2.4(b)(v)</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
nonfulfillment, nonperformance, or other breach of any covenant, obligation, or agreement of Buyer in this Agreement; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
Assumed Liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B>8.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B> <B><U>Time Limitations</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to <U>Section&#8239;8.5(f)</U>, Seller will have no Liability under <U>Section&#8239;8.2(a)</U>&#8239;(other than with respect to Seller
Special Representations and the Seller Fundamental Representations) unless, on or before the date that is 18 months after the Closing
Date, Buyer notifies Seller in writing of a claim with respect thereto specifying the factual basis of such claim in reasonable detail
to the extent then known by Buyer. Subject to <U>Section&#8239;8.5(f)</U>, Seller will have no Liability under <U>Section&#8239;8.2(a)</U>&#8239;(solely
with respect to the Seller Special Representations), unless, on or before the date that is three years after the Closing, Buyer notifies
Seller in writing of a claim with respect thereto specifying the factual basis of such claim in reasonable detail to the extent then
known by Buyer. Subject to <U>Section&#8239;8.5(f)</U>, Seller will have no Liability under <U>Section&#8239;8.2(b)</U>, unless, on or
before the date that is 60 days after the expiration of the applicable statute of limitations (including extensions or waivers thereof),
Buyer notifies Seller in writing of a claim with respect thereto specifying the factual basis of such claim in reasonable detail to the
extent then known by Buyer. Subject to <U>Section&#8239;8.5(e)</U>, any claim with respect to <U>Section&#8239;8.2(a)</U>&#8239;(solely
with respect to the Seller Fundamental Representations) will survive until the later of (i)&#8239;the date that is 60 days after the expiration
of the applicable statute of limitations (including extensions or waivers thereof) and (ii)&#8239;the sixth anniversary of the Closing
Date and Buyer is entitled to notify Seller in writing of such a claim at any time prior to such date by specifying the factual basis
of such claim in reasonable detail to the extent then known by Buyer. Any claim with respect to <U>Section&#8239;8.2(c)</U>&#8239;or <U>Section&#8239;8.2(d)</U>&#8239;will
survive indefinitely and Buyer is entitled to notify Seller in writing of such a claim at any time by specifying the factual basis of
such claim in reasonable detail to the extent then known by Buyer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to <U>Section&#8239;8.5(f)</U>, Buyer will have no Liability under <U>Section&#8239;8.3(a)</U>&#8239;(other than with respect to the Buyer
Fundamental Representations), unless, on or before the date that is 18 months after the Closing Date, Seller notifies Buyer in writing
of a claim with respect thereto specifying the factual basis of such claim in reasonable detail to the extent then known by Seller. Subject
to <U>Section&#8239;8.5(f)</U>, Buyer will have no Liability under <U>Section&#8239;8.3(b)</U>, unless, on or before the date that is 60
days after the expiration of the applicable statute of limitations (including extensions or waivers thereof), Seller notifies Buyer in
writing of a claim with respect thereto specifying the factual basis of such claim in reasonable detail to the extent then known by Seller.
Any claim with respect to <U>Section&#8239;8.3(a)</U>&#8239;(solely with respect to the Buyer Fundamental Representations) will survive
until the later of (i)&#8239;the date that is 60 days after the expiration of the applicable statute of limitations (including extensions
or waivers thereof) and (ii)&#8239;the sixth anniversary of the Closing Date and Seller is entitled to notify Buyer in writing of such
a claim at any time by specifying the factual basis of such claim in reasonable detail to the extent then known by Seller. Any claim
with respect to <U>Section&#8239;8.3(c)</U>&#8239;will survive indefinitely and Seller is entitled to notify Buyer in writing of such a
claim at any time by specifying the factual basis of such claim in reasonable detail to the extent then known by Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Upon
the giving of notice as contemplated by <U>Section&#8239;8.4(a)</U>&#8239;or <U>Section&#8239;8.4(b)</U>, as applicable, the Indemnified
Person&rsquo;s rights with respect to the claim specified in such notice will survive the time at which such claim would otherwise terminate
pursuant to this Agreement (regardless of when the Damages in respect of such claim are actually incurred), and such Indemnified Person
shall be entitled to commence a Proceeding subsequent to the applicable survival date for the enforcement of such Indemnified Person&rsquo;s
rights under this <U>Article&#8239;VIII</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B>8.5</B> <B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Certain Other Limitations and Guidelines</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to <U>Section&#8239;8.5(f)</U>, Seller will have no Liability under <U>Section&#8239;8.2(a)</U>&#8239;(other than with respect to the Seller
Fundamental Representations and the Seller Special Representations, to which such limitation does not apply) for any Damages related
thereto for which Seller would be liable, but for this sentence, until the aggregate amount of all such Damages equals or exceeds on
a cumulative basis a dollar amount equal to 10% of the Purchase Price (the &ldquo;<U>Deductible Amount</U>&rdquo;), in which event, subject
to the immediately following sentence, Seller will be liable for all such Damages in excess of the Deductible Amount. Subject to <U>Section&#8239;8.5(f)</U>,
Seller will have no Liability under <U>Section&#8239;8.2(a)</U>&#8239;(i)&#8239;with respect to any representation or warranty made in <U>Article&#8239;III</U>
other than with respect to the Seller Fundamental Representations and the Seller Special Representations (to which such limitation does
not apply), for any Damages related thereto for which Seller would be liable, but for this sentence, that exceed a dollar amount equal
to 10% of the Purchase Price, (ii)&#8239;with respect to the Seller Special Representations, for any Damages related thereto for which
Seller would be liable, but for this sentence, that exceed a dollar amount equal to 50% of the Purchase Price, and (iii)&#8239;with respect
to the Seller Fundamental Representations, for any Damages related thereto for which Seller would be liable, but for this sentence, that
exceed a dollar amount equal to the Purchase Price (the &ldquo;<U>Overall Cap Amount</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to <U>Section&#8239;8.5(f)</U>, Buyer will have no Liability under <U>Section&#8239;8.3(a)</U>&#8239;(other than with respect to the Buyer
Fundamental Representations, to which such limitation does not apply) for any Damages related thereto for which Buyer would be liable,
but for this sentence, until the aggregate amount of all such Damages equals or exceeds on a cumulative basis a dollar amount equal to
the Deductible Amount, in which event, subject to the immediately following sentence, Buyer will be liable for all such Damages in excess
of the Deductible Amount. Subject to <U>Section&#8239;8.5(f)</U>, Buyer will have no Liability under <U>Section&#8239;8.3(a)</U>&#8239;for
any Damages related thereto for which Buyer would be liable, but for this sentence, that exceed a dollar amount equal to the Overall
Cap Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;An
Indemnifying Person will have no Liability pursuant to <U>Section&#8239;8.2</U> or <U>Section&#8239;8.3</U> for those Damages covered by
insurance proceeds that are actually received by the Indemnified Person with respect to such Damages (net of any related costs incurred
in connection therewith, including costs of recovery, deductibles, retroactive premiums, and premium increases). Each Indemnified Person
shall use commercially reasonable efforts to recover under applicable insurance policies for any such Damages covered by such insurance
policies; provided, however, that such Indemnified Person will not be required to make any claim under any such insurance policy prior
to making a claim for indemnification under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Parties agree that an Indemnified Person&rsquo;s rights to indemnification or other remedy with respect thereto or otherwise under <U>Section&#8239;8.2</U>
or <U>Section&#8239;8.3</U>, as applicable, are part of the basis of the bargain contemplated by this Agreement. The representations,
warranties, covenants, obligations, and agreements of the Parties, and an Indemnified Person&rsquo;s right to indemnification or other
remedy with respect thereto or otherwise under <U>Section&#8239;8.2</U> or <U>Section&#8239;8.3</U>, as applicable, will not be affected
or deemed waived by reason of any investigation made by or on behalf of such Indemnified Person, such Indemnified Person&rsquo;s Affiliates,
or any of the Representatives of any of the foregoing, or by reason of the fact that such Indemnified Person, such Indemnified Person&rsquo;s
Affiliates, or any such Representatives of any of the foregoing knew or should have known that any such representation, warranty, covenant,
obligation, or agreement is, was, or might be inaccurate, breached, or not complied with, and such Indemnified Person will be deemed
to have relied upon such representations, warranties, covenants, obligations, and agreements notwithstanding any such investigation,
actual or constructive knowledge, or waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;For
purposes of calculating the amount of Damages to which a Buyer Indemnified Person is entitled under this <U>Article&#8239;VIII</U>, the
terms &ldquo;material&rdquo;, &ldquo;materially&rdquo;, &ldquo;materiality&rdquo;, &ldquo;material adverse effect&rdquo;, and &ldquo;Seller
Material Adverse Effect&rdquo; and other similar qualifications will be disregarded.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
anything in this Agreement to the contrary, nothing in this Agreement, including <U>Section&#8239;8.4</U> and this <U>Section&#8239;8.5</U>,
limits (i)&#8239;the survival of any claim (including any Direct Claim or Third-Party Claim) for Fraud, (ii)&#8239;the Liability of any
Indemnifying Person to any Indemnified Person for Fraud, or (iii)&#8239;the manner in which any claim (including any Direct Claim or Third-Party
Claim) for Fraud is satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Procedure
for Indemnification &ndash; Third-Party Claims</U></B>. If any Indemnified Person receives notice of the assertion or commencement of
any Proceeding made or brought by or on behalf of any Person who is not a Party, an Affiliate of a Party, or a Representative of a Party
or an Affiliate of a Party (a &ldquo;<U>Third-Party Claim</U>&rdquo;) against such Indemnified Person with respect to which the Indemnifying
Person is obligated to provide indemnification under this Agreement, then such Indemnified Person shall give the Indemnifying Person
prompt written notice of such Third-Party Claim. The failure to give such prompt written notice will not, however, relieve the Indemnifying
Person of the Indemnifying Person&rsquo;s indemnification obligations, except and only to the extent that the Indemnifying Person is
materially prejudiced by reason of such failure. Such notice by the Indemnified Person must describe the Third-Party Claim in reasonable
detail and must indicate the estimated amount, if reasonably practicable, of the Damages that have been or could be sustained by the
Indemnified Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Procedure
for Indemnification &ndash; Direct Claims</U></B>. An Indemnified Person shall assert any claim on account of Damages that do not result
from a Third-Party Claim (a &ldquo;<U>Direct Claim</U>&rdquo;) by giving the Indemnifying Person prompt written notice thereof. The failure
to give such prompt written notice will not, however, relieve the Indemnifying Person of the Indemnifying Person&rsquo;s indemnification
obligations, except and only to the extent that the Indemnifying Person is materially prejudiced by reason of such failure. Such notice
by the Indemnified Person must describe the Direct Claim in reasonable detail and indicate the estimated amount, if reasonably practicable,
of the Damages that have been or could be sustained by the Indemnified Person. The Indemnifying Person shall have 30 days following receipt
of a Direct Claim notice to dispute such Direct Claim. If no written objection is delivered within such 30-day period, the Direct Claim
shall be deemed accepted by the Indemnifying Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Payment</U></B>.
After (a)&#8239;any final Order has been rendered by a Governmental Authority of competent jurisdiction, (b)&#8239;a settlement has been
consummated in accordance with this <U>Article&#8239;VIII</U>, or (c)&#8239;the Indemnified Person and the Indemnifying Person have arrived
at a mutually binding Contract, in each case, with respect to a Third-Party Claim or a Direct Claim, the Indemnified Person shall forward
to the Indemnifying Person notice of any amounts due and owing by the Indemnifying Person in accordance with this <U>Article&#8239;VIII</U>.
To the extent not set-off in accordance with <U>Section&#8239;10.11</U>, if any amounts are due and owing by Seller to any Buyer Indemnified
Person in accordance with this <U>Article&#8239;VIII</U>, then, Seller shall pay to the applicable Buyer Indemnified Person, within five
Business Days after the occurrence of the earliest event to occur that is described in the first sentence of this <U>Section&#8239;8.8</U>,
all such amounts by wire transfer of immediately available funds to the account designated by Buyer to Seller in writing. If any amounts
are due and owing by Buyer to any Seller Indemnified Person in accordance with this <U>Article&#8239;VIII</U>, then Buyer shall pay to
the applicable Seller Indemnified Person, within five Business Days after the occurrence of the earliest event to occur that is described
in the first sentence of this <U>Section&#8239;8.8</U>, all such amounts by wire transfer of immediately available funds to the account
designated by Seller to Buyer in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exclusive
Remedies</U></B>. Subject to <U>Section&#8239;2.5(d)</U>, <U>Section&#8239;2.7(d)</U>, <U>ARTICLE&#8239;IX</U>, <U>Section&#8239;10.8</U>
and <U>Section&#8239;10.11</U>, the Parties acknowledge and agree that the remedies provided for in this <U>Article&#8239;VIII</U> are
their sole and exclusive remedies with respect to any claims arising out of the matters covered by this Agreement, other than claims
based upon, arising out of, with respect to, or by reason of (a)&#8239;any Fraud or (b)&#8239;any of the other Transaction Documents. Nothing
in this <U>Section&#8239;8.9</U> will (i)&#8239;interfere with or impede the operation of <U>Section&#8239;2.5(d)</U>&#8239;or <U>Section&#8239;2.7(d)</U>&#8239;with
respect to the resolution of the Disputed Matters by the Parties and the Independent Accounting Firm, (ii)&#8239;limit any Person&rsquo;s
right to seek and obtain any equitable relief to which any Person is entitled pursuant to <U>Section&#8239;10.8</U> or set-off and hold
back in accordance with <U>Section&#8239;10.11</U>, or (iii)&#8239;limit any Person&rsquo;s right to seek any remedy on account of Fraud
or under any of the other Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Tax
Treatment of Indemnification Payments</U></B>. The Parties shall treat each payment made under this <U>Article&#8239;VIII</U> as an adjustment
to the Purchase Price for U.S. federal (and applicable state and local) income Tax purposes, unless otherwise required pursuant to&#8239;a
final &ldquo;determination&rdquo; (within the meaning of Section&#8239;1313 of the Code) by a Tax Authority with respect to any such payment
causes such payment not to be treated as an adjustment to the Purchase Price for U.S. federal (and applicable state and local) income
Tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&#8239;IX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TERMINATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Termination
Events</U></B>. Subject to <U>Section&#8239;9.2</U>, the Parties, by written notice given prior to the Closing, are entitled to terminate
this Agreement during the Executory Period as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;by
mutual written agreement of the Parties;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;by
Buyer or Seller if any Governmental Authority has enacted, issued, promulgated, enforced, or entered any Legal Requirement that is in
effect (and, with respect to any Order, such Order is final and non-appealable) and has the effect of restraining or prohibiting the
consummation and performance of the Transactions, otherwise making the Transactions illegal, or causing any of the Transactions to be
rescinded following the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;by
Buyer if any of the representations or warranties contained in <U>Article&#8239;III</U> is inaccurate or Seller has breached any of Seller&rsquo;s
representations, warranties, covenants, obligations, or agreements set forth in this Agreement, in each case, such that the conditions
set forth in <U>Section&#8239;7.2</U> could not be satisfied by the Outside Date and such inaccuracy or breach has not been waived in
writing by Buyer or such breach has not been cured by Seller within 30 days after Seller&rsquo;s receipt of written notice thereof from
Buyer, except that the right to terminate this Agreement under this <U>Section&#8239;9.1(c)</U>&#8239;will not be available to Buyer if
Buyer is then in material breach of this Agreement and such material breach primarily contributed to the occurrence of the event that
gave rise to the termination right under this <U>Section&#8239;9.1(c)</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;by
Seller if any of the representations or warranties contained in <U>ARTICLE&#8239;IV</U> is inaccurate or Buyer has breached any of Buyer&rsquo;s
representations, warranties, covenants, obligations, or agreements set forth in this Agreement, in each case, such that the conditions
set forth in <U>Section&#8239;7.3</U> could not be satisfied by the Outside Date and such inaccuracy or breach has not been waived in
writing by Seller or such breach has not been cured by Buyer within 30 days after Buyer&rsquo;s receipt of written notice thereof from
Seller, except that the right to terminate this Agreement under this <U>Section&#8239;9.1(d)</U>&#8239;will not be available to Seller
if Seller is then in material breach of this Agreement and such material breach primarily contributed to the occurrence of the event
that gave rise to the termination right under this <U>Section&#8239;9.1(d)</U>; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;by
Buyer or Seller if the Closing has not occurred on or before January&#8239;16, 2027 (the &ldquo;<U>Outside Date</U>&rdquo;) or such later
date as the Parties mutually agreed upon in writing, except that the right to terminate this Agreement under this <U>Section&#8239;9.1(e)</U>&#8239;will
not be available to (i)&#8239;Buyer if Buyer is then in material breach of this Agreement and such material breach primarily contributed
to the occurrence of the event that gave rise to the termination right under this <U>Section&#8239;9.1(e)</U>, or (ii)&#8239;Seller if
Seller is then in material breach of this Agreement and such material breach primarily contributed to the occurrence of the event that
gave rise to the termination right under this <U>Section&#8239;9.1(e)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Effect
of Termination</U></B>. If this Agreement is terminated pursuant to <U>Section&#8239;9.1</U>, this Agreement will forthwith become void
and have no effect, without any Liability on the part of either Party, such Party&rsquo;s Affiliates, or any of the respective Representatives
of any of the foregoing, except (i)&#8239;with respect to any Liability of a Party for intentional misrepresentation, Fraud, or willful
or intentional breach of any representation, warranty, covenant, obligation, or agreement of such Party under this Agreement occurring
prior to such termination, and (ii)&#8239;that the first two sentences of <U>Section&#8239;6.5</U>, this <U>Section&#8239;9.2</U>, and <U>Article&#8239;X</U>
will survive such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&#8239;X<BR>
GENERAL PROVISIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Expenses</U></B>.
Except as otherwise expressly provided in this Agreement, each Party shall bear such Party&rsquo;s respective expenses (including, with
respect to Seller, all Transaction Expenses) incurred in connection with the preparation and execution of the Transaction Documents,
and consummation and performance of the Transactions, including all fees and expenses of such Party&rsquo;s Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Successors
and Assigns; No Third Party Beneficiaries</U></B>. Subject to the terms of this <U>Section&#8239;10.2</U>, this Agreement will apply to,
be binding in all respects upon, and inure to the benefit of the successors and permitted assigns of the Parties. Seller is not permitted
to assign any of Seller&rsquo;s rights or delegate any of Seller&rsquo;s obligations under this Agreement without the prior written consent
of Buyer. Buyer is not permitted to assign any of Buyer&rsquo;s rights or delegate any of Buyer&rsquo;s obligations under this Agreement
without the prior written consent of Seller, except that Buyer is permitted to assign any of Buyer&rsquo;s rights and delegate any of
Buyer&rsquo;s obligations under this Agreement, without the prior written consent of Seller, (a)&#8239;to any Affiliate of Buyer, (b)&#8239;in
connection with the sale of at least a majority of the ownership interests in or all or substantially all of the Assets of, or any business
combination transaction or merger involving, Buyer or any of Buyer&rsquo;s Affiliates, and (c)&#8239;as collateral to any financial institution
providing financing to Buyer or any of Buyer&rsquo;s Affiliates. No assignment or delegation will relieve either of the Parties of any
of such Party&rsquo;s obligations under this Agreement. Any purported assignment or delegation in violation or breach of this <U>Section&#8239;10.2</U>
will be void <I>ab initio</I>. Nothing in this Agreement will be construed to give any Person other than the Parties any legal or equitable
right under or with respect to this Agreement or any provision of this Agreement, except such rights as will inure to a successor or
permitted assignee pursuant to this <U>Section&#8239;10.2</U> and except as contemplated by <U>Article&#8239;VIII</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notices</U></B>.
All notices, Consents, and other communications between the Parties under this Agreement must be in writing and will be deemed to have
been duly given when (a)&#8239;delivered by hand (with written confirmation of receipt), (b)&#8239;sent by electronic mail during regular
business hours, or if not during regular business hours, the next Business Day; provided, that no &ldquo;error&rdquo; message or other
similar electronic notification of non-delivery (excluding any &ldquo;out of office&rdquo; or similar automatically generated message)
is promptly received by the Party sending such electronic mail, (c)&#8239;received or refused by the addressee, if sent by certified mail,
return receipt requested, or (d)&#8239;received or refused by the addressee, if sent by a nationally recognized overnight delivery service,
return receipt requested, in each case to the appropriate addresses set forth below (or to such other addresses as a Party designates
by notice to the other Party in accordance with this <U>Section&#8239;10.3</U>):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">If to Buyer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Cellution Biologics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">4000 Northfield Way, Suite&#8239;400</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Roswell, GA 30076</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attention: Mayur Abhaya; Mukesh Kumar</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Electronic Mail: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">with a copy to (which does not constitute notice to Buyer):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Maynard Nexsen PC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1275 Peachtree Street NE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Suite&#8239;550</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Atlanta, Georgia 30309</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attention: Brian Howaniec; Baoyi Cai</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Electronic Mail: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">If to Seller:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Elutia Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">20 Firstfield Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Gaithersburg, Maryland 20878</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attention: Matthew Ferguson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Electronic Mail: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">with a copy to (which does not constitute notice to Seller):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Kilpatrick Townsend&#8239;&amp; Stockton LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1100 Peachtree Street, N.E., Suite&#8239;2800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Atlanta, Georgia 30309</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attention: Mick Cochran</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Electronic Mail: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Entire
Agreement; Modification</U></B>. This Agreement and the other Transaction Documents constitute the final, complete, entire, and exclusive
agreement among the Parties and supersede all prior agreements and understandings (including the Letter of Intent and the Confidentiality
Agreement), whether written or oral, among the Parties with respect to the subject matter hereof. Notwithstanding anything in the Confidentiality
Agreement or the Letter of Intent to the contrary, Seller agrees that, immediately and automatically upon the Closing, neither Buyer
nor any of Buyer&rsquo;s Affiliates, or any of their respective Representatives, will have any further obligations to Seller or any of
Seller&rsquo;s Affiliates, or any of their respective Representatives, under, or be subject to the restrictions in, the Confidentiality
Agreement or the Letter of Intent. Any amendment of this Agreement must be pursuant to a written agreement signed by the Parties. No
course of dealing between or among any Persons having any interest in this Agreement will be deemed effective to modify, amend, or discharge
any part of this Agreement or any rights or obligations of any Person under or by reason of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Waiver</U></B>.
No waiver of any provisions of this Agreement by either Party will be effective unless explicitly set out in writing by such Party granting
such waiver. Neither the failure nor any delay by either of the Parties in exercising any right under this Agreement will operate as
a waiver of such right, and no single or partial exercise of any such right will preclude any other or further exercise of such right
or the exercise of any other right. No waiver of any of the provisions of this Agreement will be deemed or will constitute a waiver of
any other provisions of this Agreement, whether or not similar, nor will any waiver constitute a continuing waiver. No waiver of any
condition based on the accuracy of any representation or warranty, or based on the performance of or compliance with any covenant or
obligation, will affect the right to indemnification, reimbursement, or other remedy based on such representation, warranty, covenant,
obligation, or agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Severability</U></B>.
Any term or provision of this Agreement that is invalid or unenforceable in any jurisdiction will be, as to that jurisdiction, ineffective
to the extent of such invalidity or unenforceability without rendering invalid or unenforceable the remaining terms or provisions of
this Agreement or affecting the validity or enforceability of any of the terms or provisions of this Agreement in any other jurisdiction.
Upon such determination that any term or provision of this Agreement is invalid or unenforceable, the Parties shall negotiate in good
faith to modify this Agreement so as to give effect to the original intent of the Parties as closely as possible in a mutually acceptable
manner so that the Transactions be consummated as originally contemplated to the greatest extent possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B>10.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B> <B><U>Governing Law; Waiver of Jury Trial</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This
Agreement, as well as all matters in dispute between the Parties, whether arising from or relating to this Agreement or arising from
or relating to alleged extra-contractual facts prior to, during, or subsequent to this Agreement, including Fraud, misrepresentation,
negligence, or any other alleged tort or violation of this Agreement, regardless of the legal theory upon which such matter is asserted,
will be governed by, construed under, and enforced in accordance with the Legal Requirements of the State of Delaware (explicitly including
the Delaware statute of limitations) without regard to any choice of laws or conflicts of laws provisions, rules, or principles that
would require the application of any other Legal Requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;THE
PARTIES HEREBY WAIVE ANY RIGHT TO TRIAL BY JURY IN ANY PROCEEDING ARISING OUT OF OR IN ANY WAY PERTAINING TO THIS AGREEMENT, THE OTHER
TRANSACTION DOCUMENTS, OR THE TRANSACTIONS, WHETHER NOW OR HEREAFTER ARISING, AND WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE. EITHER
PARTY IS PERMITTED TO FILE A COPY OF THIS <U>SECTION&#8239;10.7(b)</U>&#8239;WITH ANY COURT AS WRITTEN EVIDENCE OF THE KNOWING, VOLUNTARY,
AND BARGAINED FOR AGREEMENT BETWEEN THE PARTIES TO IRREVOCABLY WAIVE TRIAL BY JURY, AND THAT ANY PROCEEDING WHATSOEVER BETWEEN THE PARTIES
RELATING TO THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, OR THE TRANSACTIONS IS INSTEAD TO BE TRIED IN A COURT OF COMPETENT JURISDICTION
BY A JUDGE SITTING WITHOUT A JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Enforcement
of Agreement; Remedies</U></B>. The Parties agree that each Party would be damaged irreparably in the event any of the provisions of
this Agreement is not performed in accordance with its specific terms and that any breach of this Agreement by either Party could not
be adequately compensated by monetary damages. Accordingly, each Party agrees that, in addition to any other right or remedy to which
a Party is entitled, at law or in equity, each Party is entitled to enforce any provision of this Agreement by a decree of specific performance
and to temporary, preliminary, and permanent injunctive relief to prevent breaches or threatened breaches of the provisions of this Agreement,
without posting any bond or other undertaking or proving Damages. The rights and remedies of the Parties are cumulative and not alternative.
Seller acknowledges that failure to provide the Technology Transfer Package, technology transfer services, manufacturing know-how, regulatory
support, or Shared Contract transition assistance would cause irreparable harm to Buyer and shall be subject to specific performance
and injunctive relief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Counterparts;
Execution of Agreement</U></B>. The Parties are permitted to execute this Agreement in one or more counterparts, each of such counterparts
is deemed to be an original copy of this Agreement and all of which, when taken together, are deemed to constitute one and the same agreement.
The exchange of copies of this Agreement and of signature pages&#8239;by electronic mail or other means of electronic transmission (including
pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, <I>e.g.</I>, www.docusign.com and www.simplyagree.com)
constitutes effective execution and delivery of this Agreement as to the Parties. Signatures of the Parties transmitted by electronic
mail or other means of electronic transmission (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of
2000, <I>e.g.</I>, www.docusign.com and www.simplyagree.com) are deemed to be their original signatures for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B>10.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B> <B><U>Rules&#8239;of Construction</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as otherwise explicitly specified in this Agreement to the contrary, (i)&#8239;references to an Article, Section, Annex, or Schedule mean
an Article&#8239;or Section&#8239;of, or Annex, or Schedule to, this Agreement, unless another agreement is specified, (ii)&#8239;the word
 &ldquo;including&rdquo; will be construed as &ldquo;including, without limitation&rdquo; and will not be construed to limit any general
statement that it follows to the specific or similar items or matters immediately following it, (iii)&#8239;the words &ldquo;to the extent&rdquo;
mean the degree to which and not simply &ldquo;if&rdquo;, (iv)&#8239;the words &ldquo;herein&rdquo;, &ldquo;hereof&rdquo;, &ldquo;hereby&rdquo;,
 &ldquo;hereto&rdquo;, and &ldquo;hereunder&rdquo; refer to this Agreement as a whole, (v)&#8239;words in the singular or plural form include
the plural and singular form, respectively, (vi)&#8239;pronouns are deemed to refer to the masculine, feminine, or neuter, as the identity
of the Person or Persons requires, (vii)&#8239;the words &ldquo;asset&rdquo; and &ldquo;property&rdquo; will be construed to have the
same meaning and effect and to refer to all tangible and intangible assets and properties, including cash, securities, accounts, contract
rights, and real and personal property, (viii)&#8239;references to a particular Person include such Person&rsquo;s successors and permitted
assigns, (ix)&#8239;references to a particular statute, rule, or regulation include all rules&#8239;and regulations thereunder and any
predecessor or successor statutes, rules, or regulations, in each case as amended or otherwise modified from time to time, (x)&#8239;references
to a particular Contract, document, instrument, or certificate mean such Contract, document, instrument, or certificate as amended, supplemented,
or otherwise modified from time to time if permitted by the provisions thereof, (xi)&#8239;references to &ldquo;dollars&rdquo; or &ldquo;$&rdquo;
are references to United States Dollars, (xii)&#8239;an accounting term not otherwise defined in this Agreement has the meaning ascribed
to such term in accordance with GAAP, (xiii)&#8239;references to &ldquo;written&rdquo; or &ldquo;in writing&rdquo; include electronic
form, and (xiv)&#8239;any reference in this Agreement to a &ldquo;day&rdquo; or a number of &ldquo;days&rdquo; (without explicit reference
to &ldquo;Business Days&rdquo;) will be interpreted as a reference to a calendar day or number of calendar days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
headings of Articles, Sections, Annexes, and Schedules are provided for convenience only and will not affect the construction or interpretation
of this Agreement. The Annexes and the Schedules are incorporated into this Agreement to the same extent as though fully set forth in
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
Schedule qualifies only the particular provision of this Agreement that makes explicit reference to such Schedule and no disclosure on
any one Schedule will be deemed to be disclosed on any other Schedule, except to the extent that it is readily apparent on the face of
a particular Schedule that information disclosed in such Schedule is applicable to another Schedule, in which case such other Schedule
will be deemed to incorporate by reference such information disclosed on the first referenced Schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Whenever
this Agreement indicates that Seller has &ldquo;provided&rdquo; (or any other word or phrase of similar meaning) any information or document
to Buyer, such statement is deemed to be a statement that Seller has posted, or caused to be posted, such information or document to
the Virtual Data Room (i)&#8239;prior to the second Business Day immediately prior to the Closing Date or (ii)&#8239;during the two Business
Day period immediately prior to the Closing Date (but in any event, prior to the Closing Date) in response to Buyer identifying or requesting
such information or document during such period, and, in each case with respect to clauses&#8239;(i)&#8239;and (ii), such information or
document was not subsequently removed from the Virtual Data Room prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
any period for giving notice or taking action under this Agreement expires on a day that is not a Business Day, then the time period
will be automatically extended to the Business Day immediately following such day. When calculating the period of time before which,
within which, or following which any act is to be done or step taken pursuant to this Agreement, the date that is the reference date
in calculating such period will be excluded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent
or interpretation arises, this Agreement will be construed as if drafted jointly by the Parties and no presumption or burden of proof
will arise favoring or disfavoring either Party by virtue of the authorship of any of the provisions of this Agreement. Prior drafts
of this Agreement or the fact that any provisions have been added, deleted, or otherwise modified from any prior drafts of this Agreement
will not be used as an aid of construction or otherwise constitute evidence of the intent of the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Set
Off</U></B>. Notwithstanding anything in this Agreement to the contrary, Buyer is entitled to (a)&#8239;set
off any amount payable by Seller to Buyer under this Agreement (including <U>Section&#8239;2.5</U>, <U>Section&#8239;2.6</U>, <U>Section&#8239;2.7</U>,
<U>Section&#8239;6.2</U>, <U>Section&#8239;6.3</U>, and <U>Article&#8239;VIII</U>) or (b)&#8239;hold back pending resolution of the related
claim the amount of any unresolved claim for Damages payable by Seller to Buyer under <U>Article&#8239;VIII</U>, in each case with respect
to the foregoing clauses (a)&#8239;and (b), against any amount payable by Buyer to Seller under this Agreement (including <U>Section&#8239;2.5</U>,
<U>Section&#8239;2.6</U>, <U>Section&#8239;2.7</U>, <U>Section&#8239;6.2</U>, <U>Section&#8239;6.3</U>, and <U>Article&#8239;VIII</U>), and
all amounts set off or held back in accordance with this <U>Section&#8239;10.11</U> will be deemed paid to Seller and no set off or hold
back effectuated in accordance with this <U>Section&#8239;10.11</U> will constitute or be deemed to constitute a breach of any of Buyer&rsquo;s
obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature Page&#8239;Follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the Execution Date,
each of the Parties, intending to be legally bound, has caused an authorized Representative of such Party to duly execute and deliver
this Agreement on behalf of such Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&#8239;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">BUYER:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&#8239;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&#8239;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Cellution Biologics Inc.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&#8239;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/ Mayur Abhaya</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Mayur Abhaya</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Director and President</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&#8239;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&#8239;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">SELLER:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&#8239;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&#8239;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Elutia Inc.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&#8239;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ C. Randal Mills</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">C. Randal Mills, Ph.D.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature Page&#8239;to Asset Purchase Agreement]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Annex A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Defined Terms</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following definitions
will apply in connection with the interpretation of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Accounts Receivable</U>&rdquo;
means all trade and other accounts receivable and other indebtedness owing to Seller with respect to the SimpliDerm Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Acquired Inventory</U>&rdquo;
is defined in <U>Annex B</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Acquisition Proposal</U>&rdquo;
is defined in <U>Section&#8239;5.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means, with respect to a specified Person, any other Person that directly or indirectly controls, is controlled by, or is under common
control with, such specified Person. The term &ldquo;control&rdquo; means (a)&#8239;the possession, directly or indirectly, of the power
to vote 10% or more of the securities of a Person having ordinary voting power, (b)&#8239;the possession, directly or indirectly, of the
power to direct or cause the direction of the management policies of a Person, by Contract or otherwise, or (c)&#8239;being a director,
manager, officer, executor, trustee, or fiduciary (or their equivalents) of a Person or a Person that controls such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Agreement</U>&rdquo;
is defined in the introductory paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Allocation Schedule</U>&rdquo;
is defined in <U>Section&#8239;2.2(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Asset</U>&rdquo;
means any asset or property of any kind, nature, character, or description whatsoever (whether known or unknown, whether real or personal
or mixed, and whether tangible or intangible) and wherever situated, including the goodwill related thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Assumed Contracts</U>&rdquo;
is defined in <U>Section&#8239;2.1(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Assumed Liabilities</U>&rdquo;
is defined in <U>Section&#8239;2.1(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Base Price</U>&rdquo;
means $8,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Benefit Plans</U>&rdquo;
means, collectively, all benefits received by any current or former employee or independent contractor of Seller employed or engaged,
respectively, for the purposes of providing services to, or for the benefit of, the SimpliDerm Business (or any of their respective beneficiaries),
as well as a list of all employee welfare benefit plans (as defined in Section&#8239;3(1)&#8239;of ERISA, whether or not subject to ERISA),
employee pension benefit plans (as defined in Section&#8239;3(2)&#8239;of ERISA, whether or not subject to ERISA), and all other employment,
compensation, consulting, bonus, stock option, restricted stock grant, stock purchase, other cash or stock-based incentive, profit sharing,
savings, retirement, disability, insurance, severance, deferred compensation, and other similar fringe or employee benefit plans, programs,
or Contracts (i)&#8239;sponsored, maintained, contributed to, or required to be contributed to, or entered into by Seller or any ERISA
Affiliate for the benefit of, or relating to, any current or former director, officer, employee, or independent contractor of Seller
or any ERISA Affiliate (or any of their respective beneficiaries), or (ii)&#8239;under which Seller or any ERISA Affiliate has or could
have any present or future Liability, in each case, with respect to the SimpliDerm Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bill of Sale</U>&rdquo;
is defined in <U>Section&#8239;2.4(a)(i)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Associates</U>&rdquo;
is defined in <U>Section&#8239;3.16(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo;
means any day except Saturday, Sunday, or any other day on which commercial banks located in Atlanta, Georgia are authorized or required
by applicable Legal Requirements to be closed for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Buyer</U>&rdquo;
is defined in the introductory paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Buyer Closing Documents</U>&rdquo;
is defined in <U>Section&#8239;2.4(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Buyer Fundamental
Representations</U>&rdquo; means those representations and warranties set forth in <U>Section&#8239;4.1</U> (Organization and Good Standing),
<U>Section&#8239;4.2(b)(i)</U>&#8239;(Authority; No Conflict), and <U>Section&#8239;4.3</U> (Brokers or Finders).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Buyer Indemnified
Persons</U>&rdquo; is defined in <U>Section&#8239;8.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Buyer Material
Adverse Effect</U>&rdquo; means any Effect that is, or would reasonably be expected to become, individually or in the aggregate, materially
adverse to the ability of Buyer to consummate the Transactions on a timely basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
is defined in <U>Section&#8239;2.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing Date</U>&rdquo;
means the day on which the Closing takes place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing Inventory
Statement</U>&rdquo; is defined in <U>Section&#8239;2.5(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing Inventory
Value</U>&rdquo; is defined in <U>Section&#8239;2.5(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Code</U>&rdquo;
means the Internal Revenue Code of 1986, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Confidentiality
Agreement</U>&rdquo; means that certain Mutual Confidentiality and Evaluation Agreement, dated as of April&#8239;11, 2026, by and between
Buyer and Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Consent</U>&rdquo;
means any consent, approval, authorization, permission, waiver, clearance, exemption, expiration of any notification requirements, or
similar affirmation by any Person pursuant to any Contract, Governmental Authorization, Legal Requirement, or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Contract</U>&rdquo;
means any contract, agreement, instrument, obligation, covenant, commitment, arrangement, undertaking, understanding, lease, license,
plan, mortgage, indenture, note, loan, bond, debenture, guarantee, insurance policy, concession, franchise, purchase or sales order,
bid, or other contractual obligation, whether written or oral and whether express or implied, together with all amendments, supplements,
and other modifications thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Copyrights</U>&rdquo;
means copyrightable works (including advertising and promotional materials, Software, compilations of data, and website content), and
any copyrights therefor (whether registered or unregistered), and including common law and statutory rights therein and therefor, and
further including goodwill relating thereto, registrations and renewals thereof, and applications for registration therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Damage</U>&rdquo;
means any damage, loss, Liability, Tax, judgment, award, assessment, settlement, disbursement, deficiency, fine, penalty, cost, or expense
of any nature whatsoever (including any reasonable costs of investigation and any defense and reasonable attorneys&rsquo;, consultants&rsquo;
and experts&rsquo; fees and expenses, in each case, incurred in connection with any Direct Claim or Third-Party Claim); <U>provided</U>,
<U>however</U>, that Damage shall not include punitive damages (unless actually awarded to a third party).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Deductible Amount</U>&rdquo;
is defined in <U>Section&#8239;8.5(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Direct Claim</U>&rdquo;
is defined in <U>Section&#8239;8.7</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure Schedules</U>&rdquo;
is defined in <U>ARTICLE&#8239;III</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disputed Inventory
Items</U>&rdquo; is defined in <U>Section&#8239;2.5(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disputed Matters</U>&rdquo;
means the specific matters in dispute with respect to the Closing Inventory Statement or an Earnout Payment Calculation that are set
forth in an Objection Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Distributor Agreements</U>&rdquo;
is defined in <U>Section&#8239;3.7</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Earnout Objection
Period</U>&rdquo; is defined in <U>Section&#8239;2.7(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Earnout Payment</U>&rdquo;
is defined in <U>Section&#8239;2.7(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Earnout Payment
Calculation</U>&rdquo; is defined in <U>Section&#8239;2.7(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Earnout Period</U>&rdquo;
is defined in <U>Section&#8239;2.7(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Earnout Target</U>&rdquo;
is defined in <U>Section&#8239;2.7(a)(iii)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Effect</U>&rdquo;
means any event, occurrence, fact, circumstance, condition, development, change, or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Effective Time</U>&rdquo;
is defined in <U>Section&#8239;2.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Encumbrance</U>&rdquo;
means any lien (statutory or otherwise), security interest, Preferential Right, charge, claim, pledge, mortgage, deed of trust, lease,
license, easement, encroachment, claim of ownership or right to possession (in whole or in part), restriction of any kind or nature,
or any other encumbrance of any kind or nature whatsoever, together with all documents and instruments evidencing or securing such matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Enforceability
Exceptions</U>&rdquo; means bankruptcy laws, other similar laws affecting creditors&rsquo; rights, and general principles of equity affecting
the availability of specific performance and other equitable remedies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>ERISA</U>&rdquo;
means the Employee Retirement Income Security Act of 1974.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>ERISA Affiliate</U>&rdquo;
means any Person that is considered a single employer with Seller under Section&#8239;414 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Estimated Closing
Cash Consideration</U>&rdquo; means a dollar amount equal to (a)&#8239;the Base Price, <I>minus</I> (b)&#8239;the Estimated Inventory Shortfall
(if any).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Estimated Inventory
Shortfall</U>&rdquo; means the amount by which the Target Inventory Value exceeds the Estimated Inventory Value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Estimated Inventory
Statement</U>&rdquo; is defined in <U>Section&#8239;2.5(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Estimated Inventory
Value</U>&rdquo; is defined in <U>Section&#8239;2.5(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Excluded Assets</U>&rdquo;
is defined in <U>Section&#8239;2.1(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Excluded Liabilities</U>&rdquo;
is defined in <U>Section&#8239;2.1(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Execution Date</U>&rdquo;
is defined in the introductory paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Executory Period</U>&rdquo;
means the period commencing on (and including) the Execution Date and continuing until the Closing (or, if earlier, the termination of
this Agreement in accordance with <U>Article&#8239;IX</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDA</U>&rdquo;
means the U.S. Food and Drug Administration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDCA</U>&rdquo;
means the United States Federal Food, Drug, and Cosmetic Act of 1938, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Filing</U>&rdquo;
means any report, registration, document, filing, declaration, statement, application, or submission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Financial Statements</U>&rdquo;
means the Fiscal Year Financial Statements and the Interim Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Fiscal Year Financial
Statements</U>&rdquo; is defined in <U>Section&#8239;3.3(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Fraud</U>&rdquo;
means common law fraud under the Legal Requirements of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
means United States generally accepted accounting principles in effect as of the date in question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Governance Documents</U>&rdquo;
means, with respect to any Person, (a)&#8239;the charter, articles or certificate of incorporation, organization, or formation, or such
other constitutive documents of such Person, including those that are required to be registered or kept in the place of incorporation,
organization, or formation of such Person, that establish the legal existence of such Person, and (b)&#8239;the bylaws, stockholders agreement,
operating agreement, limited liability company agreement, limited partnership agreement, partnership agreement, or such other governance
documents of such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Governmental Authority</U>&rdquo;
means any U.S. federal, state, local, municipal, foreign, or other court, legislature, executive, or regulatory authority (including
any self-regulatory or non-governmental regulatory authority), agency, or commission, or other governmental or quasi-governmental entity,
authority, organization, or instrumentality, or any department, agency, subdivision, board, directorate, court, tribunal, or other instrumentality
of any of the foregoing, or any arbitrator, as well as any third Person certifying organization, agency, or body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Governmental Authorization</U>&rdquo;
means any license, permit, franchise, approval, authorization, registration, certification, qualification, membership, variance, immunity,
closure, Consent, or other similar right required by any applicable Legal Requirement to be obtained from a Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Guaranteed Month</U>&rdquo;
is defined in <U>Section&#8239;2.6(b)(i)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Guaranteed Period</U>&rdquo;
is defined in <U>Section&#8239;2.6(b)(ii)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indemnified Person</U>&rdquo;
means any Buyer Indemnified Person or Seller Indemnified Person, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indemnifying Person</U>&rdquo;
means the Party against whom an indemnification claim is made pursuant to <U>Article&#8239;VIII</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Independent Accounting
Firm</U>&rdquo; means such nationally or regionally recognized independent accounting firm mutually acceptable to the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Information Systems</U>&rdquo;
means all computer hardware, firmware and Software, data storage systems (including servers), computer and communications networks (other
than the internet), and equipment, interfaces, applications, platforms, firewalls, and other apparatus that are owned by or leased to
Seller and used to create, manipulate, store, transmit, exchange, or receive information in any electronic form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Insurance Policies</U>&rdquo;
is defined in <U>Section&#8239;3.9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual Property
Rights</U>&rdquo; means intellectual property and/or other proprietary rights, including (a)&#8239;Marks, (b)&#8239;Net Names, (c)&#8239;Patents,
(d)&#8239;Copyrights, (e)&#8239;know-how, trade secrets, technical, marketing, or pricing information, plans, notes, reports, drawings,
photographs, works, devices, computer hardware, makes, models, works-in-progress, research and development, formulas, algorithms, processes,
data, designs, layouts, customer and supplier lists, financial information, inventions, and creations, (f)&#8239;Software (whether in
general release or under development), and (g)&#8239;all rights to prosecute and perfect any of the foregoing through administrative prosecution,
registration, recordation, or other Proceeding, and all causes of action and rights to sue or seek other remedies arising from or relating
to the foregoing, including for any past or ongoing infringement, misuse, or misappropriation, anywhere in the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Interim Financial
Statements</U>&rdquo; is defined in <U>Section&#8239;3.3(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Inventory Count</U>&rdquo;
is defined in <U>Section&#8239;2.5(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Inventory Dispute
Notice</U>&rdquo; is defined in <U>Section&#8239;2.5(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Inventory Dispute
Period</U>&rdquo; is defined in <U>Section&#8239;2.5(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Inventory Value</U>&rdquo;
means, as of any particular time, the value of the Acquired Inventory as determined in accordance with GAAP applied on a consistent basis
with the determinations in the Financial Statements (to the extent such determinations are consistent with GAAP).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>IP Assignment Agreement</U>&rdquo;
is defined in <U>Section&#8239;2.4(a)(ii)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>IRS</U>&rdquo;
means the United States Internal Revenue Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Key Personnel</U>&rdquo;
is defined in <U>Section&#8239;6.1(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Knowledge of Seller</U>&rdquo;
means any matters known by, or that would be known following reasonable diligence and inquiry by, Sonali Fonseca, PhD, Matt Ferguson,
C. Randal Mills, PhD, Pete Ligotti, or Jeff Hamet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Legal Requirement</U>&rdquo;
means any federal, state, local, municipal, foreign, or other law (including common law), statute, code, ordinance, regulation, rule,
regulatory or administrative ruling, directive, Order, constitution, treaty, or other restriction, requirement, or rule&#8239;of law of
any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Letter of Intent</U>&rdquo;
means that certain Non-Binding Term Sheet for Proposed Acquisition of the SimpliDerm Product Family, dated as of May&#8239;15, 2026, by
and between Buyer and Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liability</U>&rdquo;
means any liability, obligation, or commitment of any kind, nature, character, or description whatsoever (whether primary or secondary,
whether direct or indirect, whether known or unknown, whether asserted or unasserted, whether absolute or contingent, whether accrued
or unaccrued, whether matured or unmatured, whether liquidated or unliquidated, whether due or to become due, and whether secured or
unsecured).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Loss Proceeds</U>&rdquo;
is defined in <U>Section&#8239;5.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Marks</U>&rdquo;
means, registered and unregistered, trademarks, logos, logotypes, corporate names, trade names, trade dress, and service marks, including
common law and statutory rights therein and therefor, and further including goodwill relating thereto, registrations and renewals thereof,
and applications for registration therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material Customers</U>&rdquo;
is defined in <U>Section&#8239;3.6(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material Suppliers</U>&rdquo;
is defined in <U>Section&#8239;3.6(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Milestone Payment
Reduction</U>&rdquo; is defined in <U>Section&#8239;2.6(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Milestone Payment
Reduction Calculation</U>&rdquo; is defined in <U>Section&#8239;2.6(f)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Milestone Payment
Reduction Objection Period</U>&rdquo; is defined in <U>Section&#8239;2.6(f)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Monthly Financial
Statements</U>&rdquo; is defined in <U>Section&#8239;5.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Negotiation Period</U>&rdquo;
is defined in <U>Section&#8239;2.5(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Net Names</U>&rdquo;
means internet web sites and internet domain names, including all related internet protocol addresses, and including common law and statutory
rights therein and therefor, and further including goodwill relating thereto, registrations and renewals thereof, and applications for
registration therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Non-Assignable
Contract</U>&rdquo; is defined in <U>Section&#8239;6.7</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Notified Party</U>&rdquo;
is defined in <U>Section&#8239;5.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Notifying Party</U>&rdquo;
is defined in <U>Section&#8239;5.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Objection Notice</U>&rdquo;
means a written notice of any good faith objection to the Closing Inventory Statement or an Earnout Payment Calculation, as the case
may be, specifying in reasonable detail the nature and basis of such objection, as well as the specific Disputed Matters and the amount
of any proposed adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Operating Unit
Names</U>&rdquo; is defined in <U>Section&#8239;6.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Order</U>&rdquo;
means any order, award, decision, injunction, judgment, ruling, decree, assessment, charge, writ, subpoena, or verdict entered, issued,
made, or rendered by any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Ordinary Course</U>&rdquo;
means the ordinary course of business of Seller consistent with past customs and practices (including with respect to quantity and frequency)
of Seller, but in no event including any (a)&#8239;breach of Contract or warranty, (b)&#8239;infringement, (c)&#8239;professional error
or omission, (d)&#8239;act or event creating a severance obligation, wrongful discharge claim, or similar Liability, (e)&#8239;tort, or
(f)&#8239;violation of Legal Requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Outside Date</U>&rdquo;
is defined in <U>Section&#8239;9.1(e)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Overall Cap Amount</U>&rdquo;
is defined in <U>Section&#8239;8.5(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Parties</U>&rdquo;
means Buyer and Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Patents</U>&rdquo;
means inventions (whether patentable or unpatentable and whether or not reduced to practice), improvements to inventions, patents, patent
applications, and work product therefor, together with any reissuance, division, continuation, continuation-in-part, revision, extension,
or reexamination of any such patent or patent application, and including common law and statutory rights therein and therefor, and further
including goodwill relating thereto, registrations and renewals thereof, and applications for registration therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Permitted Encumbrance</U>&rdquo;
means any (a)&#8239;mechanic&rsquo;s, materialman&rsquo;s, or similar lien arising and incurred in the Ordinary Course (i)&#8239;that does
not result from a breach, default, or violation by the owner of the Asset subject to any such lien, (ii)&#8239;that is not, individually
or in the aggregate, material to the business, operations, and financial condition of the owner of the Asset subject to any such lien,
and (iii)&#8239;for which the underlying obligations are not past due or payable, or (b)&#8239;lien for Taxes not yet due or payable or
that are being contested in good faith by appropriate Proceedings and for which adequate reserves have been recorded in accordance with
GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means any individual, partnership, limited partnership, limited liability partnership, limited liability company, corporation, unincorporated
association, joint stock company, joint venture, trust, business trust, or other entity, or any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Personal Information</U>&rdquo;
means any data or information that alone or in combination with other information can be used to specifically identify an individual,
including any information defined as personally identifiable information or a similar term under any Privacy Laws and Standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>PMA</U>&rdquo;
means a premarket approval as contemplated under Title 21 of the FDCA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Post-Closing Adjustment
Amount</U>&rdquo; is defined in <U>Section&#8239;2.5(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Preferential Right</U>&rdquo;
means any purchase option, call right, right of first refusal, right of first offer, co-sale right, participation right, preemptive right,
subscription right, put right, or other similar right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Privacy Laws and
Standards</U>&rdquo; is defined in <U>Section&#8239;3.19</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means any claim, counterclaim, charge, complaint, allegation, notice of violation, notice, demand, action, cause of action, enforcement
action, lawsuit, litigation, proceeding, hearing, arbitration, mediation, citation, indictment, summons, subpoena, audit, investigation,
or inquiry of any nature (in each case, whether civil, criminal, administrative, regulatory, investigative, or informal, and whether
at law or in equity) (including with respect to labeling or marketing) commenced, conducted, heard, or pending by or before any Governmental
Authority or mediator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Profitability Shortfall</U>&rdquo;
is defined in <U>Section&#8239;2.6(b)(iv)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Profitability Target</U>&rdquo;
is defined in <U>Section&#8239;2.6(b)(v)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prorated Taxes</U>&rdquo;
is defined in <U>Section&#8239;6.2(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchase Price</U>&rdquo;
is defined in <U>Section&#8239;2.2(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchase Price
Bank Account</U>&rdquo; means that certain bank account in the United States to be designated by Seller in a written notice to Buyer
prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchased Assets</U>&rdquo;
is defined in <U>Section&#8239;2.1(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Related Person</U>&rdquo;
means (a)&#8239;any Affiliate, stockholder, director, or officer of Seller and (b)&#8239;any Affiliate or member of the immediate family
(including any spouse, child, parent, or sibling) of any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Released Inventory</U>&rdquo;
means, any Unusable Acquired Inventory pursuant to clause (c)&#8239;of the definition of &ldquo;Unusable Acquired Inventory&rdquo; that
is released or re-released after the Closing by any Supplier and becomes commercially saleable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Representative</U>&rdquo;
means, with respect to any Person, any director, manager, officer, employee, independent contractor, consultant, legal counsel, accountant,
financial advisor, or other agent or representative of such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Restrictive Covenant
Agreement</U>&rdquo; is defined in <U>Section&#8239;2.4(a)(iv)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Retained Business</U>&rdquo;
means any and all businesses of the Seller and its Affiliates other than the SimpliDerm Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Retained IP</U>&rdquo;
is defined in <U>Annex C</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Sales Shortfall</U>&rdquo;
is defined in <U>Section&#8239;2.6(b)(iii)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Seller</U>&rdquo;
is defined in the introductory paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Seller Closing
Documents</U>&rdquo; is defined in <U>Section&#8239;2.4(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Seller Contract</U>&rdquo;
means any Contract relating to the SimpliDerm Business or any Purchased Asset to which Seller is a party or by which Seller is otherwise
bound in connection with the SimpliDerm Business, any Purchased Asset, or any Assumed Liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Seller Fundamental
Representations</U>&rdquo; means those representations and warranties set forth in <U>Section&#8239;3.1</U> (Organization and Good Standing),
<U>Section&#8239;3.2(b)(i)</U>&#8239;(Authority; No Conflict), the first sentence of <U>Section&#8239;3.4</U> (Assets), <U>Section&#8239;3.18</U>
(Taxes), <U>Section&#8239;3.20</U> (Related Persons), and <U>Section&#8239;3.22</U> (Brokers or Finders).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Seller Governmental
Authorizations</U>&rdquo; is defined in <U>Section&#8239;3.12</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Seller Indemnified
Persons</U>&rdquo; is defined in <U>Section&#8239;8.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Seller IP Rights</U>&rdquo;
means all of the Intellectual Property Rights owned or purported to be owned by Seller, in each case, related to the SimpliDerm Business
or any Purchased Asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Seller Material
Adverse Effect</U>&rdquo; means any Effect that is, or would reasonably be expected to become, individually or in the aggregate, materially
adverse to (a)&#8239;the businesses, results of operations, earnings, condition (financial or otherwise), Assets, or Liabilities of the
Seller, taken as a whole, or (b)&#8239;the ability of Seller to timely perform its obligations under the Transaction Documents or to consummate
and perform the Transactions on a timely basis; provided, however, that, for the purposes of clause&#8239;(a)&#8239;in determining whether
a Seller Material Adverse Effect has occurred, no Effect will be considered to the extent directly resulting from (i)&#8239;changes generally
affecting the economy, financial, or securities markets, including political conditions, any disruption thereof, any decline in the price
of any security or any market index or any change in prevailing interest rates, or the price of commodities or raw materials used in
or related to the Purchased Assets and general changes in the tariffs, duties, or other trade restrictions generally affecting the medical
supply product industry, (ii)&#8239;general conditions in the industry in which Seller operates, (iii)&#8239;any earthquakes, hurricanes,
floods or other natural disasters, epidemics, pandemics, disease outbreaks (including the coronavirus (COVID-19) disease or the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic) or public health emergencies, acts of God or force majeure events, or
any escalation or worsening of any of the foregoing, whether or not occurring or commenced before or after the date of this Agreement
and any mandate or guidance of any Governmental Authority or any actions taken by Seller related to any of the foregoing, (iv)&#8239;the
failure of Seller to meet internal or published projections, forecasts, or revenue or earning predictions for any period (but not the
underlying causes of such failure unless such underlying causes would otherwise be excepted from this definition); (v)&#8239;acts of war
(whether or not declared), armed hostilities, or terrorism, or the escalation or worsening thereof; or (vi)&#8239;any changes in applicable
Legal Requirements or GAAP or the enforcement, implementation, or interpretation thereof, in each case, after the Closing Date; provided,
further, that any Effect arising out of or resulting from any change or event referred to in clause&#8239;(i), (ii), (iii), (v), or (vi)&#8239;shall
only constitute, or will be taken into account in determining the occurrence of, a Seller Material Adverse Effect to the extent such
change or event has a disproportionate impact on Seller as compared to other companies that operate in the industries in which Seller
operates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Seller Privacy
Requirements</U>&rdquo; is defined in <U>Section&#8239;3.19</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Seller Products</U>&rdquo;
means the SimpliDerm&reg; family of products offered for sale by Seller as of the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Seller SEC Documents</U>&rdquo;
is defined in <U>Section&#8239;3.23</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Seller Sites</U>&rdquo;
means internet websites owned, maintained, or operated by Seller, in each case, related to the SimpliDerm Business or any Purchased Asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Seller Special
Representations</U>&rdquo; means those representations set forth in <U>Section&#8239;3.5</U> (Intellectual Property; Information Systems);
<U>Section&#8239;3.7</U> (Distributor Agreements); <U>Section&#8239;3.10</U> (Product Safety and Product Recalls); <U>Section&#8239;3.13</U>
(Compliance with Legal Requirements); and <U>Section&#8239;3.15</U> (FDA and Regulatory Compliance).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shared Contracts</U>&rdquo;
means all Contracts listed on <U>Schedule 3.14-1</U>, which, except as otherwise stated on <U>Schedule 3.14-1</U>, relate to or are used
in connection with both (i)&#8239;the SimpliDerm Business or the Seller Products, on the one hand, and (ii)&#8239;the Retained Business,
on the other hand (each, as amended, restated, supplemented. renewed, extended or replaced from time to time (and including any successor
Contract thereto)).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>SimpliDerm Business</U>&rdquo;
is defined in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>SimpliDerm Sales</U>&rdquo;
is defined in <U>Section&#8239;2.7(a)(iv)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Software</U>&rdquo;
means computer software programs and software systems, including all databases, compilations, tool sets, compilers, modules, libraries,
files, or other components, higher level of &ldquo;proprietary&rdquo; languages, source code, object code, and related data, records,
documentation, specifications, manuals, user guides, and materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Standard Pre-Tax
Profit Margin</U>&rdquo; is defined in <U>Section&#8239;2.6(b)(vi)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Supplier</U>&rdquo;
means each supplier of the SimpliDerm Business that is listed on <U>Schedule 1.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Target Inventory
Value</U>&rdquo; means [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Tax</U>&rdquo;
means any U.S. federal, state, county, municipal, local, or non-U.S. tax, duty, levy other similar charge in the nature of a tax imposed,
assessed, or collected by a Tax Authority, including (a)&#8239;any gross or net income, gross receipts, business, license, capital, capital
gains, goods and services, value added, service severance, stamp, franchise, occupation, production, capital stock, sales and use, property
(real or personal), ad valorem, transfer, registration, license, lease, profits, environmental, payroll, employment, unemployment, disability,
social security (or similar tax), escheat, unclaimed property, excise, recapture, wealth, estate, inheritance, surplus, alternative or
minimum, estimated or premium tax, (b)&#8239;any withholding on amounts paid to or by the relevant person, (c)&#8239;any fine, penalty,
interest, and addition to tax imposed by a Tax Authority with respect to a Tax, whether disputed or not, (d)&#8239;any tax imposed, assessed,
or collected or payable pursuant to tax sharing agreements or other contracts relating to the sharing or payment of taxes levies, or
fees, and (e)&#8239;any Liability for any amount described in clause (a),(b), (c), or (d)&#8239;as a transferee, successor, by Contract
or by operation of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Tax Authority</U>&rdquo;
means the IRS and any other Governmental Authority that is charged with the administration, regulation, collection and assessment of
any Tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Tax Clearance Certificates</U>&rdquo;
means certificates from all applicable Governmental Authorities in those jurisdictions that impose Taxes on Seller or where Seller has
a duty to file Tax Returns (in each case, related to the SimpliDerm Business or any Purchased Asset), evidencing that all applicable
Taxes of Seller related to the SimpliDerm Business or any Purchased Asset accruing on or before the Closing Date, have been fully satisfied
or otherwise provided for by Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Tax Return</U>&rdquo;
means any return, report, statement, or other document required to be filed with a Tax Authority with respect to any Tax, including any
applicable schedule, attachment or amendment required to be filed by a Tax Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Technology Transfer</U>&rdquo;
is defined in <U>Section&#8239;6.8(c)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Technology Transfer
Package</U>&rdquo; is defined in <U>Section&#8239;6.8(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Third-Party Claim</U>&rdquo;
is defined in <U>Section&#8239;8.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction Documents</U>&rdquo;
means this Agreement and all other Contracts, documents, and certificates contemplated by this Agreement, including the Seller Closing
Documents and the Buyer Closing Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction Expenses</U>&rdquo;
means (a)&#8239;all of the fees, charges, expenses, and other costs and Liabilities incurred, paid, or required to be paid by Seller in
connection with the negotiation of the Transaction Documents, the performance of Seller&rsquo;s obligations under the Transaction Documents,
and the preparation for and consummation and performance of the Transactions, including (i)&#8239;all of the fees, charges, expenses,
and other costs of legal counsel, accountants, investment bankers, brokers, financial advisors, and other Representatives and consultants
of Seller engaged in connection with the Transactions, whether or not such fees, charges, expenses, or other costs have been assessed
or billed prior to the Closing, (ii)&#8239;all of the fees, charges, expenses and other costs associated with Seller providing any necessary
or appropriate notices, making the necessary Filings, or obtaining any necessary or appropriate Consents of any Governmental Authority
or other Person in connection with the execution, delivery, and performance of the Transaction Documents and the consummation and performance
of the Transactions, and (iii)&#8239;all of the fees, charges, expenses, and other costs associated with obtaining the release of all
Encumbrances on the Purchased Assets, and (b)&#8239;all Transfer Taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transactions</U>&rdquo;
means all of the transactions provided for in this Agreement and the other Transaction Documents, including the sale and purchase of
the Purchased Assets and the assignment and assumption of the Assumed Liabilities contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer Taxes</U>&rdquo;
means all provisional and final sales, use, transfer, recording, documentary, stamp, registration, value added, gross receipts, and all
other similar Taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transition Milestone
Payment</U>&rdquo; means $2,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transition Milestones</U>&rdquo;
is defined in <U>Section&#8239;2.6(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Treasury Regulations</U>&rdquo;
means the United States Treasury Regulations promulgated under the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>TSA</U>&rdquo;
is defined in <U>Section&#8239;2.4(a)(iii)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Unusable Acquired
Inventory</U>&rdquo; means, any Acquired Inventory that is (a)&#8239;expired, (b)&#8239;within two months of its expiry date as of the
Closing Date, (c)&#8239;not commercially salable or otherwise unavailable for commercial sale due to a regulatory hold (including any
Acquired Inventory pending release or re-release by any Supplier), or (d)&#8239;solely with respect to the SD.090.1616P Acquired Inventory,
in excess of 16 units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Virtual Data Room</U>&rdquo;
means that certain electronic documentation site located at https://vdr.dfsvenue.com/project/documents?id=3000001725&amp;fid=4256252&amp;treeId=4576.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Annex B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Purchased Assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                            product rights, SKUs, configurations, thicknesses, sizes, packaging formats, labeling,&#8239;IFUs,
                                            artwork, product claims, branding, trade names, and trademarks (other than the Retained IP),
                                            in each case to the extent related to or used primarily in connection with the Seller Products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                            Seller IP Rights.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                            inventories relating to or held in connection with the Seller Products or otherwise used
                                            in or useful to the sale, use, manufacture, maintenance, development or improvement of the
                                            Seller Products, including parts, work in process and finished goods (but excluding raw materials)
                                            (the &ldquo;<U>Acquired Inventory</U>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                            complaint files, FDA correspondence with or to Seller (including all communications, submissions
                                            and correspondence with the FDA or otherwise related to any FDA action), inspection reports,
                                            361 HCT/P filings, and adverse event and/or vigilance history files or documentation, in
                                            each case, relating to the Seller Products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                            books and records, sales history, pipeline information, pricing files, customer purchasing
                                            histories, marketing materials, training materials, pre-clinical and clinical publications,
                                            competitive differentiation studies, and claim-substantiation materials, in each case to
                                            the extent related to or used primarily in connection with the Seller Products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                            Assumed Contracts.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                            rights of Buyer under the Shared Contracts to the extent allocated to Buyer in accordance
                                            with <U>Section&#8239;6.1</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                            Operating Unit Names.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                            payor coverage decisions and reimbursement-related materials used in connection with the
                                            Seller Products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                            other Assets of Seller used or held for use exclusively in the SimpliDerm Business (other
                                            than any Tax Asset).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 58; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Annex C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Excluded Assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                            Contracts of Seller other than the Assumed Contracts;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                            Accounts Receivable of Seller existing as of the Closing and arising out of the operation
                                            or conduct of the SimpliDerm Business prior to the Closing for goods delivered or prior to
                                            or in transit at the time of Closing or services provided prior to the Closing;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                            rights of Seller under the Shared Contracts to the extent allocated to Seller in accordance
                                            with <U>Section&#8239;6.1</U>;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                            inventory other than the Acquired Inventory, including but not limited to inventory in the
                                            possession of Millstone Medical Outsourcing, LLC or its Affiliates used or held for use exclusively
                                            in the Retained Business, including for the avoidance of doubt, any raw materials, parts,
                                            work in process and finished goods for Patch, VasCure, ProxiCor and Tyke;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                            equipment of Seller;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                            Information Systems used by Seller;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                            taxpayer identification numbers, Tax Returns, Tax work papers, Tax information and Tax records
                                            of any Seller (except to the extent that any such Tax documentation relates solely to the
                                            SimpliDerm Business or the Purchased Assets);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                            rights to any Tax credit, Tax refund or similar Tax asset relating to (i)&#8239;any Tax of
                                            Seller or (ii)&#8239;the Purchased Assets or the SimpliDerm Business with respect to a Tax
                                            period (or portion of a Tax period) ending on or prior to the Closing Date;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                            Tax Returns and other Tax information that is not solely related to the SimpliDerm Business;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                            Intellectual Property Rights of Seller other than the Seller IP Rights (the &ldquo;<U>Retained
                                            IP</U>&rdquo;), including but not limited to &ldquo;Aziyo&rdquo;, &ldquo;Elutia&rdquo; and
                                            any mark or domain set forth below, in each case, that is not related to or used in the SimpliDerm
                                            Business, and any associated logos and any variations or other derivatives thereof; and,
                                            in each case, whether in block letters or otherwise, whether alone or in combination with
                                            other words or elements, and including all translations, adaptations, and other derivations
                                            and combinations thereof, and any marks confusingly similar thereto or embodying any of the
                                            foregoing either alone or in combination with other words or elements, and all common law
                                            rights, registrations, applications for registration thereof and social media handles and
                                            domain names associated therewith, together with any extensions and renewals thereof, and
                                            together with the goodwill associated with any of the foregoing:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Aziyo Biologics,&#8239;Inc.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Elutia Inc.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">elutia.com</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Medicine Humanized</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 59; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="text-align: left; width: 0.25in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Sans-Serif; font-size: 9pt"><B><IMG SRC="tm2620864d1_ex10-1img001.jpg" ALT=""></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                            employer-employee relationships between Seller and its current employees (provided that,
                                            for the avoidance of doubt, Seller acknowledges and agrees that this Excluded Asset does
                                            not limit Seller&rsquo;s obligations under this Agreement or the TSA with respect to making
                                            Key Personnel available in accordance with the terms of this Agreement and the TSA);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                            real property of Seller; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All assets of Seller or its Affiliates that relate solely to the Retained
Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 60; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>tm2620864d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Elutia
Signs Definitive Agreement to Sell SimpliDerm</B></FONT>&reg; <B>in Transaction Valued at up to $11 Million, Strengthening Balance Sheet
Ahead of NXT-41x Launch</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><I>Transaction
                                            provides $8 million in cash at closing and up to $3 million in technology transfer and commercial
                                            milestone payments over the next 18 months</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><I>Proceeds
                                            provide additional non-dilutive capital to advance NXT-41x toward anticipated clearance and
                                            targeted commercial launch in 2027</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><I>Divestiture
                                            sharpens Elutia&rsquo;s focus on NXT-41x and the $1.5 billion plastic and reconstructive
                                            surgery opportunity</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">GAITHERSBURG, Md., July&nbsp;16, 2026 (GLOBE NEWSWIRE) -- Elutia Inc.
(Nasdaq: ELUT) (&ldquo;Elutia&rdquo; or the &ldquo;Company&rdquo;), a pioneer in drug-eluting biomatrix technologies, today announced
the signing of a definitive agreement to sell its SimpliDerm&reg; human acellular dermal matrix business to Cellution Biologics Inc.
for total consideration of up to $11 million. Elutia will receive $8 million in cash at closing, along with up to $3 million in technology
transfer and commercial milestone payments over the next 18 months. Closing is expected to occur in the second half of 2026, subject
to customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The divestiture completes Elutia&rsquo;s previously announced strategic
process for SimpliDerm and focuses the Company&rsquo;s resources on NXT-41x, its next-generation antibiotic-eluting biomatrix for plastic
and reconstructive surgery. The proceeds further strengthen Elutia&rsquo;s balance sheet without equity dilution and provide additional
capital to support its planned commercial launch in 2027.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;This transaction is another decisive step in fortifying Elutia&rsquo;s
balance sheet with non-dilutive capital and sharpening our focus on NXT-41x,&rdquo; said Dr.&nbsp;Randy Mills, Chief Executive Officer
of Elutia. &ldquo;SimpliDerm is a well-established regenerative solution developed by Elutia, and this transaction places the business
with an organization committed to its continued success. Looking ahead, we believe NXT-41x has the potential to redefine soft tissue
reinforcement for women undergoing surgery after breast cancer, a setting in which serious complications still affect as many as 1 in
3 patients. We are committed to changing that.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of the agreement, Elutia will receive $8 million in
cash at closing, along with up to an additional $3 million in technology transfer and commercial milestone payments payable over the
next 18 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NXT-41x is being developed for the approximately $1.5 billion U.S.
plastic and reconstructive surgery market, where Elutia believes antibiotic-eluting biomatrix technologies fulfill a significant unmet
need in soft tissue reinforcement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Elutia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elutia
develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need
them. With a growing population in need of implantable technologies, Elutia&rsquo;s mission is humanizing medicine so patients can thrive
without compromise. For more information, visit <U>www.Elutia.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SimpliDerm&reg; is a registered trademark of Elutia Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains &ldquo;forward-looking statements&rdquo;
within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act
of 1934, as amended. Forward-looking statements can be identified by words such as &ldquo;projects,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo;
 &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo; &ldquo;believes,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo;
 &ldquo;estimates,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;potential,&rdquo; &ldquo;promise&rdquo; or similar references
to future periods. All statements contained in this press release that do not relate to matters of historical fact should be considered
forward-looking statements, including any statements and information regarding whether or when the sale of the SimpliDerm&reg; human
acellular dermal matrix business (the &ldquo;Transaction&rdquo;) will be consummated; the total consideration to be received by the Company
in the Transaction, including whether any of the technology transfer and commercial milestones will be achieved or any of the related
milestone payments will be received; the application of the anticipated proceeds of the Transaction; and the size of the U.S. breast
reconstruction market and the potential of the Company&rsquo;s next-generation drug-eluting biomatrix pipeline to compete in that market,
including the timing and success of NXT-41 and NXT-41x. These forward-looking statements are based on our management&rsquo;s beliefs
and assumptions and on information currently available to us. Additionally, such forward-looking statements are subject to a number of
known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to
be materially different from any future results, performance or achievements expressed or implied in the forward-looking statements,
including, but not limited to the following: (i)&nbsp;the occurrence of any event, change or other circumstance that could delay the
Transaction or give rise to the termination of the agreement related thereto; (ii)&nbsp;the risk that the technology transfer and commercial
milestone payments are reduced, delayed, or not earned or received; (iii)&nbsp;the outcome of any legal proceedings that may be instituted
against the Company following announcement of the Transaction; (iv)&nbsp;the inability to consummate the Transaction due to the failure
to satisfy the conditions to closing in the agreement related thereto; (v)&nbsp;the risk that the proposed Transaction disrupts the Company&rsquo;s
current plans and operations as a result of the announcement of the Transaction, including the distraction of management and the Company&rsquo;s
employees; (v)&nbsp;costs related to the Transaction; (vi)&nbsp;changes in applicable laws or regulations; and (vii)&nbsp;the other risks
discussed in the &ldquo;Risk Factors&rdquo; section of Elutia&rsquo;s public filings with the Securities and Exchange Commission (&ldquo;SEC&rdquo;),
including Elutia&rsquo;s Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2025, as such factors may be updated from
time to time in Elutia&rsquo;s other filings with the SEC, accessible on the SEC&rsquo;s website at www.sec.gov and the Investor Relations
page&nbsp;of Elutia&rsquo;s website at https://investors.elutia.com. Because forward-looking statements are inherently subject to risks
and uncertainties, you should not rely on these forward-looking statements as predictions of future events. Any forward-looking statement
made by Elutia in this press release is based only on information currently available and speaks only as of the date on which it is made.
Except as required by applicable law, Elutia expressly disclaims any obligations to publicly update any forward-looking statements, whether
written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investors:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Elutia Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>ir@elutia.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>elut-20260716.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWauMabOdzZR+2YkxtmBybZmafycneja1xSkbgPNGsUwO -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:elut="http://elutia.com/20260716" elementFormDefault="qualified" targetNamespace="http://elutia.com/20260716">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://elutia.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="elut-20260716_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="elut-20260716_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>elut-20260716_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>elut-20260716_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="elut-20260716.xsd#Cover" roleURI="http://elutia.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://elutia.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2620864d1_ex10-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2620864d1_ex10-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !I 5T# 2(  A$! Q$!_\0
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MJ[[Q_P"-=5\,>'=(O[1(//NL>:KKE<[0>/QK9T9II/J0IIJYZ'17SX/CGXC
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MTUZQN)FVQ1S*S-Z"OJ'QOIEYK/A*^T^P0/<SIM4%MH_.O#E^#/C _>MK9?\
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MT?3K?3GT^*R@2S?.Z 1@(<G)XZ5!IGAO1M&\TZ=IMM;&48<Q1A2P]#BE*HI
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< 5/L[^GZTOD/Z#\ZM44 5O(?T_6K(Z444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 16, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 16,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ELUTIA INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001708527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-4790334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">20
Firstfield Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Gaithersburg<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">247-1170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class&#160;A
    Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ELUT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tm2620864d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://elutia.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>elut-20260716.xsd</File>
    <File>elut-20260716_lab.xml</File>
    <File>elut-20260716_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2620864d1_8k.htm">tm2620864d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2620864d1_8k.htm": {
   "nsprefix": "elut",
   "nsuri": "http://elutia.com/20260716",
   "dts": {
    "schema": {
     "local": [
      "elut-20260716.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "elut-20260716_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "elut-20260716_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2620864d1_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://elutia.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2026-07-16",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2620864d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-07-16",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2620864d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://elutia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-26-085061-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-26-085061-xbrl.zip
M4$L#!!0    ( ,6@]%R"@0=^)0,  -P+   1    96QU="TR,#(V,#<Q-BYX
M<V2U5MMRVC 0?>],_T'U:\8VAD(: LFDR23##+D,-&F:EXYL"Z(B2ZXD!].O
MKV1;W PNT)8G:?><L[O2KDSG/(T(>$-<8$:[EN?4+(!HP$),QUWK<6A?#"][
M/0N<G[U_!]2O\\&VP35&)&R#*Q;8/3IBI^ .1J@-;A!%'$K&3\$3)(FVL&M,
M$ >7+(H)DD@Y\DAMT'*:/K#M'62?$ T9?QSTYK*O4L:B[;K3Z=2A[ U.&9\(
M)V#1;H)#"64BYFJUM%;\=J/?8A',R4?PHCD]3@?X>8SHIZ0/&R_!5YC<0O\^
M_/4R.*I_FZ0R^CSS7R(XF@44_8!>.ISXXX>[&_$XO<]#=D3PBB((U%U0T;5T
M?45YTX;#^-BMUVJ>^WS;'V8X*P>V4X+I9!/<.SDY<3.O@9:0J<^)D6ZXVNU#
M@>;*RHLK\)@*"6FP@@_EG+ ,;KJY<P6*-T);.10;:(C6< (%SIB]N<JA\/6F
M 2;"'D,8S\$C*/Q,M'"L@ 679: RKH-L.8N1V C-72L$1)*%K-Y@J#M28UJU
M8Z^EQHJ@"%%YS7ATA48P(0K_,X$$CS *+2 A'R.I6TS$,$"56J9+(:5,-;,:
MJ,*B;7&,5;?.#<JD;[?-&4%?5-I +]0T;0J@7>XE4\^!!7#8M?+EDI01"]$(
M4YP%+F;' [:>E$27J)89L^.N@\M*B4#A/3W+UC%'0M&S@OK*4/ +2#4W@"1(
MR$'417Y5S,)NCK%TOF:$!F@$LM%KZR;I6@+KM\\J;*\<C;J6/G+;W.9W5;:C
MFLA =(2*T<ON:/VDBL!& O*@I%)Z&I0(BQ&76'7RTOSGJ6.IZ0]+88".(RS@
M_L/*"?3WK5Q1$/F/)?>U?KG6CKLZ5VJ_/GL=52[C$M#2"%>]G_G+WV=!)E5!
MT3O;\&QMLKVZW?"<5(2+3/=)8G$"^R5A> <DL>45WQ1?;(/KA6ZAYJY!MWP-
M*H-NY*BG4@IC.3B%Y6_'7^20R>R5Q,IUAI*[6D*+?K1KGKK$[>G\B9GMQ4%-
M$+"$2C[;IQ&6*69SV&TLOOJ[783!YY>@_P@<&O: +B@'W]0"'3=74\O?4$L#
M!!0    ( ,6@]%SMA>!J_0H  '^&   5    96QU="TR,#(V,#<Q-E]L86(N
M>&ULS9U=;^.X%8;O"_0_L.Y-"XSCB8-=(-G)+C*>9&%L-DECSVS;1;&@)<81
M(I,!)2?VOR\IB;)$\DA*BI*<BQF/^![JI?B8I+Z./_VTVZ3HA? L8?1\='ST
M<80(C5B<T/7YZ.MB?+&8S><CE.68QCAEE)R/*!O]]..?_X3$GT]_&8_154+2
M^ Q]8=%X3A_8#^@&;\@9^IE0PG'.^ _H&TZW<@N[2E+"T8QMGE.2$U%0[O@,
M?7_TW0J-QP.J_49HS/C7^WE=[6.>/V=GD\GKZ^L192_XE?&G["ABFV$5+G*<
M;[.ZMH^[C]6?,OQ3FM"G,_G7"F<$B<-%L[-=EIR/Y'ZKW;Z>'#&^GDP_?CR>
M_//7ZT7T2#9XG%!YV"(R4E&R%EO<\>GIZ:0H55)#N5OQ5.WC9*+LU#6+TJ1#
MWW"2)6=98>^:13@O>KUW-PA4R/^-E6PL-XV/I^.3XZ-=%H_4P2^.(&<IN2</
MJ&CF6;Y_%B1EB01A5&U[Y.3!;B;E?"+C)Y2L<4YBN:-3N:/C[^6._EIMOL8K
MDHZ05 H^P':=MNJJ@B:NS=X1GK#XDK[/M1[MR;[X[O#\?VA ,]YY$Y8LQ^F[
MS#<CG=N^(>\[XH<X]T=:#//D?4>Z$?E_L9V;EM]\>.W'-94;K\6GED6RR\4$
M1F)E4E;1,0(7>R@FAJKNNG86M>I-Y6C.N-EV.3,6=68D.EJSETE,$E'W]#OY
M82P_%,T6__ECQL1"X&*5Y1Q'N:JI:,;YR%(^T2U)Y057OC"/>AI7*281$U/3
M<SY.R\-8AC]PMK'NMFHULQ3^D:[J^/*PB%T 1ELR3C*VY1%Y4Z\TW4)'J7*T
M285"KJ@('7]=C'XL-.AWI?K/I\FA%@<=+99 VPVA^5+4:&E!N]A5-]M,J5YN
ME@71R19#>A\K"9(:QQU\(78<RYU?I7AML:^5N^IBJRW5QZW"(#K9YDCOY5J#
MI,A7-W\A6<239[F<[VI'2^:\TRTFC;YO:,)"P#0&D]#0>AK8[\DZD5.+M"#/
M;XG<V#&, 7K70W^G;7TNL(J#@&:(0W"V: :A.LH31Q>4;G%Z3YX9[\*G+7--
MC<VD#DM3$Q0C%F,@&J46E6)/1/QC*\[8"4_WO5 82M=< %9U-#194'38O8&
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M5 .)GZ%>>'@\(B$?3BGG+GLC K27E^F!V-]A8O?[? /@;U[<^=V>6N#LMXH
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M9X*(V*94FW5MGNR\NA0T #AK*(&F46[O?Z><?Q9R+H:4:"EH4ESJA^[P>XM
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MR)GANOVM"ENGZ666>25?>:F>/!"FKT[9U.D)# ,:UF3D%MOQ&V(!O$4SC=\
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MA_4EIS9C_AVWRVVNU@W(2CSORDQUW#&GF,*YW27CK0[\!T');U<O)'/K[99
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M4 8J N''6K-0:Q;81+XITYCU2>WWUWQD&M<)CH19*)Z!>-ND*?17JV,3M[W
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M/#1;TP17JT6A7-)-0IAFBJN[HX3;-R/W&O8@FY]?R.T-IG5ZKL@S:P2@\ !
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M:7//&AV!!=7ROF/P*<^FLW)RK0GPN:X$GU_UF[ ^!UM4P5VR]^;T\Z>WF(/
M_VY[WE'%.?+J=SE.02OK)&+D4ADOQ^_<MN:/P.QE_I-(2<J"RYY(@KC6&XR/
M=#X=2A%\6N,SJ83'9U$2N]9<\\%;(*+A#2E/JOP*+N,)I6J=>J,A_DT'<)*4
ME^5S2IS[9%9ZT01;6$\.L2[!9RR0B4-L/YPL['JD<!7Q2Y$!JR9^7B"C0_Y8
M3%O$+QJ2[H&;PWC*BT=U8Z'40N:+DU2GZ)-">#"I:WM0^=V[PY*O+$-FS__C
MZ0Y6.9( I2JA\R_)*/&9D/[K@DC_4P-(L7^D+_"?C4E!1)#B.DR)'",E.DF7
M04R*P)8Q&S1-Q*9O^QJ9HH]$2;-U0L%(T08F)LEEHE4V_+K[YYIAS1\TD86P
M-78:]GN^B?3R*4875!IC$U"A6F$;R.>:Z7A;>U#WD#F8$6Z99+$'B2<91+"F
M*)7*[;05=3[PF#[E%[Y*,"U."@?XS]$']W>FU)N" _V>D+)F:24L#V;KA4)\
M"P:^59XCW[7+'"W!B'J(NXUHQ5*"9W*2:?LOHDLR*-@$Y7!%:Z-*"BRW+8?I
M>.4(BD,6$F.K' X6Z-89Q-Y$[W%BMC1B7C>G%JHBKCJD"XN8, $RFRE4&D_%
MW[Y,R$A=/^ (W^T;]OLN%2/<+C0Z?&E;PU#P>6+]9/(#VA='L^V43*)K"V0K
M<17!4KOVD^L"&)Z6V'#W^I'P2K7L$*OV@_=Y-(^960B9=&"!X%'3I) L"Q7V
M-JL)&PC$'<#36YH 9-=T8^H'7(FM^>?1YZ&%H8P3E#J'D4=3R&F N:L)W+2+
M504>K1-^VF#1E]%L.D'7I6QJ83!WOQR!E5YHFN=J/1MG&!UJQ(4>R9;ODFL.
M 93$CIV7I2PZM]EAY7,.CK_/H;LDCBL4\D)HRG)8!.KAA3XQ70W/GO*-4#G*
MQ^H\TYQ,=<4NT71]?1@VP+898$$Y[.RLK)"&H86BB12Z4XKR@C8-PUGDAF=Q
M=Q?,T?D1F!H722U)7-\R;;EK*O"FL:._9@_6C>;AC+<KER:GR*07:Y_5B3D^
M2TF>J\ML1#E1C^3!G)T[U'3WV%9<+B#]ZX\<D'[Q&)#^OEZ*6H^7,L:B@XH*
M&Y.UF''0\U*YL)96'>5<1_5K0G23Z\L&MI("+TSJ\^W"/(KY<)J4W>_DY@K2
M?$>L06;U)!X^4H5M7V88!DZ,QC3%NR@O:AU!;+V#]'[.IC/POE/J*]EFW#C^
MD1M8QW*\CKG06MM@"YN>VB*P-EU]=;>K+#W=])ZF<E-8BVHJ7C>*<+4\CX8,
M<DN"-9[GM"AZZ3&XA?>*2L_5MKY+C^!I,T6BK(.;.)7W8''2JYW(>DM$_7R>
MH%&1HA%,]09(7A@3757%-?8]IJ-QQY4*OAR+F.E:NLI0*?[5-%8WP#9#XM*8
M.<U2J3FB<V"#YK6CQ_<R+&R:%!<U-+?\7M#<@H!J'S,=@*LL_P*Z=L;V9%QC
M#>)$"A5PT":XW)F=)TBS7SDC0&28/P0L95&%O";B=7>K5TT,4K^-N32U5TD_
M&<>\PH7F=KQUEM"HDP@Y,F/QJ[,9<DW/4T3?8.LL?M R.\\,K: =$LH#+;DZ
M'O"]?J#%_DJ+,M=,;EUCP(,G2*9":3(US3>R2 FY_7"8F2YJ&S:W(\3 +W@'
M'&W6[0?M^]C$;)>+&O!A@@B%HI0'ZI !>_G<)$4*Z9KO!^N74 1CBAJF]K2@
M^K#*4_P"@ZK0Z#**I3>$@'0"!NK^J(/V=+F!FQ,S#9>Q7*POGWI!.M)=3+:W
MA CK3>NX#*F^' -F?@9TR^\NH4LF'7YBO62$E31%Y+ !C7%CM8W'HE+&( X$
MV$K)&'>68F[56ZW?6\.U%JQXJ[%+J0>FL96US/&2("5M6CA&A2270[?JQ<L!
M.!%_+;0(ITI&R0Q#DCHE_O4)_I;AAZ#T1I'>'V2KUJ9$IS&W4*CP0]E<&DCP
MK4+J^G6E9 ;_/%:"JU5?X7$.=K3[!0*'$%+Z.'";JI@C[I[BA'"<J.F=D\$Y
MM8(28B:X21\KHHF#[W4.G27@1*Q!G(S'%-FB?E)+GG>1U[I@+'$26\R"U;23
M1!^D%Y5=EB(P8:/%2JMI#LMEB&(A$D?$L/H:88$'\EF8ZD6VOKIC7'B&_V,W
M)-)/LE-,215X6V16D*'_'R^>&O9_2: 6F7L7Z"N G\$2V[5^&&F9LA$G=GEA
M4@PT/G@FEIC329+Y_,<S.P@:D(P1Q58RL@;HA\>!S8';G8>73_\3%,6.V@GI
M]3_C>[?=?'(</'<^LN=^A(>]T^^=.4H3S3/7"Z.@@\2?XCEC!_XUC\]%=\HJ
M"/6&1&&[IK "%;V6()U'I;8>\+2\Y*83TYFB*\DON1^;I*88/!+T)T*0)1MO
M/*CDYGB=^!R"L[6HN:ZX_RIB0 Q<$K46Q47V A>;ZZ CJO[F,#U7M&@C8:EX
M9NJDAL3:,%E"5ROK5%B7!_0PI.A\_:V+I"X/?0>NV=4'F8ZN8[RU@Z[;6X<U
M%LM*^S!R2U&[6/NL&9]5:VVS5>DRPQUC\)?4,F:[J?=-"%-!AT:;OW+#2I+%
M.T626 $C?*D.3,]VG[DM<+;IDFIN65)O"*$7>\1%TM[OV/DDEYJVA[.O"%;Z
M)BMVGT_0<HF#W:<_<N;@Y6/FX#[0EK]<AP9'^E)#F-KOU9I3U@KC-W0AUUD4
M[_%XU'LN=O;^W')K27V_K!5*M$WU H0Y*ESN#HT.(Y(*[,5UV=S*0XKU=6,F
MFQMRJ'.G>J1^C[.@TN+L?2,?;I- %3[20 RO#M/3;]-:7[D3]&?8'=;UW+_/
ML6URB3B1/T"4+@I)N_1[-FR@K17+3=JV1\0;WM:Y=M]C.NG:8;^3[3N/:,4V
MWK6S73A3LJVJ4Y48,8I.]H6;2FE&!KN_C;.$ R@CY!ZR!^[,= -P)"\PS$F[
MK^K5(@R:QL_5-Z%U:)K9Q1^;*S3T(G3FP>"0H"2NXK4>RO_]^]___O])O"JI
M'82@^QPL)8"$@EE: FU"L[8,2TN3?88.@WGDF:V:A&0\-$-IZHS&'<J=RL-E
M!)?$@IZHI14$][N)JS<L#@1Y?L:"5LTOX0X03JOMMJ.)-O5JN]WOU;;;Z[EH
MO)N+[$I=JIQ_IC5P<*FP4(G";'WSOL1S6_EAPGNV>1%(KS"^\46$1K_Z.L+<
M(_N]%/N$M=+!XZ[-]Z-^NMRVJCL[=NE**K;YC.4%F+B(N6K0#HWD%OJ"0(('
M_)_.[?"4$VD$-]U.;\<:[>;7D^JX[O@VZ@?^=<.1+IM*E.SUOW7D/WB+_F,U
M+@D>_ZFF41W5:S_AJD(ZE_RG)16>=_'#(5YTU.[^EB:WM+H5H/#ER-!F'!TU
M:T-W"75$E*R6#'DONZ2Y<M)K3[B98ELHVMN^"JV]EM(^+4/'L(JCU9KZ:W8?
MJQOKP>HP;VBE<-H8!MAR=K:WEY5:(X']WET9BE:HU*1Y_1BN[X>VJNT\D>>S
MN9_G0O58KW6-N8,?)_IYS::BH1HY+DQ]8;_'3V)6E&H/L]C!A&_7[J2 V12Z
M3(;V.=AKAB.TU#\83[,UK;<X.YNJ+CUC-LK"PX5X1C*%VQ)QXYZJ:9E,&ER8
MQC%*<J1K_!9T98=-?=_\>]8V02:H/0O@%JDS[U>"\\#<LL-7Q*BT"S6)0TL8
MR!T/8S6)KE6\S7M/QE+C(IE^B7:8"74.=Z$MI!\:&W"C!^FTN"!L%=];#IC'
MI!S%9F\Q1' HO.WN<);H=*Y7D4HAJ-)!%:,\&0H L+G@)5;C9)2H%/Y_42&6
M(JJ@R/U>!20TFA-*C% 1]BFAM3FT9U@9.I6HTW,+AJXHOQ=Y?5&P@76)LS3L
MTZ2V,E"<&6$=3.93KYYA-#&+X@F2X9EL%EY+"VGE@>U H3&ZB4X)@V%67MB(
MONW]+)!%54?Z6Y#\U04SSJ#Y; ?5=O;($T'(Z"0Y3ZB&E0L:Y$X4F][4('0;
MJ_LV"NY]W9YQJM.]6; %,]18XY6WS&6) TE!<Z?6A26!U8?T?\"3VJP\ J,[
MG(ZDOO)P4U[X$-3&95)BHMMYO'3AI@@]7U#-$]*=4+G,@KMH$7@2D9$8,#"
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MZ+P63"&AKT[GI*9SQ(JQ>(_RA. !7IJ<8, $'ILJ50I&C3]?B(M3Z$=*K,6
M-$JS/EGN73H=EU-(NOON3.W L[0;*- OO3M%#\@A(GT8IVD]Q=K[!>E-1B5%
MV",3H=X$1@J#X9SX-]-,2"T=7*%F ;7&BTJ)+)0<'+Y9VG(+C3VT6&<V-='2
M^#C;3,MOBN7?Z0Z$J*$SU#(61;\G[H[?Z,I1_LZ%(6BRK6IB!W52E[?DO/?
M?LMSG!A@N.0WZT7I%08< AZZA]O\0D4YJA&ZG]$)@[5R2[_\!J1,5NHWC#"&
M%7410$R2!PQ:M.[N+"J.Z^X+EC+?;JF."*G4DEFYXKMTL;46-+$>BBKQ$N)5
M7:)P;\)B=+'8[+YX J/566X6B9GE.%Q2'#X:LNPZC>Y.<,B8"3IE'4_I]ZJ/
M609#V8QV#&_>.1/<WQNWS@QLY\S0FE;TT6&6?=',MW@;\[]=,CL-06+E0FA,
MC@];J.628G*?+X\E4Y][/W+J\]5CZO/!TH-HQB6')K2-_W,QB9!@$9L_Z75S
ME8ZRZ.IR<[,Y^H<%T8DC0IMJ<C0+ISLX\??TL&OPU>6O+ODJ*EN*@U,]&WK_
M&4=.Y*KI8'Z4*P4L!C9CJ$[!?6)6Q::O<H=S;VRG1Q4"T#/THLZ1,"\]5X8B
ME*BPOI::'K"HP]UAS?"6/:_SN.I1XC/R2$>^ZF(!6Z/PM4DQI<]&VIMKA:B"
MV+H$4X6.!XDU91]GN%\O:1WYU54RO8;:JV]^V6QTFD^3571G^8C+XA>FE%@B
MUP<?Q^[U49XB %DVIG!H*1Y<:FX])!7?"#;^R_>%C=_VB?2_L W+<;-\BPZ*
MUA^1,V"TD^-S"#BC(?9R[[,[-UOQ-2UYPUI7W3M>:B:?-]=NZ%%9<(J&ZEDQ
M'*=&<^HK2$![DZV%#<HQ*L.^9^'QCC>6Q/=[A(JF3&U;L2:-PNA*=G$EQ4*<
M^K8J%WU@73]KK8=Q4F#++!G; Q2;NY:;NL#44%8N<.KAK>CENA;4XL+[/4(2
M-)S!1MR&+_ZAQIGG&!W%)CMMF0)^VN_[^Y]"4S,)KG1R*;3!8"D3H$%.C01E
M/C%+0Q%LI8J"6[DJYSD.+E=##HN $0HB,01'''^ ]82MP+Q'CH7]% ","B*F
M)3 ;5J>"EW!^44I-7S*;$1=,5!1/Y$XUU+.Z-04%=;"DCJ B-$S^ +PD0PLW
MHJPM,]5NZYH>LORKR]72%D&P(1X9% @=[-/H HSDB;(6 !@P#X=]=3TU?$="
M85PK?N B6 ;65/0X)]UI,_1?6-<L9"%QOZ(]&QM']U_3#.WT$@S"\^GR9E0X
M&*K6NAZ[,$'#_V^XQJBL5.XQ =#4GD]5O/5FMFSN%,[SR41%H$S#XI"9FUJ:
M>.JL*D77X)F;YJI1S*6V47U"#T.VUX,!O&FRZF5GLJJJIAJ24X&?FX)K8QW)
MJ<8CVZA)=6;*M"3J2$U1.$;JYW7C[Z)2&Y^V'N*JJFA,=/5[0<U<,4]J2V\1
M"TK'AV^6T9*^NJNDM!I:H"^1T>H:.36"<#P)G2SM2F,%E2Q6Q_-OF+FBWKJ-
MJ:O@V=-E,U=Z6$MEJ=QYF"]HQ^>[)*0"FX]B0^>[):2\TV7#@FXPD$[(TA>A
M1\VV\$H,O!O1T(> ?L5[4':!$;"&:<_W03,X5KYR:"%<LP#37-E##7JZ2>?P
M"\9ES7JXS_?BDGFX9S]R'N[7QSS<0T0P/\@\7-T<6C+YYEZ670VQ5T^^+3 W
M>$R=^3:X[[Y=PBWHR+>Q;U\-[E<ZNMPRX=:Q7 _$PUH/N/8]UA2Y_4^LO=)]
M*AA,O7P"N^;K.)1Y.HC6V$B3HV@$2:^3RUD/WD=*59P878_3BDRTK@(WC/RB
MU,RV_W+L2SQC*M8*Q;!SQ>""3K(9&V;PXD+#TC_JB-D!F$\%66':(O7:1U:7
MQ^L8R6,"U[="F5;58]5B![%T&]Q-7240:@">]RXR*K^D9-C!K$L3Q1!['M'&
MU(\WJ_[-F'0B4K10:((V"Q0:]B-<7_ISES!1]U.]W(2CAC^0MJVNW$XP^(J^
M&XJ,^HJM/0MTD_W>L(M[L\(2D$:LHP>L;M0*-:0ET1VY"#:=S[FL6#X2VC 3
MLH7B$[NVQ.13= N5.-@'%P8#NM97P;_#;^<HCQ\2+C$@2K4"3S#/;"L3UTK_
MKNZY;/O@<9A.F2<L:OBBJPC%/ 6C2'?\=!B@1<2T?]LP&7;/Z]/0)[)A OK-
M6K#QH]/H"XD(9KTHZBT-E_CN,R<J5J.D2)RN=H[+J*M)\?*E?%N>S7+-0^B?
M'+AKZ(X#T?3N6\H_\TA@#S-#5"H!/Y*J631R^J)J5FF>4<WY@Y7OK'M!+Z[)
M@ZLW@5S@OSH*+KM2.I" 'O$U>%]XE(AF*=<-@>?E-;-H\A9H)L.V)'U8J5J"
MC^H=HXVTG7II-9 3,$=%G+#IHT?3Q$SL^^MK.C-U#DLYT76Z0=@LZ@9(TP 9
MDB!'MS:WK+@-!AY?45G>3(^FHR</PXA93TV#D>817EH3%9]+THI"84) 2RX!
MY<)(+8^49J6L&CFUCI86;>(<(Q. ,M*-]QMJ^_*:;TA."%R!_L'$&\>FL*&M
M5C=+A)U>NX?*O'$$A^<ZN,Q*BK7$"<;1TIC$?)+  &(I7B.VS=<4F'1/IC=H
MMJ!(#63<&WB$$*TQ-HE5W H +S.<_6NW#:T9S%!%N?!P\ORJ'5_EC=Q(&B6?
M5H?:PX#[0T=AB]>*0O=8D01/B:@(+V>?+9.2(D,%?D7*(*&6FM'H>OMA'([U
M &?_DNX)#9SH)KZW#"5_<\I 6';1SJ]&!QO2OV@-=%XCW8E'.QH_4R'CP9:^
M2:Z,;)&,.&:>Z2\/BS%/8^-U5_K4O8O2+[I7Z:8+EMOSZ]4ZI M;-$5?^SV4
MLHML@D8T[B3"*6\79C 5QLKI0!N3:63L,7PA&Z)48,P=;@S-L[^MH;5N-*%S
MK7ETN^;WV(8THWFN;(MSIEKF\7%O:LO3;OI5<B]&H_=I,!_4.1R^$WX.TRHT
M6$%B36G)GVFRZH]6<5:_5BV:<IK#Z-P+=EL^.44K<ZJ5Q9-?EVR,^QR;/ERZ
M(9S,TG6KM(@H #;3?IYSL&W=MIO[L2DL?9GP/LB6BS5&.T[NIG11UGZ$WUUA
ME+'9V, Q+JV+,>RA)@GI.V4[7\8F>.&\4(RZTG(<S%!3ED3OO\K6UJD2T"W1
M0H7R5&2>#!FZ;FEAD("=*-628DT:)\9K[5D15^V92MRQH>VM*&9['B.BA<>9
M$S$\O5JK2S!HF#;&<0\<1@&[ANXYQ4=1^YVIABJE6>MRP]Z,QPK!5F4SM*KM
M&GE%,!.:K\-;3DSV>O;BMVE*\P!S#)SK:C+&0)L82$<1-%&4=^?:=!BA ^;\
MRC8U#E BRXHY2'8<FY0NNJ3[9" "P-5/:.19WZ,FF?<Z1KIDMNWYCYQMVWWZ
MF&Y;OY'%NTSVU/[)V='!AX$&X1T=O7EW J\\&7PZ&9P.CL_VSXX^'I\&^\>'
MP5_[)R?[QV='@U/^S,?WP>G@PX?!R0/HA2H&IMSDJ'.&3L!',!<2[2E,C!JO
M%PU[^4J8=E!IA])T2+J1A@@=GX G:FDJHA*\O0OX&6-SDZR@CBR"&2V"K1%\
M$77KI9I<5V$LA^8;_9Z&F7IM1.]S)<EJEOZSG=TU6?H?\_,H3?X=L9F-._L[
MVE:G8M];P]_"SB(DYIEE$B*%5<<H(ST%N_P08\X$X<1)40JQ2VQL-N,W6".K
M?G$9<Y]RK2A5AVH2@<0I?IB63!0L+)J895<2.XY,(W1$C5V1#<(T*4U11(KD
MQ.8S<:BM'Q8WXGW3($'*95Z309=F5_5ODM&:21PG:\T$X(,2PH[C4SAUC$U;
MR#QT%YF6U9P6WAFXZA&AS6Y39D/DM,!%?8V%,.Y?\SPIXD1BFFQ$D&-V$2'V
MDIWJ9=;'71"QC\#4QA-+S>H])!R&R2\I$!L*<T]72@&=(25=Z672(Q8OP]'$
M2XQV7;_GSD@F9%?.JIBN-4OJC8LK4'4X<P\!IRY*)" MLH=G.;@CY4&5E\8_
M ?LE X<I'<.*ET9MZ*EN\ *NM^K2:[MFN[C1\3<$9*1.\4[E>Y-E73O*GH^W
M%6$FA$ 52(#%F_-OR=<K?2^'+A;ZV@1+MJF!E.&'HK@L*F=1ZOPM#>1U'!=S
M^N$5F$T?*?)(--F@/IIUEP]1N51A&A+>41*\^A'$K];OP?S(A;(VP\#[A.2&
M"142?-9X8C,Y+G31!HFCP,8>(%)^:SJ,"&=<$8K*:?O[C5><$F$2N\K+:]-B
M1V.1D'@6B5:-A[<=,&; \737OT/X!JX!ID%E8[U3A$3RMRI8::><2]RD<4*^
MRL/Z72[B[V/X*X?'$,NV;14\AV,:KBW#JR_7]TSEE#.I7&:+X@5\/7>+$55K
MN0EDVZ*/#[M(CCCVB-@P](3:WE(:DF'$>--OIW5640VLH"Z\ZO=@#)RNT'EX
MCNF9XZN/+L6<14S<KGEN'T+9)"MX9KN0\S/747%0&\)2N>PCG2>1,L!,80[V
M*EG@ 1Y[^8F(1'48"?,I.A0+IEPT*[B8JH2MHS@:J*'MT,F#<L3^4J6*VI'2
MC4Y/"IDZM)A/&$L27";9Q$S!C[I10+APD)J:20ZCG2G-TRP0#4<K*"<]>B<#
MJ4?C&_1 ,:?2AM#/K-[V_:$?EHS5.,)OD JA1YSKA#6O"B5()S;FRT@;)\-]
MF7U1C%V-\^@*0\+@KV">>(0+BM5LDN_CW,@TB^'(T0MDJDWOT9>5DPINFC@G
M/^Y\YA)Z]B8:J]&$>S'H+Q+].#)N%HH1+M1M\EH_$$M[)IP=X-0*>"6)7*K^
MP<ILKL@.9N'J:7S) :T+R DE&VQ"W"X(G6U8!;TBX.R85#?+XR %J1_F-" J
M?^K N7AI]$\F0^$\HG@@B?+U%!NN=@6,Y JP:H%Q%38?:*36E)FQZTJ_>P]&
M#F9$]"G)AH0)Q#\=(,\#V@DFLVDS+G!04BG#<LJI&RX>RA>M>/,TW3:4R*P\
MJ'K1W&>A6C)W\.*'SAWL/N8.[D/8]ME=QVO?)V@[(3[]R-*</[!P"QPZ.&3G
M>08W])-1-LGRW]!@*]7:XC#[DH6@\MJFR^&9L%;(+\@XP:)DW>S4]*L>9;/$
MLH#,TV@>DT,\-OMFJLR[T*]T99&"CVNUF]<JRM'W1B[T0_ 1IT-P566@NV&P
M]W3O.7T/_O&B.X/RGOE\_HEX/RM8IL+)2Z:$ULF]\:P"?U(47+C 'O);S[:E
M1:R4+_/L_HC '/*G]A+,KJXI':'>3:8+I\.%N4V?0EQ)SA4$! %MZ]K.QKE=
M 6/G,1 ?#4*:[5)H9R=[%A,2V5TCS0&%[Z7(-ML")H" Z!NB.&BEK#'=0(B>
MG3#N!<%5F)?=XV*S[QNALV"#.8V+M<7A( SR\X*,HL)8%%V;P>W@4E1AN*;8
M. BM)Q3N)\CL$,6H'^0E9!,1?,0"4W152TB.[V42SZF*! USL<--V76(6!&]
M@;8+4#0LE-@_XRPKX5F*WA5Q0;6!TX;2%@>M07 )$(;HE*V020>.%)+]ZQ8%
M/(!^;]$!VWX@UOOW#^ \,P$<L=X-FIF."04"G.( !]EO4814+!/E"87N9%O=
MTXKE)G)<)5P]SMPZ,_\%8]11NMM*H7(DBM(!5Q'0[O/A!D*PK18<5Z\F"*3-
M=-MJJDN#H8)P-^E0Q#"ERAXEK:UPSB&M@**2-W+D::FHJ".4+*.7^)-"*=@C
M:GAAL.<V"*.=9J=(A.@?QGC@!8HYR[,QK"O3Z:@\SRC#F$T3^AVQ=%$,@%AA
MV+^F\K("?I,+/9 )TL)YS;/T?#R?$*J ^+6"T21*IK3713)-$-JL%Q/O$!"M
MT UEM(2.Z/N?L"R::LOJI79TZEU7;""L6@_CG*^)$@C3&H+.QEY86,=!^0E;
MAT'I#2\.[YW3F:998S8W+ Y$[!QN-AR\A+H,ZK]H]BHOEFIQMH9AI>F6;CYI
M;$LT30#M1'UVHS0V=>S_1]>TN)D9;=;@%_$V;<C%)+G.EPF=7,E%\0):T(JF
MX-11>ATZ>DA?BCQ,[JC$/"=F#(X5XK%*AE9/T.,9USH?CY-1HC,OFDZHW0BA
M98(O4EPEP+BE+L94!9PL>T Y#HC :%4^R<9CCM1QW,\H$V:7P?@'"D662T&#
M[((O1;:*RRTYR%FJI(F3-)ZI?GO'O6T"O&=&KB,@I:1HKP<3L*DTLTNC,-#B
M-NMC7E]Z L7]^*YC(\9%B3<\]V%HEO4P6Y!F<?N!;5DLBK'<0VNBXP^VMY-D
MV-7H(D6":[>QV+:G1E#Z4K Q+Z+)V#E-!AJ'-JD/ #YQZB<ON3ZV*0[HAN1\
M' WS:^!G_DQR8K"$@QK!EN -GA3-WJGI(5ES9CBQ:JK16*KI>(&TY7/E<*.A
MA-L'C.5FUL7C]#F_D)X^8I.9AD2/!-K=''PUW/@3%>$D'X9<KX?B837+6(EE
MS(JIUF%M2S/+D3]6UJ^,1L\%A8S[AX7(S(]Y"Q :8O%#AE'^%S-9S?"%_$,<
M3:-S[<"26":1KH]QP.R$X2JO=>R=O4!3'$YV.HFA_AS^Z7^QS$>29A$(4G2-
M7A^9I)1[1X.@Z_Z6[TOTAHS7!":+/S0L&@,!2VF/R&F!6.J'--^9<42U%3-*
M\M%\6A 'G7/M[@3[S3N3: B>-57&&"ZAQ9N@4ZF)Q)R$4'/.J-_SDT:-KV/W
M%;61_A45JMB@P7DZ-5&#AW$^UUN]3 B3\TSLG)'*4PW6)#%'Q F(*<*@',\.
M<SY#+>^NQ2L8U"&8;5-%<*,N><8P%O?5,WA:+"U2.=L[VNI$(?8!FK4D)-V"
M#D>"F)!--U01G*-SIL7/J_#4("IS"7K5^H+^Y$: 6"-8H#9)B@LYO^Z'%7Z*
M3$UTP%VJ&[\09_?I[M:SO6UMTWY.$SH)I,4**@K-Y[-R=$V%7EC;Z-69FM7"
MSH6$U'7KG!QTE?F[ZY$ONLZ%&@%_;2OC+A+.2<=@LC+4)%;C/)K'T@/7:!+X
MRWA.'C@XPV#"9KEKQMLJ=!0M6WONH:YDXVG (0-39A.D(H=QT.^U'&:YM_A#
M=9VA#*-@"*Y+Y+@BH-&0F*24L'W@:.\UY<&2><67/W1><>\QKW@?\HK/UW%K
M(9R;-+[))X+58'"Y"PW-YU[\%54,EB-XT%28\Q=5\MV'%>#$P +V2RO\Q=Q,
M(7:G::_)Q(?(BX\^!2=$DQ'HWM!)U<(QAF#UA=OF.RTC I,;=.Y-C; *<(>N
M:3 &F<2Y?NWFMM;9LC)AM4ABJW4P\9,0BDE,@"LF[T"_-<HE3JT-;C_J*\]/
M%9.?$8F58F0>Q:SYP4ZD6[\C#,#[A,$H]SON<&PQ/;ETVA'$ETG8&,D-BQ*L
MT-*--H7-4D"9'MDZNSF8<)$/^,ZEU--TI=KD&L6>SK;XYEA6ATO81%"<O3#S
M: \0NA<L7*D8G';B"5P@!:I@CB[QG)RB.$%NKN&<]JC@@M_X9R)&PZ.B/%BQ
MZ28QEAL>.TP[@H8D5Q/N9DZ]IR4+-4[(BA]33+XH*>Y'%#"C^]X<<^4"EQ=W
MI FQ3(8+7#!'0W%9C+%\$I/PM8N^"$ZO"W 4BP>&PE@;V*+I[GCAXRML3HV5
M+M\[4=H"NG CK[DZQ]QVSO ![*ER#!<7VC'PST]1:='X!]GLF@F5].4DYQOY
MQ_V',&;._0)I.!P )LO<,VJO'U,]IWG#FUR"QFHX.=T511@&54YZ3'R/R)?1
M"H%\*&?TE4&%4BWGMJ;"47@E@J% $)*BF).*XC<D$ZZ0Q&?G4B^:SA%\XG#_
M,3<6-[K!#(!1B/"'@O>'QT'7OZX-M2Q:4H?1=)V'2UR[L#K+W+M'*<=W"*N0
MI#X:' V72((CH:M=== UTD6%3%'7J"#Z/1&"*N"SB0FFZ9)J$P&]G$-AL(PD
M-49E3FYI3Z&C-=C"TV1JT+?+$4<^(O)3X^Z:G2F<72!A:IR>%G'#2;/IE\@Z
M80QG> <W&:?=Z4#<DL[%UZ6M(2F8D#'RLTF6>&6"RR<WFT6.3!\K8\5\6.C"
M;I 4JK\FJ6,))(R. T]B.CF5"L2>5(@."!-P(!K"9\'P0ONKJ?+&KYM;!O+<
M6&'3@)UN"LC 9.S5XX/ZP4(M!- /%JY'G.K3NDCI>6BUQ+P032?;X\ZAIN4H
MJ$^]N@1SSBI=KI2&3&U,G$@>]6V2&3XA4XDFW'_.[2$1+&5Y;"F(@\45V74T
M89")8=@R/%F9H\X>QK%?#ZK!B0%SJ(WP+G1PIDEA>9Z$\1$YU_%?F)9F'(I0
MK3I8NE950.>"]TGNF4;UXM59I9DI0BAN/;JJ&-<BC<+.27Q&<-*DR0WZ1O-4
M:OV+I2]'G5:)=!]-AL3:HPNZ4YUS/#LJW:%HU%%<F2:I(YJF:%*>)8]WB;77
M!Z+*FDOO)TV8(6Z03[0H!BJ#0C24PR_&YYR.74)+PTV1J.9TM9$\C*.Y1EA
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MLUL1@PW=Z-Q1GJTE"C[QTNL-Z0C?UI6_65]'^;=\8AG=W^_=L?(/'I[N=Y&
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MY>ZON\'6*39]<QC/=I^&P>ZOO^YN+Z5L[=2HWE&L0Y[BPSC*Z^G*+7 ]K\K
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M\6X7V\RE+R(F>=-VT".C-[\F_1&E'HN^)7;E#I&FX_>#D+#U5/E7X4)"YXM
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M?N(,^)+<R-$7G2S#-(O^<Q'JB0A$CH"4S+\9NLR<)5'L+KT/7N/DMGVHD.;
M?4*-NPRY"N[\H<5XZN"NL! M%+U4EECV)K5>B+]@876U[$=+XJB3B#%>AD(>
MK^]N0AJZ2^+2G_J;)*/PMSUP=WW+:::GS0:^QBGQ*-DO[ $OA>H.PL$U1+JI
M9FVLL%58J\M!E(#DF&(NL,CF.?$!V&C7A$@^85\\>];BAVB0GN[8TK!-3S$P
MK@8$0B]/M[R1Z;;@D'>)"#7I=D)C3359L)C_4AJGA-<9R"H*%VJL*4O/; +/
MI@,\G,/QXI;CXSFQ%^:8>ISCI["98%KP:M*_XP0_@4_5'\5*9_HREL?*C$W?
M5]C[C*@QR 3.QMOFBS"BBV \R:[HTXQ"J7^<W0'Z@HTRV/!<^WN,\';$EP/\
M;)GA^M !@9\H-H\4J@158.M_'0(9=,FC%C-B#[^QG"UQEW2*V4[P%TA6-B^1
M+FB:F,K\<SC).0,'Y!B;IGWA+?6_YH;&/U7O N1Z6^8R")R[P%>F[;JT9;>J
MUQ_K4H/X$(@' EHOT*OAH&,0H[(@P2$@FOY45>=6KV-=EV* 755?S+8LB IF
M984'Z H%]T)W9:I-\CD'Y6#YMEMEW 6W(K%=#.\[)^/:C)5)UJ1.JZF:@M-?
MB2;?=F^>L3>Y6TZ"+F"P:2.;-.0-K.WN8N-'HM(-7'5U**B87<;E-^3'-JE9
M@>UII>+^U5L8EBDK3U'7G8VJBZ,'GO&CD)#D&^@*L+JIB)>&4)280C$M1$99
M <OA7CSV;G)JH3&+8%?SFA V_"^K]UUS08ZG%CMND(:U@"@PWC)[\Z; B9:K
MX;RD0TOJC8ZL%@?]G&ZA;K\6*/U15V*LGSA&7FB^HK)+A0SI9J(L,XZZ;LLV
MV_0KG9Y^S^B =@7IB=4Z;Z!^SXK5/0[*^(XQAS_(!Z[-]MT)O/%D\.ED<#HX
M/ML_._IX?!KL'Q\&?^V?G.P?GQT-3H./[X-WG_\Y.$$7=F,FW1D-8#%$O31T
M;CYQU\Q][9P8$S;V \KX!VX:6?SV,%8&9.3YSFW1 &VQDX_Y>91*-S &R?Z.
MVICPFW#";9B$]P>#%=BW>9;IMI!S2LGK7Z&#=PF3BB?(8I04)==+4W*74^6%
M/%F"U[B!]8HC0BR0'BHE)W (Q@WB)3?GB"]DHWZ^<]OLJYF H:8V5:RO,?5Z
MD*7C"=R2CUS5R_WG#+SW?L^Z[R;=3%(N%* BVZAS. %F[,*X[OX7Q7RJ[6"O
M\U[H MV]PB.3)MPFHQ#6 $EAN!LNM>J3$R9-*Q.A6QM.=&C1B<*D1(S"/4$%
M)"[GN-X4 R]P*NO!H6GDH7F"< C!]+3Q(Y&K@?<) 2U2&CLP)59F;ERKI]6U
M7CO3\<#T L9?ZB(D&ZM$WAS,=2%'EE%&5#0=FN]+=[?F!]QT/ZS=P27:&?^#
M8C,EQP0X1VJ2RMM<YF7W[TZWKYK!I@A1=3]+TUQ)0ASM^QJLM*UR4T<LD@(@
M)#:@D&^0R)328\D,GQ1W3=LB[(OV/:AN.W\STW4=?K ?[A"SJ(6Y;>[FQ:$M
M2]6U(Y9_CY6% T?!)#G:ZB;]:VY+^;8Y"9M^NZV3A?J80S.,>6BL$N*J%;?"
MQPD=-Z<_C I*)>KG575V/;#?\TJ'S(/PW+?!6H,M.ID9(T R]B:IQV >3*(9
MUT<Q,AOI;\J+;1\@6>8@9"E!E/ABY])P"NP(@R31^CJ%/KE4G>C!F_YGE>7Y
M/;O$"FJ<IET=JXJ<\/'=C*-F\S4<-J$#,GI+%_\R%;0>!DN!'DEH7\KCX==6
M2T8IVG!%,# N.C*EAD-R5KF2!X9$C1Y@*CRH%DA@*!'VSC7B)D!AL-0:A>[5
M@7V#QA%^8V[ <=BHSBWS,JJ8&.W5:$+4$^:+%(U'*&RA.'*.BQY?ZP=BZ=]$
MD4:2F")7,-4/0&8A<'8P(_SK)-0MR G?GW,IX+4/OC#M6\L,UL/?;I>JT?E3
M%7.+$R-JJ!O+A9$)69T0X^:X',Y"\)=I7OI;IA6W  /=4L>[$JA^;]- IB:2
ML0SDY.4/#3G9>X2<M$G/]S-6UD/M3:?;T-"ZT$"CN.7J1]>!\&?X.T:Y!N:B
MX'X(@32^+@SPV%'\+>D&:R"9Y&1S'?5"$ZG),%J*[L+7SE)PS+,.9:8T23TS
MEU%%NBA$$Q#W^)KM:NK-&DI^S"P. P#(VP)-V_H9$RXTP6M]:9NT.!4#4'I2
MR/CU;GD#MUA!9PJR3_1KF4Z-I*+A;L FH*M;&YMS-RP.:]X6'K[A10D:!_M8
MD_ -9>ZVB,.;P! KU5IKPR&R0-T3&.+1D8=_Z_?J +C@MOBW%0&,<BS8![H1
MA-'#LN'+Y<#=",#2[]T0P1C<-8"Q!616V<(&"..M=] B&,WFW!3#&-P)A-$,
MX^8@QN!.,(QB1*X%,K8RA'$=V+*;2%>_MYIXW27Z,;#@1\I0?C?TH_]I24+<
M%OVX(N@QJ& >A9^L+L'KQ3S6H+7B:'QKN6S0>IW(>PN7#)9'2][TKN&\3!=:
M\@;WCM';3J'=*HA)J]DZ=?<W0$P:DN8J9#*H(R:7JW(SPK\,&-*!C=&:W H,
MV3:^Y7&.94NG3>M4K 4"6:<UQ'.,6N7;0B#;- >?H6^D.CK!D_U>-WHR^*;@
MR<H.^>C)8*W@2;Y>!#M9LZ4]\&2P%NQDRV&C4[P0\']W",DVH>OW[E#J[G$$
M8,GLPR\_=/;AV6/VX3OB>O^\4Z1NZTL_G0R>''SX>'IT_'MP\/'/P?'^\1F#
MA_=_/QD,_AC CP\',PP3?K$V9.P^T>'RK7_D!LT:.;(8A)SEE)=)LMB4!--=
MP^BPE-(03FK8MH2S,$(+;93@@ X#F%B3B2)6[SMQ;0W-E2;TE5X$*5[G$VLL
M7B!QEB&9;33X\ _5)B "\L(_[2.<#O[PP9K(+HV=T'+0Q#G%U7QY=\^*S#QC
MEH3:;R9."W)[Z,XB@E7&&5NSQ:V(<GFREYZJ3GXU3!2WLA:@Z9Y)?>>%D,KD
M(#G_4PD65Q^#>:*,5T&@?DM+"!@(_@?\:/#JZ],A"6"F=IR/0 @[IHI=?>,D
M3$%K@/=.7#/_/4\-Q^53)I>KGJO_G[TW76X;R[*%_S."[X"HZ.Z0*F"5+8]9
M[LXO9%EVJ<O3)RDSNZ*C?X $*")- BP E,QZ^KO',V"@2$E,2[1N]*VT2! X
M..,>UEY+%)J>/H89L!"V&@D%M,K3F]L3?5WS_AQ7:%QYFLS 2QE S]4NAW6M
MN$'E$<N'I$T8VQ@;4[G#<"$]C;3XV7-J\:Y3E);@;!8H+#T]M(A)LUZ@TV9F
M)B-_=TS6M+7;'1J9919JK>"'Y6-43V97\J78%RHW*:WCLC3JFZ6:&A_QD@FF
MM+5AIZ9A+B=1Z,0FEOS&^G8SI-=C,LTN=0(X8C+96P@7*E#58TJO3%N;!+,5
M["2D3A6;G/A+C??\%B>7':DZAY$[)QV4:[+LC4K3L]2;)<_Y?N\ ILVD/LWP
M53Y&RG/U5)@6]X+CD5O.R 4P-/_<UJ(6+#H%&#N+<*M<:$A:9AE<E/GO /Y6
MCJ(0? (U)PBUG<8,5:9E/K1J2)@0<\7QQLCPE.MZ6225#82W=EJ_5^LU.PGO
MLENR9CW(\PW4@QPRJ^85@2$9$-FNZUOU0_7(:O_A[F-\\G)SL$E[VCDZ2TE/
M/5RNE8@A^E)1/' 9/A5 69;Y,"5R,@8:6<)XU?,AO1A<:,2NG[O<R_ )+/FN
M$%_K47,%2VKJL;:N1]KJO^!29M4WJS*KXM]_3Q1@E243,5+EA@?:?:5+U]I)
MI=K1KHUSJZY"J!JH#$6);+PKDZEV=74'N:S+PEU:<8T&US:T2S^##=]VQ?LO
MGTMENSY^^TG>S>\@9O^]J*\%(]/C-T)Z>N$1=I/^PI#2+'8*U@3%C._AH=\0
M&H>GH@K >B%Y,D+,Z=\"FFN?M,'__T2.>*5+YIUCQ15B.H#Q')2?#(/S(J=,
M!6Z:U+"C-\=G;P^6M.2^'Z^;+$BY!MM)O"Q@('A)#UI@]UV+V3"V$@VOFZSG
MB@?G3(AJ:!UT!3G6#;]%-51:\EJZLJ, ^E+J,110B?3MOM^(*BA%@@MJMW:T
MH45G]V=8=C _I>9 ,GP(4W,+!"BJKJA8MSXE%)QL]LBA@@_K:C1T*[RHI)5:
M.:Y_FP@*%@^J3VO/A&A("%W_J!-4)]J;N%EZWT$'S/*RCJ"M.\CLCZ):)W6M
M?(A@062G$5"P"U-=RI3*$%)*>=KJD+CQT%WW7*H46AR)/,X,JQ@JYR-RC6&D
MB>TR5*I3!A/"9ZRM97_?64<CV%7;&4-EFF==&JX4,4SS<,# %$H'!CSF"R@C
M 3X:GM0Z\FBNJ?K&,%]S*AE$)GU.@5-&VPG&6JM3@MBDIS@A:E;Q7=X25TR$
MO/JA$R'/'A(A=R%NORGH]]&WX036_@4<#<9S71J*;!Y@G@ S?\J[FXN@J5&1
ML:%EL-4MN HUY.I0'.=&>'BB%]:EBF)M@S2#;91.!3GV0M[,K$CH'/<^F-G@
M*9(<VB@:8F26?H,-S3,"I3-$?,B%X1EZFG@LI8DI_)CR&6#K1^'<DUP_I>X]
M>-9 S1,]-O!@GLT'T$0W,K];+V/I]W:<?/BJJ0$\DUBFM :IW\6#9I@4&7YM
MK1&2H#'B;QC1"AGA0PX4:UOR04^O"L:T$Q7_0[UG:Z4$.S6@ #:;IDZ&QVI>
M= 4'=OGD>^.^/-D<I=A1QD4!ZVI@"ANC:30YCZ9:02L4]/ \<B#S":*5BG.O
M&D*A&I6#&V")IB5T4G" CQ/^>57,AXA9I/08RD21.!$/#U9.(?$$_Z6/KA(&
M[HQ&;D.HAVM!:;B=C4D?V-='<4::R%XLVK6=6146P3&\F-+Z+$7B 0F02BV7
MQ0(3]TWB>'D=7 0-NP?V16S1;J"5XOH(7IN.Z+;8+*KS=;O+1S-GW5L1/[[?
M:^M3/Z@3S? =$@XD<,HG5NE%LJ'Q5JW7Z SA#83;(*_-#4'KFE%MB->&G;I(
MQOF$:G6FE*[AR:'J9"Y^K;W=Y#Y=W+CEY(<I\X5G9_+#)TE5<9-(HA(/' .X
M3A$6CJJ0L\@L-OMUZ*YA]^-\UOBD4 "J+E!CW^YHSY+K5"D-R:[K-BWM).F
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M")&-#%ZH?CJN)A);*Q'F_8R._BG5"AH?R-P7J:4RS#;/QGF5<U?O+M>:Y>[
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M(73G()G 45?E!:9]3)&<V.)NN5O26N>FQH:"Z4P^QY5DLL@IK2:\YYO,1O.
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M![$50SC:R!#*?[8#14;]=/X LUO>0>.-=!!S>#J\+JVRF(:!H%5"5]D&#+F
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M->U^Z\;O<BD7Q2ALW/H-5C!^=1E<:?W*>7E=\S=8;OUBR<>#^7OGS-]:<BW
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M>3(D_TG2X]8!,T6.ZBA&W?P>;JI^E:Q=R.A2S(26&G]0*C0)-X3USR>+KF_
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M'W,%:3KC):X?8C'BC(M>Z)-^#PP;"YC6R^:5_K.=2G$+!\S?Y@@KP_O<6HP
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MW[P1H@.P2))'9]&W?H^+)8./=.LUQ52P2'); :A2SM&RP,A=++7<HZD.:6Q
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M7(:NW#FZRW.2Y^2F4O6<<]H+0'T]VU-3:S2?8!)@,2HA4UY6P*+O%&3)X3W
MLN4T$0PY>TE8L4+3I54::V9.K7"$8]X4DLX\E.=(@YM46> [T6N[GN+V(&KU
MVH(?ZJ#S=.7IVO1TM84)<N+"\LJHR7:0#9,6I^>E!-A?V5\WD&G4:$2K5N?'
MSQ7+3='E%DE=1'*TY<9NI'RF^J9NUODJ5HGZR)Y^\B*:9\+7O%=R&KKVMZVP
M@X5:PZ#3U5+<'H11LBPKG-OSN:;9HX(^<K,GK\1I$1R+ C5*QDEJ7ECX,VIC
ML321AM(U%CXQ^J*Z<#+"0?D&[H:<TE<^.XB2X-Z+PBR364"A^2]_FQ]!;9-.
MQH(D'HB);Y"&ZR# EI!0P/5"$F168U-L>,0C.".UZ0_]:68>F-"L1V?-+DCS
M5<S8YK\2T6< [P?\@&.@.=-R8R3RC%] !HOA2I, K],N#1BB<0)7",6S@_WT
M^.DV4?GFR%^NLU$MDH+"94D1A89HA#1K^>MZS)2(*E*[Q7)WZZ,:M]*5<S-#
M35BD,K'G"=X)1@!$5\?DE23U(H<=\TD;,CL)EX"-M7]2QU2Z< ^8_5"[7@HY
MP&7^XOQWSW_*M[S6.ZWUO[YDK4]>M/;BBN*="=!A$4%J>'<FP2O^-;;^:]!2
M[O'H_R>C'^+H [LB#_[6!Q]/@J%K^W(NOX/X&@Y_-&SYFQ\?6]YE;#D'A?J@
M8/M=%([D'0MAXL0KWX$L6;LZ<.)5?#1IIBAQ*_.L_>H]WN"(G9V^N[K^X-U^
M[LKKQD?'1^W7Q[\,#_\.'P[;^X<B'K?;AZ_^F8Y;7J?7?]]J*80_;W^YU-4P
M> .%P>6:H/ZCN(E@^;D3T]0;A-D2=(94<0OK"9G,WT'&:I+ICTN3=@Q@%^H^
MCF64IR!4^L[!_2191N%P'*K*#@BL*+YL5%PI-I/(CX>.Q0M33/->H)!5D'A1
MYO=O.Y73'!(\<C/D8[A2>D634*;&AN^]@"G-DVBY.,<*1EXK/"/-XF-8#AX;
M.(8-?93.H?IXCOX"S_O^.C\[5(8J-M%6 :88<*B>7<10>'F!7Q>GOW_Z_..V
ME8[T_#3[WZ8?1\[IQQ9S@8.S3^=_02@[N.Q?]T[_!5!+ P04    " #%H/1<
M0RJ(W6D-   ',   %@   '1M,C8R,#@V-&0Q7V5X.3DM,2YH=&WM6VUS&[<1
M_LX9_@?4DWKL&8HR[<1I)$93O="V6L7V2'3<? 3O0!+5W>$,X$0QO[[/+G#'
M$TE9EM.T:B?^$)&X [#8EV>?73##-^.?S@ZZG>&;T>$)_@KZ-QR?CL]&!\/=
M\!=/=^/CX=&[DU_$Q?B7L]&/CZ:F\'MB\*ST8JQSY<1;M1#G)I=%+PSTQ(6R
M>OH($S'U?3TOEW:FBSWQ[-'!XV+BROWA[ONU5[RZ]CLRTS.\9O5L[O=%:];P
MZ&!T/=<3[<4//_0'P]VC@\TEOF"7+SU :W.\2@*\>O=VW%YE9RISG2WW[E($
M29Y57LMNYP*'<^)$376AO;Y2XG!FE<I5X84W>#_+Q(7.RTR?*)N'(]*N!X^M
MFNT++*0+,;:R<#+QVA3B9YE5*A72BZJD%;X9#,1/.LOP#-M[JXJ9GZM"%S-Q
M)#-9)$I<S)7RW<[A7,E4F*EX^X_QSK>#:W$FJR*9;U?K5^MLS0CCPZ.SD3@>
MG9V]/SPY.7W[^L='SQ[Q]XOWA\?U]X^G)^,W/SX:/'OVYT=?*\&.-R5+T0Q,
MC/<FYS&89'Q>KWREK->)S&K/PT3RW>'XI'YCH5,_#SZX.SXYV/*D__P[77RU
MA^P+?M?I7U4XXN=6NECF$Y-!L[E.4^/WHX,T?X* !\/3@Y:?Q!#_PG^E-5<Z
MA;S?_$7DP9D$_"Z1;DZ>EF3&D4/)(JV][D7[/:^2>6$R,UL*3R),E>5W$Y/G
MRB9:9O<3!TLKYTVA1"F7%"I.&!A-P+%% <@0 X@)%<W=</<T:F!W?$[_(7?[
MPY7_]UWYO36)4JG[*C\6,DTU18',1&&*G503& -[$UEJCT%XL$RO&!QK,/1F
M(2UPM8 ^=2D],#;)E+3\$ISY?H)XF$WQ&DT(B(SAEN+E^;/GW__AN?^GGGL"
M1W->^\JJ^_F,FTM;*I"%0!T>6_>I,OL.4B85 +!H7)6@E:#PFT'_.S&),%QF
M$KLF_-"JQ!3.VRHAK[^G%!4\URZ%*4MC?072LOQ/NNIO7_#UX>GXS>C\XNC#
M^>N>^"GM]\3?JFP9]AF\[%'TO11/7I^].QJ)MZ./%Q]/ST=/Q<Y.U+LX+9)^
MM_/DK72I_+0G1F<?QD_%D\=92N:H;<-?A DY*3X[-GDIBV5\^+0GI"AA&H7,
MA:!/;37;430=F72B<1)O]?4J=VHZDC>I7,*&A0%6*( .+>\0(#0)U$V*=,4D
M99M).F*2&IERQ28#A9Q7T)F0"9Y7F;18P.9 H[C]I$)F5\[1$L?T"I/,(\T2
M)2XJ8TH'-82<Y%A 6"OY/4BT8J&1$/1K/2[PG5Q1D:R?)1;05&9PP(7V\SL(
M!C2RG6'<@S3TQ7$D--H)=5VJA) :FYHDJ=A6K'4*HE3,93:E<Y+7]! =DW_B
M=4AA!*(2R"81*S4_H@F<=US_]V/4OWW!,4Z7KE"*E%AFR%8;R%-:=:5-Y;*6
M2PK@"K(CG*/;*2E).T(HVW([-@R#%E8D339Q$9>URIG*8F8+U'KLNV2GG9DJ
M:O^B;(Q0 :YMB1S:-:)>M[,)>S62]06=MXQ\0DPK"YDL'2.62NNGGL2RR5'9
MQ#YI*B_4IPI0* *58-'2+72CVVE1#%<QAO+)(&A1?(X//&B/B0 WGB-@?*L8
MQ5=9&-9GJA+M6.U>E70HF,?KZ9)L=E/!W<ZFAK?3--)QS(J,?PC.]638JZ'8
M29V*$]L/9S_'U"77Q3C3\5RKJ1A=JR0L_VXZU8FRW0[".HC6KR&\Y<5T-K$
M).X@4.0DTY"6?*QV3SJJB<Z0JBN5F1+/)\NX9"^FZ36-P0^2&!8U]'8[K &
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MG_X'@'\!4$L! A0#%     @ Q:#T7(*!!WXE P  W L  !$
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4!08     !@ & (T!  !:00$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>tm2620864d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="elut-20260716.xsd" xlink:type="simple"/>
    <context id="AsOf2026-07-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708527</identifier>
        </entity>
        <period>
            <startDate>2026-07-16</startDate>
            <endDate>2026-07-16</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="AsOf2026-07-16" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2026-07-16" id="Fact000004">0001708527</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2026-07-16" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2026-07-16" id="Fact000010">2026-07-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2026-07-16" id="Fact000011">ELUTIA INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2026-07-16" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2026-07-16" id="Fact000013">001-39577</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2026-07-16" id="Fact000014">47-4790334</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2026-07-16" id="Fact000015">20 Firstfield Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2026-07-16" id="Fact000016">Gaithersburg</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2026-07-16" id="Fact000017">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2026-07-16" id="Fact000018">20878</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2026-07-16" id="Fact000019">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2026-07-16" id="Fact000020">247-1170</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2026-07-16" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2026-07-16" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2026-07-16" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2026-07-16" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2026-07-16" id="Fact000025">Class&#160;A     Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2026-07-16" id="Fact000026">ELUT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2026-07-16" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2026-07-16" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
